f hoffmannla roche ltd basel switzerland trademarks legally protected wwwrochecom e roche annual report x annual report landmark year roche personalised healthcare annual report highlights progress made advancing strategic priority shared entire roche group successfully launched new tests medicines tailored needs specific patient popu lations made good progress developing others also promise make treatment safer effective roche believe medically differentiated products benefit healthcare stakeholders patients physicians regulators payers rochearfront coverengindd rochearourbusinesstopicengindd landmark year roche personalised healthcare annual report highlights progress made advancing strategic priority shared entire roche group successfully launched new tests medicines tailored needs specific patient popu lations made good progress developing others also promise make treatment safer effective roche believe medically differentiated products benefit healthcare stakeholders patients physicians regulators payersour business precise diagnosis targeted therapy together potent new drug blood test guide use life changer patients roche global leader sectors worlds biggest biopharmaceuticals company leading supplier vitro diagnostics innovator across major disease areas cancer virology business sciencedriven using exceptional research development capabilities develop drugs diagnostics drugdiagnostic combinations address medicines pressing challengeskey figures roche group index sales mchf free cash flow mchf research development mchf total dividend mchf operating profit mchf number employees income taxes mchf total employee remuneration mchf net income mchf patients clinical trials core earnings per share chf ecoefficiency rate index index price development nonvoting equity security genussschein chf roche nonvoting equity security swiss market index rebased key figures indexed figures annual report core results full index global reporting initiative gri proposed board directors indicators used report see development phase iv numbers exclude patients wwwrochecomreportingandindices genentech studies initiated prior merger calculation ecoefficiency rate see wwwrochecomenvironment x key figures highlights february march march roche group index study avastin shows women roche annual general meeting votes launch innovative fully auto sales mchf free cash flow mchf newly diagnosed advanced ovar increase shareholder dividend mated clinical chemistry module ian cancer live significantly longer cobas c eu without disease getting worse research development mchf total dividend mchf operating profit mchf number employees april april may roche announces positive clinical fda approves cobas hpv test investigational medicine metmab test results investigational medi cervical cancer screening combination tarceva doubles cine tdm aggressive form detects highrisk genotypes time people lung cancer live metastatic breast cancer without disease getting worse income taxes mchf total employee remuneration mchf net income mchf patients clinical trials august september september us marketing approval targeted roche named healthcare super tarceva receives european approval skin cancer medicine zelboraf sector leader dow jones firstline use genetically distinct core earnings per share chf ecoefficiency rate cobas braf test companion sustainability indexes third type lung cancer diagnostic year running index index october november december price development nonvoting equity security genussschein chf investigational medicine ocrelizumab fda grants priority review new marketing applications submitted shows significant reduction drug application vismodegib eu us pertuzumab multiple sclerosis disease main advanced form skin cancer positive metastatic breast cancer tained almost two years roche nonvoting equity security swiss market index rebased key figures indexed figures annual report core results full index global reporting initiative gri proposed board directors indicators used report see development phase iv numbers exclude patients wwwrochecomreportingandindices genentech studies initiated prior merger calculation ecoefficiency rate see wwwrochecomenvironment rochearkey figuresengindd rochearhighlightsengindd contents key figures inside cover highlights inside cover letters shareholders managementbusiness review group results outlook responsible business market environment group strategy research development pharmaceuticals unmet medical needs accessing external innovation diagnostics better treatment decisions conducting responsible r manufacturing procurement manufacturing green logistics quality compliance procurement marketing distribution access healthcare customer relationships valueadded services patient safety advocacy people great place work employee development talent attraction reward recognition community involvement humanitarian social projects arts culture science education community environment environmental stewardship health safety biodiversity environmental footprint pharmaceuticals environment corporate governance remuneration report corporate governance remuneration report independent assurance reportletters shareholders roche business report letters shareholdersdear shareholders deepening debt crises europe united states turbulent currency markets slower global economic growth profound impact business landscape increasing pressure government budgets also weighed heavily healthcare markets resources stretched many countries focusing shortterm savings targets budget controls number governments particularly europe sought ease deficits imposing substantial price cuts pharmaceuticals including innovative patentprotected medicines along measures aimed controlling reducing healthcare expenditure amid challenges roche posted strong results year group sales advanced constant exchange rates excluding tamiflu billion swiss francs earnings performance improved significantly faster net income rising billion swiss francs also pleased dow jones sustainability indexes named us super sector leader healthcare ranking roche worlds sustainable healthcare company third consecutive year convinced sustainable corporate policies practices create longterm value promote innovation therefore support primary mission company prolong peoples lives improve quality life excellence science researchbased company like recent developments healthcare policy policy makers shortterm focus costs major cause concern course understand roche leading pharmaceutical diagnostics company indeed industry whole must play part efforts overcome current financial debt crises pre pared constructive dialogue aim contribute finding fair sus tainable balance health policy industrial policy balance encourages rewards type innovation society whole benefit nearly four decades working healthcare industry rarely optimistic medium longterm outlook researchbased innovationdriven companies fundamental trends point right direction growing ageing global population increas ingly affluent emerging markets rapid scientific technological advances paving way targeted costeffective treatments undiminished need medical progress since many diseases still effectively treated must forget increasing economic significance innovation fact nations regions communities around globe compete investment jobs see countries increasingly taking targeted action promote research innovation within borders impressed progress shanghai beijing singapore cities emerging markets made strive become global leaders life sciences particu larly pharmaceuticals diagnostics moreover positive attitude openness towards new scientific discoveries technologies definite assets letters shareholders roche business report countries recognise researchbased healthcare industrys high productivity translate significant economic growth generating skilled jobs investment exports high expenditures research development lead ultimately strong value creation much roches r activity continues located headquarters switzerland precisely countrys competitive advantage switzerland remain one best places world investments science maintain strengthen innovationpro moting advantages particularly optimistic companys future decade roche maintained strategic focus innovative diagnostics therapeutics worlds biggest biotech company biopharmaceuticals market ideally equipped transform growing knowledge disease biology novel treatments tests spent billion swiss francs research development sum puts us among top r spenders regardless industry unlike competitors intend continue invest ing heavily research development particularly areas competitive advantages oncology diabetes inflammatory autoimmune diseases neuroscience time maintain strong focus optimal use resources continued productivity improvements roche remains worlds leading supplier cancer medicines number one vitro diag nostics company combined strengths pharmaceuticals diagnostics proven expertise molecular biology company uniquely positioned make personalised healthcare reality achievements past year us launch zelboraf record time euro pean medicines agencys positive opinion novel treatment skin cancer progress projects development pipeline testimony costeffective targeted medicines diagnostics key role play overcoming health care sectors current difficulties pricing pressures increase payers shift resources products services offering greatest incremental benefit patients company focused developing medicines tests create real value patients physicians well equipped compete successfully increasingly challenging healthcare market strengths serve us well today even important tomorrow view companys strong performance positive outlook difficult economic financial environment notwithstanding board directors proposing dividend increase per share nonvoting equity security swiss francs subject approval annual general meeting march roches th consecutive annual dividend increase finally want inform andr hoffmann prof sir john irving bell two highly experi enced distinguished roche board members agreed stand election term forthcoming annual general meeting standing reelection chairman would honoured continued confidence franz b humer chairman board roche business report letters shareholdersdear shareholders given significantly harsher market conditions faced easy year company nevertheless successful one lets look roches financial performance first met targets despite significant impact strong swiss franc reported results excluding sales influenza medicine tamiflu anticipated sharply previous year group sales advanced constant exchange rates pharmaceutical sales line market growth diagnostics division posted increase sales reinforcing position leading supplier vitro diagnostics group profitability continued improve ongoing productivity gains cost savings impressive given price cuts imposed products major markets core earnings per share key metric underlying performance excludes noncore items global restructuring charges amortisation impairment intangible assets increased constant exchange rates core operating profit grew strongly faster sales rising currencyadjusted basis billion swiss francs divisions increased core operating profit margins solid earnings performance enable us continue investing heavily research causes disease advancing growing number latestage projects product pipeline success rate clinical trial programmes extraordinary makes opti mistic roches future fewer major clinical trials new medi cines reported positive data excellent mark also compared industry whole results help position us even strongly future growth roche owes success employees thanks tremendous dedication hard work met annual objectives ever challenging market environment behalf executive committee take additional opportunity thank roche employees valuable contributions importantly landmark year roche personalised healthcare due advances molecular diagnostics therapies increasingly targeted particular patient populations already roughly half new molecular entities latestage portfolio tailored subsets patients identified using specific diagnostic tests letters shareholders roche business report zelboraf novel personalised therapy metastatic melanoma aggressive form skin cancer major milestone patients doctors roche us food drug administration approved zelboraf companion diagnostic test august followed late year recommendation approval european medicines agency first time roche simultaneously launched new medicine companion diagnostic close collaboration pharmaceuticals diagnostics divisions crucial bring ing zelboraf market record time five years metastatic melanoma extremely difficult treat every hour every day patient somewhere dies disease zelboraf inhibits mutated form braf protein occurs half melanomas detected roche test first targeted treatment shown extend survival patients metastatic melanoma significantly improve quality life expect approvals many additional markets course make zelboraf companion diagnostic available patients worldwide also filed regulatory approval novel biologic pertuzumab treatment breast cancer another instance new drug addressing significant medical need breast cancer common form cancer women million new cases diag nosed annually worldwide breast cancer still claims lives women every year despite major advances therapy pertuzumab effective roughly breast cancer patients whose tumours carry genetic mutation causing overproduce protein known receptor herposi tive tumours highly aggressive fast growing associated high risk recurrence pertu zumab designed specifically prevent receptor pairing receptors process believed play important role formation growth several types cancer adding pertuzumab treatment regimen roches medicine herceptin chemotherapy found reduce risk disease progression death impressive indeed clinical trial data encouraging drug combination could become new standard firstline treatment herpositive breast cancer aspire make good treatment options better one goals see cancer certain death sentence increasingly become chronic condition unfortunately many cancers eventu ally develop resistance therapies cancer cells masters evasion often start growing multiplying combination regimens attack cancers several fronts simultaneously thus gain importance zelboraf pertuzumab tangible examples field cancer deliver significant benefits patients excellence science intend build successes like oncology therapeutic areas developing effective targeted strategies fighting serious diseases addition new cancer therapies working personalised medicines hepatitis c asthma drugs alleviate cure various disorders central nervous system including alzheimers disease schizophrenia depression currently drug development projects also research could lead companion diagnostic roche business report letters shareholdersmolecular biology ushering new era medicine clear strategic advantages field figure prominently r successes going forward understanding underlying biology diseases grows ability develop targeted medicines companion diagnostics increasingly making personalised healthcare reality holds tremendous potential patients healthcare systems roche encounter significant challenges opportunities years ahead roche respond boldly decisively continue serve interests patients employees shareholders thank continued confidence company severin schwan chief executive officer letters shareholders roche business report board directors dr franz b humer prof bruno gehrig andr hoffmann dr andreas oeri prof pius baschera prof sir john irving bell paul bulcke william burns lodewijk j r de vink dr christoph franz dr deanne julius dr arthur levinson board directors per december peter r voser prof beatrice weder di mauro roche business report managementboard directors name year birth term ends first elected board directors dr franz b humer e chairman prof bruno gehrig c e vicechairman andr hoffmann c e vicechairman prof pius baschera e prof sir john irving bell b e paul bulcke b e william burns e lodewijk j r de vink b e dr christoph franz c e dr deanne julius b e dr arthur levinson c e dr andreas oeri e peter r voser c e prof beatrice weder di mauro b e secretary board directors dr gottlieb keller honorary chairman board directors dr fritz gerber corporate governance sustainability committee b audit committee c remuneration committee presidiumnomination committee e nonexecutive director committee chairperson management roche business report corporate executive committee dr severin schwan dr pascal soriot daniel oday dr alan hippe silvia ayyoubi dr gottlieb keller dr richard scheller dr jeanjacques garaud dr dan zabrowski osamu nagayama dr stephan feldhaus dr sophie kornowskibonnet member february corporate executive committee per december roche business report managementcorporate executive committee name year birth position corporate executive committee dr severin schwan ceo roche group dr alan hippe chief financial officer dr pascal soriot coo division roche pharmaceuticals daniel oday coo division roche diagnostics dr gottlieb keller general counsel silvia ayyoubi head group human resources enlarged corporate executive osamu nagayama president ceo chugai committee dr richard scheller head genentech research early development gred dr jeanjacques garaud head roche pharma research early development pred dr stephan feldhaus head group communications february dr dan zabrowski head roche partnering february dr sophie kornowskibonnet head roche partnering secretary corporate executive committee perolof attinger statutory auditors kpmg klynveld peat marwick goerdeler sa reporting years roche holding ltd kpmg ag since auditor charge john morris ian starkey since chief compliance officer dr urs jaisli management roche business report swiss francs core earnings per share roche business report business review group results roche posted strong overall results challenging business environment core operating profit grew faster sales core earnings per share eps increased doubledigit rate outlook roche expects sales pharmaceuticals group grow lowsinglemidsingledigit range diagnostics sales expected grow market roche targets high singledigit core eps growth market environment changing healthcare sector cost pressure vast potential modern science transforming development delivery healthcare innovation centre group strategy strive benefit patients make healthcare efficient innovations built excellence science response medical economic challenges facing society roche business report business review key figures group sales millions chf cer core operating profit millions chf cer net income millions chf cer millions chf changes sales cer chf usd group sales excl tamiflu pharmaceuticals division excl tamiflu diagnostics division core operating profit pharmaceuticals division diagnostics division operating free cash flow core earnings per share chf cer constant exchange rates average fullyear group results outlook group results groups cost base located outside switzer land roche group posted strong overall results challenging market core operating profit grew faster sales solid sales growth core earnings per share eps increased con group sales increased constant currencies stant exchange rates swiss francs strengthen swiss francs us dollars billion swiss francs ing swiss franc major currencies notably underlying growth able compensate expected us dollar euro significant negative impact decline tamiflu avastin sales impacts health results expressed swiss francs care reforms austerity measures price cuts excluding tamiflu sales increased constant currencies however underlying currency translation exposure arising pharmaceuticals division represented group sales nonswiss franc revenues mitigated majority diagnostics division contributed pharmaceuticals sales pharmaceuticals division excluding tamiflu grew full explanation core results concept see finance report part annual report including tamiflu sales expressed constant cur roche business report business reviewpharmaceuticals division sales region key products certain asiapacific latin american countries notably china venezuela brazil western europe united states decrease sales japan excluding tamiflu due primarily direct indirect effects disastrous japan earthquake march emergency relief efforts rapid implementation chugai recovery programme ensure international product supplies restore production took priority marketing activities normal operations could resumed excluding tamiflu towards end ensure uninterrupted supplies constant exchange rates average fullyear medicines patients shipment controls introduced number key products immediately following earth quake cases controls maintained well rencies remained stable swiss francs us fourth quarter promotional activities reduced accord dollars total billion swiss francs sales reflected ingly solid growth key medicines including recently launched products demand cancer medicines herceptin mabthera diagnostics rituxan xeloda tarceva continued grow initial diagnostics sales grew significantly faster vitro sales new targeted skin cancer medication zelboraf diagnostics ivd market constant exchange rates launched us august encouraging swiss francs us dollars totalling billion additional major growth drivers eye medication swiss francs market share roche continued lucentis actemraroactemra rheumatoid arthritis lead global ivd market business areas professional mircera renal anemia negative impacts included expected diagnostics tissue diagnostics decreases sales tamiflu avastin metastatic breast main contributors cer indication neorecormonepogin bonvivaboniva cellcept us healthcare reforms european austerity mea sales professional diagnostics far largest business sures base effect japanese biennial price cuts area driven continued strong momentum immu combined negative growth impact million swiss noassays solid instrument placements early roche francs equivalent percentage point divisional sales professional diagnostics took leading position market includes ivd solutions clinical laboratories hos oncology continued account majority pitalambulatory pointofcare testing tissue diagnostics di visions sales continued growth herceptin demand advanced staining products detection mabtherarituxan offsetting expected decline avastin genes proteins tissue samples continued fuel growth sales virology sales tamiflu continued decrease sub around twice market rate diabetes care stantially overall pegasys sales declined year molecular diagnostics new generation accuchek began recover second half following us launches blood glucose monitoring systems viral load tests new hepatitis c medicines used combination infectious diseases respectively remained main growth pegasys sales inflammationautoimmunetransplantation drivers applied sciences sales impacted increased due strong uptake actemraroactemra yearonyear decline hn influenza virus testing increas growth mabtherarituxan rheumatoid arthritis ing competition sequencing slowdown research compensating negative impact continued generic funding erosion cellcept diagnostics sales grew regions significant regions growth us pharmaceutical sales driven contributions established emerging markets mainly demand lucentis rituxan actemra lower strongest gains recorded asiapacific driven sales western europe due primarily government mainly professional diagnostics immunoassay business austerity measures budget constraints including manda reflecting roche diagnostics strong presence china tory price cuts higher rebates increased utilisation con latin america business areas grew trols countries excluding tamiflu sales inter greatest contributions professional diagnostics dia national region grew helped increasing demand betes care professional diagnostics also drove sales business review roche business report diagnostics division sales region sales growth positive effects ongoing pro ductivity improvements europe middle east africa emea net income core eps significantly net income grew strongly mainly due good operating japan performance lower financing costs lower tax rate advancing currency adjusted basis billion asiapacific swiss francs swiss francs latin america core eps excludes noncore items global restructuring charges amortisation impairment north america intangible assets increased constant currencies swiss francs constant exchange rates average fullyear strong operating free cash flow improved net debt position emea europe middle east africa region pricing groups operating free cash flow remained strongly posi pressure budget constraints felt north america tive billion swiss francs advancing con roche gained market share ivd core business following stant currencies swiss francs launch new immuno assays molecular tissue tests decline diabetes care sales due postponed mainly due free cash flow net debt position launch latest product portfolio us offset group end decreased billion swiss francs strong sales ivd core business sales japan contin billion swiss francs start year bil ued grow several times market rate driven gains lion swiss francs net debt asset ratio reached level professional diagnostics tissue diagnostics operating profit improved groups core operating profit increased constant outlook currencies swiss francs resulting increase core operating profit margin percentage points roche expects low midsingledigit sales growth con reported exchange rates continued pressure stant exchange rates group pharmaceuticals sales prices compensated increased sales division pharmaceuticals sales growth expected volume efficiency measures operating costs decreased accelerate driven strength established product primarily result operational excellence programme portfolio well planned new product launches sales announced november diagnostics division expected outpace market core operating profit pharmaceuticals division grew constant exchange rates billion swiss francs despite challenging market environment based core operating profit margin division increased signifi expected sales growth continued efficiency improve cantly percentage point reported exchange rates ments roche aiming high singledigit increase core driven genentech integration synergies resource prioriti eps constant exchange rates sation productivity improvements achieved spite expected decline tamiflu sales billion roche continue attractive dividend policy swiss francs lower sales avastin metastatic breast cancer indication impact healthcare reforms austerity measures core operating profit diagnostics division increased constant exchange rates billion swiss francs divisions core operating profit margin increased percent age points sales reported exchange rates driven roche business report business reviewkey achievements businessfinance group sales rise excluding tamiflu significant foreign exchange impact percentage achievements points due appreciation swiss franc overall group sales billion swiss francs pharmaceuticals sales excluding tamiflu line market diagnostics sales increase significantly ahead market core operating profit increases significantly faster sales driven primarily savings operational excellence programme continued productivity improvements core eps rise due solid operating performance lower financing costs lower tax rate strong operating free cash flow billion swiss francs dividend increase reporting year board proposes dividend increase swiss francs th consecutive year dividend growth responsible business roche named healthcare supersector leader dow jones sustainability indexes third consecutive year established system process reporting contributions individual healthcare profes sionals meet new regulatory requirements research development excellent progress latestage pipeline trials deliver positive results key drug approvals major regulatory filings diagnostic tests instruments launched key markets leading position personalised healthcare strengthened targeted melanoma medicine zelboraf companion diagnostic test successfully launched us tarceva approved eu egfr mutated nonsmall cell lung cancer launch egfr mutation test marketing applications filed us eu targeted cancer medicines vismodegib pertuzumab rich pipeline new molecular entities nmes designed first class best class pharmaceuticals diagnostics divisions collaborated projects manufacturing established unified sustainability audit protocol suppliers together procurement industry members marketing distribution basic principles swiss health technology assessments developed joint initiative pharmaceuticals industry santsuisse association swiss health insurers continued exploring differential pricing models increase access medicines emerging markets patient assistance programme china hosted third annual international experience exchange patient organisations share challenges best practices build relationships people ran firstever global employee survey roche group participation rate prepared worldwide launch chris global solution hosting employeerelated information major human resources processes increased number women key positions line year goal increase community involvement commenced building equipping two schools haiti one pakistan following devastation caused natural disasters laid foundation stone new teachers training college malawi designed house train teachers environmental stewardship improved ecobalance impact per employee target improving ecobalance levels reduced energy consumption track year goal efficiency improve ment levels growth rates constant exchange rates average fullyear business review roche business report market environment group strategy operating environment genetic differences patients one main rea sons even best treatments sometimes ineffec industrys operating environment characterised two tive people different medicines yet differenti opposing sets forces experiencing driving forces ated differences identified efficacy form constantly increasing demand better healthcare medicines increased significantly diagnostic testing solutions industrialised emerging markets coupled also holds tremendous potential improving response rates dramatic progress medical science technologies today accounts healthcare spending even help provide tools meet demand con though diagnostics adds value along entire healthcare trast industry faces resisting forces unprecedented chain prevention diagnosis monitoring directs pricing pressure increasing regulatory hurdles innova medical decisionmaking tion view agent bringing decisive positive change environment achieving sustainable demand better healthcare also driven growth expanding world population expected grow seven billion nine billion additionally sus growing demand better healthcare options tained economic growth ageing populations unhealthy despite continued breakthroughs treating serious diseases lifestyles point rising prevalence acute chronic dis need medical care new treatments tests eases cancer diabetes rheumatoid arthritis respira remains enormous twothirds known diseases tory diseases parkinsons alzheimers diseases four still go undiagnosed untreated even treat main noncommunicable diseases cardiovascular disease ments exist response rates unsatisfactory cancer chronic lung diseases diabetes already kill three patients average respond favourably todays medicines five people worldwide cause great socioeconomic moreover many treatments cause serious side effects harm especially developing world patients worldwide waiting better treatment options million diagnosed cancer year oncology million living asthma million living rheumatoid arthritis inflammation autoimmune disorders million infected hepatitis c virology million die cardiovascular disease every year million living diabetes metabolism million living schizophrenia million living multiple sclerosis neuroscience roche business report business reviewincreasing price pressure major markets offset higher upfront investments generate clinical data dem growth emerging markets onstrate medical value slowdown growth pharmaceutical markets low singledigit rates recent years reflects rising number time healthcare authorities researchdriven major products gone offpatent conse companies working closely together adapt quence face generic competition addition political pres rapid advances medical science improve regulatory sure contain healthcare costs led several countries science science developing tools standards ap impose significant price reductions pharmaceutical prod proaches assessing safety value new products ucts concerted austerity measures taken govern ments germany france spain uk greece pharmaceutical companies also challenged justify european countries governmentmandated price cuts value products many countries imple introduced japan china india brazil russia mented health technology assessment hta procedures us government imposed fee branded pharma improve healthcare services making pricing reimburse ceutical products part ongoing healthcare reforms ment funding decisions using methods evidence savings expected coming years medi based medicine rapidly evolving field europe care medicaidfunded medicines result us countries meanwhile introducing value cost containment measures overall growth developed mar based decisionmaking valuebased pricing hta kets expected remain stagnant systems meet expectations needs citizens consequently decisions medicines administer contrast modest outlook industrialised countries increasingly made public agencies health expect continued high growth emerging markets insurers rather physicians robust outlook underpinned rapid population increases rising personal incomes efforts improve access expanding knowledge disease biology basic healthcare expect favourable longterm presents vast potential trends lead rising awareness health issues even though science transforming delivery healthcare increased voice patients virtually major emerging todays medicines address targets among markets two million proteins human body many may implicated disease clearly begin today eight emerging countries among top health ning understand disease processes care markets asian market grown twice fast overall global market recent years population vast potential advances steadily billion china worlds secondlargest economic revealed findings new branches research power third largest pharmaceuticals market nearly one genomics proteomics researchers refine knowl quarter chinese population reach age edge diseases molecular level insights lead incidence rates cancer chronic dis ing new strategies detecting fighting disease take eases increase population ages addition govern example knowledge derived molecular research ments rapidly building diagnostics infrastructure often cancer cancer term covers approximately requires highly automated instruments bridge gap different conditions almost affect body number skilled laboratory personnel tissues thanks ultramodern methods sequencing genome scientists know genes involved even though political volatility talent retention signifi genesis cancer include breast cancer genes cant challenges many emerging markets hold signifi brca brca recently discovered mutated gene cant potential industry found malignant melanomas approx imately solid tumours rising regulatory hurdles safety value healthcare authorities particularly us europe search identify genes critical development continuously raised standards assessing ther cancers means complete scientists worldwide apeutic benefits safety new drugs takes ten participating cancer genome project integrated twelve years average bring new pharmaceutical prod research venture aims detect mutations uct market new diagnostics require increasingly cause common types cancer efforts hold enormous promise rapidly expand knowl business review roche business report edge disease biology turn transform treatment continue anticipating creating new trends disease targeted diagnostic methods medicines harnessing increasing understanding disease biology adapted genetic constitution degenerated cells make tomorrows treatments safer effective personalised better fit patients genetic characteristics past decade roche pursued roche strategy strategy developing medically differentiated medicines diagnostics believe products likely roches mission remained virtually unchanged since obtain regulatory approval accepted patients physi company founded improve health help cians payers provide value entire patients live longer better lives entrepreneurial spirit healthcare system turn stakeholders inventiveness founders still define culture today provide basis medical advances focus innovation pharmaceuticals diagnostics pioneered roche development therapeutic anti convinced innovation healthcare driving bodies led company becoming world force discovering developing better cost leader cancer medicines efficient treatments focusing prescription medicines understanding disease mechanisms new technologies allow better understanding diseases number plausible targets pathways dna structure genetic code human genome cellsorganisms observational disease biology basic biological mechanisms mechanisms pres today roche business report business reviewworking together discovery market diagnostics research assay technically validated ivd assay clinically validated ivd assay biomarkers tools pipeline projects medicines antibodies eg sequencing eg lung cancer tests disease mechanisms asthma hepatitis c pharma research development commercialisation vitro diagnostic tests ivds create real value diagnostics diagnostics division far worlds patients physicians roche positioned succeed leading supplier ivds market share increasingly challenging operating environment cost pres develop instruments tests disease screening diag sures mount payers channel funding options offer nosis monitoring laboratories point care greatest incremental benefits patients patient selfmanagement divisions continued success depends focused pursuit testing efficiency strategically aligning organisation around pharma medical value testing efficiency mean offering lab ceuticals diagnositics divisions encouraging inter oratories complete test menus solutions efficient work divisional collaboration throughout value chain flow information management ensuring patients discovery commercialisation created distinct receive fast accurate reliable test results also competitive advantage targeted therapies offer medical devoting substantial resources acquiring intellectual prop economic value exceeding options erty developing novel ivds high medical value provide patients physicians answers key medical pharmaceuticals diagnostics divisions must questions validating demonstrating medical ever succeed right given distinct business economic benefits tests models success factors therefore maintain separate organisations business including product leader leverage expertise molecular biology ship responsibilities aligning groups across rapidly expanding knowledge base disease biology value chain advancing personalised healthcare causes disease holds enormous potential pro vide significant benefits patients early understanding pharmaceuticals pharmaceuticals division strives molecular biology prompted us make significant investment discover develop first bestinclass targeted thera genetic engineering related molecular sciences pies provide unique benefits patients pursuing sci exciting new approaches still infancy today entific excellence maintaining high levels r roche worlds largest biotechnology company expect continue delivering medically differentiated prod biological products market biologics constitute ucts address unmet medical needs keep focus product portfolio compared industry aver areas believe expertise make differ age ence oncology virology inflammatory autoimmune disor ders cardiovascular metabolic disorders diseases understanding molecular mechanisms disease central nervous system grows ability develop targeted treatments make important contributions healthcare management business review roche business report society strengths biotechnology research devel talent management processes designed opment manufacturing mean ideally equipped recognise drive innovation also focus creating transform breakthrough innovations science benefits working environment everyone feels valued patients respected fostering diversity essential success striving increase number females key posi deliver personalised healthcare tions least levels combing expertise strengths diagnostics pharmaceuticals paving way roche personal creating sustainable value ised healthcare drawing growing body knowledge commitment discovering developing innovative research findings molecular causes dis products services commercially medi ease demonstrate many cases personal cally successful continue important ised healthcare contribution society roche business sustainability identifies patients likely best respond specific creation shared value aim provide value treatment stakeholders patients doctors employees inves enhances cost effectiveness healthcare tors society large indeed success improving stratification patient population patients lives hinges largely ability integrate ele increases efficiency productivity research ments sustainability social environmental economic development throughout operations culture supports development safer effective treat ments thus reducing risk cost side effects strive therefore achieve following aspects improves medical outcomes quality life patients business innovation focus pharmaceuticals diag today interweaving knowledge pharmaceu nostics ticals diagnostics divisions increasing effectiveness broader access products patients need new throughout development process new medicines medicines tests respect employees including offering highquality many novel active substances made excellent rewarding employment showing scientific studies skin cancer drug zelboraf companion test making sustainability part everything coor approved us record time dinating efforts corporate sustainability cancer drug tarceva received approval eu committee encourage corporate culture seeks additional indication linked use roche diagnostic highest levels sustainability roche moreover acknowl test edges united nations guiding principles business onehalf medicines latestage development human rights recognises follows international companion tests tailored specific patient popula standard iso guidance social responsibility tions pharmaceutical projects biomarker pro effectiveness approach reaffirmed grammes roche named sustainable global health care company third consecutive year dow jones foster innovation empower people sustainability indexes roche relies global network specialised research cen tres operating high degree autonomy addition roche pharmaceuticals partners companies worldwide approach reflects view innovative research stems fresh ideas likely flourish company strong inhouse capabilities diverse external network partnerships goal lead innovations science combin ing critical mass big pharma flexibility entrepreneurial spirit smaller business units extends roche business report business reviewroche personalised healthcare common cause landmark year roche personalised healthcare features highlight subject four different angles personalised healthcare works today findings new basic research disciplines enabling scientists refine understanding diseases molecular level identify subgroups outwardly similar patients whose disorders different causes roche making personalised healthcare reality combining strengths pharmaceuticals diagnostics proven expertise molecular biology roche committed systematic pursuit personalised healthcare concept becoming reality development projects intervening molecular level cancer case point important insights derived molecular research thanks ultramodern research techniques including series innovative systems roche todays scientists identified genes involved genesis cancer may serve behand blu en gg ins n ta est ws oche targets fo thr e w rt ao ph c ih ee enrapy personalised treatment strategies infection hepatitis c virus cause liver disease information infecting viral subtype help doctors choose right treatment wochen duration predict likelihood lasting virological response therapie einstellung der behandlung test woche test woche hcvkonzentration virusmenge roche personabliusesidn ehsesa rltehvciaerwe rroocchhee bbuussiinneessss rreeppoorrtt signifikant gesunken v geir ru insm gfe n gg ige gesunken wochene di en rs bte el hlu ng dlung virusmenge therapie keine abnahme rochearboxed featuresengindd responsible business corporate culture built values integrity cour cluded six regional meetings local compliance officers age passion passionate improving patients reported implementation roches comprehensive lives courage take appropriate risks anticorruption programme marketing sales knowing manage risks competently compliance questionnaire furthermore roche line managers high standards integrity values also underpin cor signed assurance declaration confirming compliance porate responsibility employees comply commitment implementing controlling enforc laws regulations standards commitment responsi ing roches integrity standards ble behaviour goes beyond strict legal compliance demand conduct ethical open creates longterm roche requires partners suppliers third parties value stakeholders collaborate adhere high standards employees local managers responsible monitoring reporting compliance roche integrity standards integrity compliance responding quickly noncompliant behaviour roche business partners assist work introduced roche group code conduct guides employees anticorruption compliance questionnaire roche busi business behaviour worldwide clearly expresses roches ness partners expectations employer code conduct covers top ics corporate personal integrity social responsi fair correct behaviour competition mandatory bility compliance management provides information every roche employee updated behaviour find help advice raise compliance competition compliance questionnaire enables per concern sonnel affected competition law selfassess monitor behaviour well behaviour help comply roches standards business behaviour employees reporting additionally updated provide employees appropriate instruction guidance roche guidelines appropriate behaviour event support including mandatory series interactive elearning investigation authorities programmes roche leaders moreover obliged carefully consider business behaviour guidelines selecting new regulatory requirements involving transparency structing monitoring people reporting socalled sunshine act provisions us similar provisions countries require companies publically chief compliance officer supported network report payments contributions granted individual compliance officers group audit risk advisory line healthcare professionals institutions meet new management committed ensuring roche group reporting requirements roche set extensive internal code conduct consistently complied throughout reporting system monitor contributions patient company officer serves contact shareholders organisations health institutions healthcare professionals employees customers suppliers general public well ensure payments comply roches issues relating implementation compliance integrity standards code conduct reporting compliance roche also maintains worldwide network export control employees expected report code conduct viola compliance officers ensure conforms foreign trade tions either line manager local compliance officer control legislation chief compliance officer alternatively also encouraged report noncompliance issues anonymously strengthening compliance roche speakup line established addition already comprehensive compliance pro accessed languages countries addition gramme launched several initiatives focus ally material violation roches integrity standards must anticorruption good marketing practices reported business ethics incidents reporting system roche business report business reviewroche tolerate violations code conduct political donations employees violate code held accountable sanctioned appropriate way may include termina roche remains independent political affiliation tion employment received incident reports roche speakup line business ethics switzerland roche spends around million swiss francs reporting system investigating incident taking contributions donations various organisations safe corrective measures necessary employment con guard interests include payments interpharma tracts terminated account unethical behaviour economiesuisse scienceindustries swissholdings vari ous chambers commerce financial assistance trade unions donations political parties cantonal risk crisis management federal level donations political parties lowdou bledigit thousand franc sums overall less total risk management charter sets approach iden contributions donations tifying managing reporting internal external risks also use stakeholder feedback help manage social environ employees us make personal political contri mental ethical risks risk management charter butions roches good government committee available website along list principal risks genentechs genenpac voluntary bipartisan non business profit political action committees employees donated us dollars political campaigns com using consistent methodologies processes routinely mittees perform risk assessments levels organisation group risk report covers material risks annually discussed corporate executive committee web audit committee board directors regularly update risk management processes raise awareness roche group code conduct wwwrochecomcodeofconduct group policies positions guidelines wwwrochecom understanding risk throughout roche group policiesguidelinesandpositions drug development instance developing risk man risk management compliance wwwrochecom riskmanagementandcompliance agement methodology identify manage risk responsible marketing wwwrochecom could impact achievement development projects businessintegrityandresponsiblemarketing goals additionally established incident management teams throughout roche group ensure act quickly emergency teams regularly rehearse different crisis scenarios alerts escalation procedures strengthened business continuity management including establishing business continuity management task force ensure sites respond effectively cata strophic events importance efforts high lighted tsunami struck japan march widespread flooding thailand fall task force developing groupwide business continuity framework well guidelines local implementation work con tinue goal establishing strategies responses mitigate business continuity risks business review roche business report collaborations pharmaceuticals diagnostics roche business report research development collaborations pharmaceuticals committed million swiss francs invested research development diagnostics innovative pharmaceuticals pipeline one strongest industry january included projects involving new molecular entities additional indications line extensions existing medicines successful pharmaceuticals division filed major marketing applications including three new molecular entities gained major approvals announced positive results latestage clinical trials impactful diagnostics division launched tests delivering enhanced information medical decisionmaking new upgraded instruments key markets integrated pharmaceuticals diagnostics divisions collaborating projects across therapeutic areas interest roche roche business report research development key figures core r expenditures roche group millions chf cer sales pharmaceuticals millions chf cer sales diagnostics millions chf cer sales decrease due resource prioritisation savings operational excellence programme constant exchange rates average fullyear employees r roche group pharmaceuticals diagnostics patients clinical trials pharmaceuticals clinical development projects phase phase ii phase iii registration new molecular entities investigational new medicines line extensions additional indications new dosage forms marketed investigational medicines r strategy company world invests quest continue develop newer better diagnostic systems innovative healthcare solutions roche invested expand range tests perform already billion swiss francs r core basis decline one broadest vitro diagnostics industry currencyadjusted basis versus patients currently enrolled clinical trials people react differently medications due variations involving investigational currently marketed roche group genetic makeup identifying specific gene variants medicines plan maintain high levels r investment determine well certain treatment works tolerated continue move advanced projects key element research development efforts towards market launch ensuring steady flow promis drives personalised healthcare approach fitting ing new compounds latestage development also treatments defined groups patients success depends systematically leveraging combined capabili ties pharmaceuticals diagnostics divisions last years roche shown interweaving full explanation core results concept see finance report part annual report diagnostic pharmaceutical expertise increasingly paving roche business report research developmentunique structure fosters innovation research latestage early development development roche pharma pred genentech gred pharma medicines pmed roche partnering chugai pharmaceuticals roche diagnostics way personalised healthcare especially oncology pharmaceuticals diagnostics divisions also immunology neuroscience aim although different r processes two divisions provide healthcare professionals patients pow share research facilities technologies discoveries erful diagnostic tools targeted treatments based new working together internal projects unique insights diseases arise molecular level advantage sets roche apart companies diagnostic tools finding increasing use pharmaceutical diversity approaches research importantly close cooperation basis successful implementation personalised healthcare scientific breakthroughs likely occur scien strategy roche identified multitude potential biomark tists free tackle problems different angles ers used evaluate disease processes different ways roche scientists freedom believe stand disease diversity identify drug targets recognise diversity views cultures approaches promotes differences patients biomarker found creativity especially research early development pharma standardised diagnostic test developed dur research early development pred genentech research ing clinical trials prepared regulatory approval along early development gred roche diagnostics chu side drug gai operate independently within group forming hubs innovation network includes alliances today roche biomarker programmes dedicated bio outside partners universities research institutes marker teams every drug development pharmaceu biotech companies roche recognised ticals diagnostics divisions currently collaborating one industrys top partnering organisations together projects across therapeutic areas interest partners turn multiplicity ideas medical roche half projects oncology innovation one third current projects roches followed inflammationimmunology neuroscience virology pipeline come alliances find details metabolic diseases groups partnering activities accessing external innovation collaborative efforts improve prospects effective healthcare better use healthcare resources also efficiency bringing new therapies collaborate discovery diagnostic tests market commercialisation past years continuously improved biomarker characteristic measured evaluated indicator normal biological process disease process organisational technological framework cooperation response treatment research development roche business report number collaborations roche pharmaceuticals roche diagnostics improving development r pipeline personalised healthcare continue intensify efforts improve r produc tivity innovate drug development personal ised healthcare approach areas roche growing number new drug groups expertise molecular biology gives us clear com candidates diagnostic tests petitive advantage roche produced steady flow new drug candidates understanding heterogeneity diseases using diag diagnostic tests key therapeutic areas past nostic tools improve drug discovery clinical develop years leveraging strengths biotechnology vitro ment identify better drug targets select patient diagnostics end latestage pipeline included subgroups likely benefit treatments investigational new medicines new molecular entities core roche personalised healthcare nmes compared two seven targeted approach already proven effective reducing developed personalised therapies attrition rate drug candidates better profiling drug candidates early stages develop goal case produce new medicines ment first class best class commitment following improving clinical trials results better selection science translated positive results late endpoints stronger data stage clinical trials seven already formed increasing efficacy drug candidates clinical studies basis regulatory approvals filings results sug recruiting suitable patient subgroups gest many investigational medicines potential offer significant advances areas new allows us pursue projects might otherwise treatment options needed including breast lung skin stopped side effects lack significant efficacy cancer asthma adult childhood forms rheumatoid patient sample whole despite promising results arthritis patients end pharmaceuticals divisions clinical development portfolio phases iii registration included new molecular entities nmes year earlier additional indications filed marketing appli cations fewer three nmes roches pharmaceuti cals development pipeline shown pages report details available wwwrochecom diagnostics divisions r efforts resulted launch tests new upgraded instruments key mar roche business report research developmentroche companion diagnostics market late development disease area disease drug diagnostic test technology application virology cmv valcyte cmv viral load pcr monitoring hbv pegasys hbv viral load pcr monitoring antivirals hbv pegasys peginterferon hbsag levels immunoassay monitoring alfab mercksp hcv pegasys peginterferon hcv viral load pcr monitoring alfab mercksp hcv merictabine r hcv viral load pcr monitoring hcv danoprevir rg hcv viral load pcr monitoring hiv antivirals hiv viral load pcr monitoring hiv abacavir glaxosmithkline hlab genotype pcr screening oncology breast cancer herceptin lapatinib expression ihc ish selection glaxosmithkline gene amplification breast cancer tamoxifen erpr expression ihc selection hormonal therapies breast cancer pertuzumab rg expression ihc ish selection gene amplification breast cancer trastuzumab emtansine expression ihc ish selection tdm rg gene amplification cancer compound merck p mutations microarray selection colon cancer cetuximab merck kras mutations pcr selection colon cancer panitumumab amgen kras mutations pcr selection gastric cancer herceptin expression ihc ish selection gene amplification melanoma zelboraf braf mutation pcr selection nsclc tarceva egfr mutations pcr selection gefitinib astrazeneca nsclc onartuzumab met expression ihc selection metmab rg nsclc tg transgene muc expression ihc selection nsclc crizotinib pfizer alk ihc selection pancreatic cancer cp clovis oncology hent expression ihc selection sarcoma mdm antagonist p mutations pcr selection rg inflammation asthma lebrikizumab rg serum periostin immunoassay selection levels rheumatoid mabtherarituxan rf anticcp ab immunoassay selection arthritis others osteoporosis bonvivaboniva bcrosslaps immunoassay monitoring bisphosphonates pnp levels transplantation cellcept mpa levels immunoassay monitoring projects pharmaceutical companies disclosed confidentiality reasons available markets selection patients eligible firstline treatment black type market grey type development monitoring monitoring patients response particular treatment screening screening patients particular genetic variation hla associated hypersensitivity abacavir selection selection patients eligible particular treatment alk anaplastic lymphoma receptor tyrosine kinase anticcp antibodies cyclic citrullinated peptide braf bisoform rapidly growing fibrosarcoma oncogene cmv cytomegalovirus egfr epidermal growth factor receptor erpr estrogen receptorprogesterone receptor hbv hepatitis b virus hbsag hbv surface antigen hcv hepatitis c virus human epidermal growth factor receptor hiv human immuno deficiency virus hent human equilibrative nucleoside transporter hla human leucocyte antigen ihc immunohistochemistry ish situ hybridisation kras member ras family oncogenes mpa mycophenolic acid nsclc nonsmall cell lung cancer pcr polymerase chain reaction pnp procollagen type nterminal propeptide rf rheumatoid factor sp schering plough research development roche business report kets product launches enhance information avail results two clinical studies brim brim able guide treatment decisions drive efficiency clini demonstrated significant clinical benefit zelboraf cal laboratories research centres patients braf vmutated unresectable metastatic melanoma filed marketing applications number countries worldwide including australia new zea pharmaceuticals unmet land rates malignant melanoma high roche medical needs diagnostics braf test received ce mark certification august addition progress key investigational compounds roche also passed significant regulatory develop zelboraf vemurafenib rg plx codevel ment milestones several currently marketed medicines oped licence collaboration agreement overview found tables clinical trials approv roche plexxikon member daiichi sankyo als filings pages main regulatory group zelboraf designed target inhibit mutated clinical highlights programmes fields oncology forms braf protein found half cases immunology ophthalmology summarised melanoma deadliest aggressive form skin gether status updates promising investigational medi cer braf protein key component rasraf cines developed address viral diseases disorders pathway involved normal cell growth survival certain central nervous system mutations position v keep braf protein active state may cause excessive signalling pathway lead ing uncontrolled cell growth survival roche con oncology ducting broad development programme zelboraf includes testing combinations medicines currently new compounds development approved investigational roche genentech oncology addition obtaining positive results ten key companies well studies tumour types clinical trials filed marketing applications december collaboration bristol myers squibb advanced investigational new medicines us initiated phase iii study combined zelboraf yervoy european union zelboraf metastatic melanoma ipilimumab brafmutated metastatic melanoma approved us switzerland brazil vismodegib basal cell carcinoma form skin cancer pertuzu vismodegib filed us eu bcc skin cancer mab herpositive metastatic breast cancer addition november fda accepted filed genentechs new made significant progress development drug application vismodegib treatment adults investigational compounds projects aimed extend advanced basal cell carcinoma bcc surgery ing approved indications introducing new dosage forms considered inappropriate application granted pri marketed products avastin herceptin tarceva ority review status fda assigned action date march december roche submitted marketing zelboraf approved us metastatic melanoma application indication eu applications august us food drug administration fda based results pivotal phase ii erivance bcc approved zelboraf treatment braf mutation study showed vismodegib substantially shrank positive inoperable metastatic melanoma determined tumours healed visible lesions patients locally fdaapproved test fda simultaneously approved advanced bcc patients metastatic bcc vis roche diagnostics cobas braf test companion diagnostic modegib rg investigational oral targeted medi used identify patients treatment zelboraf cine designed selectively inhibit abnormal signalling appropriate approvals enabled genentech launch hedgehog pathway underlying molecular driver bcc new oral targeted cancer medicine us less four implicated cases roche develop months marketing application filed five ing vismodegib collaboration agreement curis years start clinical trials marketing approval bcc common type skin cancer generally also obtained switzerland brazil fourth quarter considered curable surgery however advanced december european medicines agencys committee medicinal products human use chmp unanimously recommended zelboraf granted full eu marketing certification vitro diagnostic product complies approval approvals recommendation based requirements use eu roche business report research developmentr projects therapeutic area roche genentech research early development late development discovery programmes phase ii projects phase iii registration projects projects ophthalmology ophthalmology virology metabolic metabolism neuroscience neuroscience inflammationimmunology inflammationimmunology oncology oncology bcc cause disfiguring debilitating effects hensive blockade signalling pathways pertuzumab patients ultimately lifethreatening studied current standard care herceptin plus chemotherapy herpositive breast stomach cancer pertuzumab filed herpositive breast cancer december submitted marketing applications us avastin regulatory update eu pertuzumab treatment previously untreated breast cancer july european commission approved herpositive metastatic breast cancer filings based extension avastin eu breast cancer label avastin may results cleopatra first randomised phase iii used combination xeloda capecitabine study pertuzumab compared combined pertuzu firstline treatment women metastatic breast cancer mab herceptin trastuzumab docetaxel chemotherapy chemotherapy options considered appro herceptin chemotherapy alone people previ priate september japanese authorities approved avas ously untreated herpositive metastatic breast cancer peo tin treatment inoperable recurrent breast cancer ple received pertuzumab combination herceptin november fda issued final decision revoking us chemotherapy experienced reduction risk approval avastin treatment metastatic breast disease worsening death progressionfree survival cer followed recommendation july fda pfs median pfs improved months months expert panel agencys initial notice revocation decem herceptin chemotherapy months pertuzu ber appeal roche removal mab herceptin chemotherapy indication fda decision affect medicines approved indications us elsewhere pertuzumab rg first new class targeted anticancer agents known dimerisation inhibitors ovarian cancer avastin received eu approval december designed block dimerisation pairing treatment women newly diagnosed advanced members family receptors dimerisa ovarian cancer based results phase iii icon tion believed play important role growth gog trials new approval allows use avastin formation several different cancer types mechanisms combination standard chemotherapy carboplatin action pertuzumab herceptin believed comple paclitaxel frontline treatment firstline treatment fol ment bind receptor lowing surgery advanced epithelial ovarian primary perito different regions thought provide compre neal fallopian tube carcinoma roche filed additional eu research development roche business report pharmaceuticals division major clinical trials product indication trial phase outcome aim actemra moderate severe rheumatoid actray iiib efficacy remission additional data arthritis actemra monotherapy vs safety combined actemra methotrexate actemra rheumatoid arthritis doubleblind ran noninferiority efficacy registration subcutaneous domised parallel subcutaneous formulation new dosage form formulation group study iii versus intravenous formulation actemra ankylosing spondylitis builder iii builder meet proto registration colspecified primary endpoint potential new indication programme terminated avastin recurrent platinumsensitive ovarian oceans iii significantly improved pfs registration cancer versus chemotherapy potential new indication avastin previously untreated advanced avaperl iii significantly improved pfs additional data nonsquamous nsclc maintenance treatment combination pemetrexed chemotherapy avastin herpositive metastatic breast averel iii study meet protocol registration herceptin cancer specified primary endpoint potential new indication dalcetrapib patients chd chd risk dalplaque iib data suggest possible exploratory equivalents beneficial vascular effects safety efficacy generally well tolerated dalcetrapib patients chd chd risk dalvessel iib endothelial function preserved exploratory equivalents change blood pressure safety efficacy generally well tolerated herceptin herpositive early breast cancer hannah iii comparable efficacy registration subcutaneous subcutaneous formulation new dosage form formulation versus intravenous formulation personalised medicine lebrikizumab adult asthma adequately control milly ii significantly improved proof concept led inhaled corticosteroids prebronchodilator fev personalised medicine lucentis diabetic macular edema compared ride rise iii rapid sustained improve registration sham injection year data ment vision significantly potential new indication improved eye chart scores versus baseline lucentis wet agerelated macular degenera harbor iii efficacy data support registration tion comparing alternative dosing initiation highdose new dosing regimen regimens monthly lucentis studies mg prn dosing discussed fda obinituzumab relapsed indolent nhl headto gauss ii higher response rates proof concept ga head comparison mabthera ga versus mabthera phase rituxan iii testing initiated ocrelizumab relapsingremitting multiple sclerosis randomised multi significant reduction disease dosefinding centre placebo activity maintained openlabel extension controlled study ii weeks onartuzumab nd rd line nsclc combination oamg ii final significantly improved pfs proof concept metmab tarceva data including os os personalised medicine pertuzumab herpositive metastatic breast cleopatra iii significantly improved progres registration cancer combination herceptin sionfree survival personalised medicine docetaxel tarceva metastatic nonsmall cell lung cancer eurtac iii significantly improved pfs potential new indication epidermal growth factor recep personalised medicine toractivating mutations firstline treatment versus chemotherapy trastuzumab herpositive metastatic breast tdmg ii significantly improved pfs proof concept emtansine cancer previously untreated personalised medicine tdm positive versus herceptin plus chemotherapy vismodegib advanced basal cell carcinoma erivance bcc objective response rate tumour registration singlearm trial shhg ii shrinkage lesion healing zelboraf previously untreated braf v brim iii significantly improved os registration mutationpositive metastatic pfs personalised medicine melanoma versus chemotherapy braf bisoform rapidly growing fibrosarcoma oncogene chd coronary heart disease fev forced expiratory volume volume air forced one second taking deep breath measure lung function human epidermal growth factor receptor nhl nonhodgkins lymphoma nsclc nonsmall cell lung cancer os overall survival time start treatment death pfs progression free survival time start treatment disease progression prn pro nata needed roche business report research developmentmarketing application august seeking approval avastin herceptin used treat almost one million patients use relapsed ovarian cancer eu filing based herpositive breast stomach cancer worldwide results phase iii oceans study results approved countries also presented annual meeting american society clinical oncology asco june show avastin tarceva approved genetically distinct type nsclc based regimen halved risk disease getting worse august eu authorities approved tarceva use women recurrent ovarian cancer data add patients locally advanced metastatic nonsmall cell lung growing body evidence supporting potential role cancer nsclc egfractivating mutations based avastin disease includes icon results phase iii eurtac study additional data gog trials avastin newly diagnosed ovarian cancer approval enables use tarceva firstline mono roche plans make decision whether seek us mar therapy people genetically distinct type nsclc keting approval avastin ovarian cancer final overall treatment tarceva setting shown survival results phase iii trials available expected triple number patients whose tumours shrink ovarian cancer sixth type cancer response rate nearly double progressionfree survival avastin approved time patients live without disease progressing com pared chemotherapy roche filed marketing application upon initial approval us metastatic colo indication swiss health authorities august rectal cancer avastin bevacizumab became first anti regulatory submission us planned angiogenic therapy made widely available treatment patients advanced cancer today avastin continues tarceva erlotinib oncedaily oral nonchemotherapy transform cancer care proven survival benefit treatment advanced metastatic nsclc advanced across several types cancer approved us pancreatic cancer shown potently inhibit europe treatment advanced stages colorectal epidermal growth factor receptor egfr protein involved nonsmall cell lung kidney cancer also available growth development cancers tarceva developed us countries treatment patients partnership osi pharmaceuticals member glioblastoma type brain tumour avastin approved astellas global group companies countries including eu japan breast cancer onartuzumab extends overall survival metpositive nsclc herceptin sc achieves positive phase iii results final data key phase ii trial presented asco october roche announced phase iii study hannah annual meeting june showed people metastatic achieved primary objectives demonstrating compara nsclc whose tumours high levels met determined ble efficacy new investigational subcutaneous sc roches tissuebased companion diagnostic lived twice mulation herceptin current intravenous iv infusion long without disease getting worse lived three times formulation women herpositive early breast cancer longer overall received onartuzumab plus tarceva herceptin sc uses halozyme therapeutics enhanze technol compared tarceva alone phase iii trial combined ogy enables injection large volumes medica onartuzumab tarceva second thirdline treatment tion skin sc formulation takes around five min patients metastatic metpositive nsclc metlung utes administer compared around minutes started january iv infusion subcutaneous administration may allow patients spend less time hospital receiving treatment onartuzumab metmab rg unique monovalent case intravenous delivery onearmed monoclonal antibody designed target met protein associated poor outcome many cancers herceptin trastuzumab humanised antibody designed compound blocks met signalling cancer cells binding target block function protein produced specifically cellsurface met receptor onartuzumab specific gene cancercausing potential herceptin acti investigated potential treatment metastic vates bodys immune system suppresses nsclc breast colorectal cancer target destroy tumour herceptin demonstrated unprecedented efficacy treating early advanced metastatic herpositive breast cancer well positive advanced metastatic stomach cancer since research development roche business report pharmaceuticals pipeline roche business report research development noitacidni tcudorptcejorp di tcejorp sruomut cigolotameh dna dilos tsinogatna mdm gr sruomut dilos bam rehitna gr sruomut dilos bam rfsc gr sruomut dilos rotibihni kemfic gr amonalem citatsatem bamumilipi faroblez gr recnac bam kaewt gr amonalem detatumfarb rotibihni farb gr sruomut dilos rotibihni laud kem far gr sruomut dilos bam fglpitna gr sruomut dilos bam dcitna gr sruomut dilos rotibihni kem gr sruomut dilos rotibihni kem gr recnac mdm gr sruomut dilos rotibihni tka gr recnac bam rfgfitna gr recnac yparehtonummi ruomut gr recnac etatsorp etagujnoc gurdydobitna gr recnac nairavo etagujnoc gurdydobitna gr amohpmyl dna sruomut dilos tsinogatna pai gr seicnangilam cigolotameh etagujnoc gurdydobitna ditna gr sruomut dilos cinegoignaitna gr sruomut cigolotameh etagujnoc gurdydobitna gr sruomut lailehtipe citatsatem bam rfgerehitna gr amoleym elpitlum etagujnoc gurdydobitna gr recnac etagujnoc gurdydobitna gr recnac etagujnoc gurdydobitna gr aimekuel citycophpmyl cinorhc rotibihni lcb gr amohpmyl ro sruomut rotibihni khc gr amohpmyl snikgdohnon ro sruomut dilos desolcsid ton gr recnac rotibihni kip gr recnac revil bam nacipylgitna gr recnac gnul llec llamsnon rotibihni kla uhc sruomut dilos rotibihni esanik ip uhc recnac eniccav recnac editpep tw uhc enildn recnac tsaerb citatsatem evitisopreh bamuzutrep gr recnac cirtsag citatsatem evitisopreh bamuzutrep gr recnac tsaerb ylrae evitisopreh mdt gr amonicrac llec lasab elbarepo bigedomsiv gr recnac tsaerb citatsatem bamtem bamuzutrano gr enilts recnac latceroloc citatsatem bamtem bamuzutrano gr sruomut dilos ag bam rfgeitna gr recnac dioryht yrallipap faroblez gr sruomut dilos rotibihni esanik ip gr sruomut cigolotameh dna dilos rotibihni rotmk ip gr enilts recnac latceroloc citatsatem bam lfgeitna gr mrof egasod cs amohpmyl snikgdohnon naxutirarehtbam gr tnemtaert tnavujda recnac tsaerb evitisopreh nitsava gr tnemtaert tnavujda recnac tsaerb evitagenreh nitsava gr tnemtaert tnavujda recnac tsaerb evitagenelpirt nitsava gr enildn recnac tsaerb citatsatem nitsava gr tnemtaert tnavujda recnac gnul llec llamsnon nitsava gr dionicrac ksirhgih nitsava gr enilts amotsalboilg nitsava gr senil elpitlum hguorht tnemtaert crc citatsatem nitsava gr enilts recnac nairavo nitsava gr mrof egasod cs recnac tsaerb evitisopreh nitpecreh gr sraey tnemtaert tnavujda cb evitisopreh nitpecreh gr recnac tsaerb ylrae evitisopreh bamuzutrep gr enilts snoitatum gnitavitcarfge clcsn avecrat gr tnemtaert tnavujda clcsn avecrat gr recnac tsaerb citatsatem decnavda evitisopreh etagujnoc gurdydobitna mdt gr enildr recnac tsaerb citatsatem evitisopreh etagujnoc gurdydobitna mdt gr enilts recnac tsaerb citatsatem evitisopreh etagujnoc gurdydobitna mdt gr recnac gnul llec llamsnon citatsatem bamtem bamuzutrano gr aimekuel citycohpmyl cinorhc ag bamuzutinibo gr despaler amohpmyl snikgdohnon tnelodni ag bamuzutinibo gr amohpmyl llec b egral esuffid ag bamuzutinibo gr eniltnorf amohpmyl snikgdohnon tnelodni ag bamuzutinibo gr noisufni tsaf amohpmyl snikgdohnon naxutirarehtbam gr recnac nairavo despaler nitsava gr enilts recnac tsaerb citatsatem evitisopreh bamuzutrep gr amonicrac llec lasab decnavda bigedomsiv gr amonalem citatsatem faroblez gr sesaesid enummiotua bam liitna gr amhtsa tsinogatna htrc gr amhtsa bam rplstitna gr sesaesid enummiotua bam liitna gr sitirhtra diotamuehr bam liitna uhc amhtsa ereves bamuzikirbel gr sitiloc evitareclu ateb bam uhr gr susotamehtyre supul cimetsys bamuzilatnor gr sitirhtra diotamuehr bam ahpla tlitna gr amhtsa bam emirp mitna gr sitilucsav detaicossaacna naxutirarehtbam gr mrof egasod cs sitirhtra diotamuehr armetcaorarmetca gr sitirhtra diotamuehr ylrae armetcaorarmetca gr bamumilada sv ridramd sitirhtra diotamuehr armetcaorarmetca gr airacitru cihtapoidi cinorhc rialox gr yhtaposehtne lynevus uhc c sititapeh tsinoga hrlt gr esaesid suoitcefni desolcsid ton gr c sititapeh enibaticirem gr c sititapeh riverponad gr c sititapeh rivubortes gr esaesid yendik cinorhc ni ksir ralucsavoidrac tsinogatna tac gr aimedipilsyd recudni acba gr sesaesid cilobatem desolcsid ton gr setebaid epyt tsinoga laud plgpig gr sesaesid cilobatem rotibihni dsh ateb gr esaesid ralucsavoidracemordnys yranoroc etuca bam nitceles pitna gr stneve ralucsavoidrac noitneverp yradnoces bam ldlxoitna gr setebaid epyt ni noitcuder ksir ralucsavoidrac razatilgela gr noitcuder ksir ralucsavoidrac sisorelcsorehta biparteclad gr setebaid epyt tlgs nizoflilgofot uhc ekorts cimehcsi etuca wodniw emit dednetxe esavitca gr sredrosid evitingoc tsinoga esrevni aabag gr msitua tsinogatna rotpecer v gr esaesid sremiehzla rotibihni ecab gr esaesid sremiehzla bamurenetnag gr esaesid sremiehzla rotibihni boam gr noisserped tsinogatna rulgm gr noisserped tnatsisertnemtaert tsinogatna rulgm gr esaesid sremiehzla bam atebaitna gr sisorelcs elpitlum gnittimergnispaler bamuzilerco gr sisorelcs elpitlum evissergorpyramirp bamuzilerco gr smotpmys evitagen ainerhpozihcs rotibihni ekatpuer enicylg nitrepotib gr dellortnoc yllamitpobus ainerhpozihcs rotibihni ekatpuer enicylg nitrepotib gr mrof egasod yrevileddeniatsus emdovrdma sitnecul gr yhporta cihpargoeg bam rotcafitna gr dedeen sa atan er orp gm dma sitnecul gr amede ralucam citebaid sitnecul gr aimena decudniyparehtomehc hcope uhc approved eu rgno roche andor genentechmanaged submitted eu chu chugaimanaged approved us chmp rg mabthera branded rituxan positive opinion eu us japan submitted us rg actemra branded roactemra personalised healthcare eu project amd agerelated macular degeneration mab monoclonal antibody bc breast cancer nsclc nonsmall cell lung cancer crc colorectal cancer rhu recombinant humanised dmardir diseasemodifying antirheumatic sc subcutaneous drug inadequate response dme diabetic macular edema rvo retinal vein occlusion ygolocno noitammalfni ygolonummi ygoloriv cilobatem ralucsavoidrac snc ygolomlahthpo srehto noitartsiger iii esahp ii esahp esahp roche business report pharmaceuticals pipeline pharmaceuticals pipeline roche business report seitenzahlpharmapipelineengindd ddnigneenilepipdrraehcorpharmaceuticals pipeline research development roche business report noitacidni tcudorptcejorp di tcejorp sruomut cigolotameh dna dilos tsinogatna mdm gr sruomut dilos bam rehitna gr sruomut dilos bam rfsc gr sruomut dilos rotibihni kemfic gr amonalem citatsatem bamumilipi faroblez gr recnac bam kaewt gr amonalem detatumfarb rotibihni farb gr sruomut dilos rotibihni laud kem far gr sruomut dilos bam fglpitna gr sruomut dilos bam dcitna gr sruomut dilos rotibihni kem gr sruomut dilos rotibihni kem gr recnac mdm gr sruomut dilos rotibihni tka gr recnac bam rfgfitna gr recnac yparehtonummi ruomut gr recnac etatsorp etagujnoc gurdydobitna gr recnac nairavo etagujnoc gurdydobitna gr amohpmyl dna sruomut dilos tsinogatna pai gr seicnangilam cigolotameh etagujnoc gurdydobitna ditna gr sruomut dilos cinegoignaitna gr sruomut cigolotameh etagujnoc gurdydobitna gr sruomut lailehtipe citatsatem bam rfgerehitna gr amoleym elpitlum etagujnoc gurdydobitna gr recnac etagujnoc gurdydobitna gr recnac etagujnoc gurdydobitna gr aimekuel citycophpmyl cinorhc rotibihni lcb gr amohpmyl ro sruomut rotibihni khc gr amohpmyl snikgdohnon ro sruomut dilos desolcsid ton gr recnac rotibihni kip gr recnac revil bam nacipylgitna gr recnac gnul llec llamsnon rotibihni kla uhc sruomut dilos rotibihni esanik ip uhc recnac eniccav recnac editpep tw uhc enildn recnac tsaerb citatsatem evitisopreh bamuzutrep gr recnac cirtsag citatsatem evitisopreh bamuzutrep gr recnac tsaerb ylrae evitisopreh mdt gr amonicrac llec lasab elbarepo bigedomsiv gr recnac tsaerb citatsatem bamtem bamuzutrano gr enilts recnac latceroloc citatsatem bamtem bamuzutrano gr sruomut dilos ag bam rfgeitna gr recnac dioryht yrallipap faroblez gr sruomut dilos rotibihni esanik ip gr sruomut cigolotameh dna dilos rotibihni rotmk ip gr enilts recnac latceroloc citatsatem bam lfgeitna gr mrof egasod cs amohpmyl snikgdohnon naxutirarehtbam gr tnemtaert tnavujda recnac tsaerb evitisopreh nitsava gr tnemtaert tnavujda recnac tsaerb evitagenreh nitsava gr tnemtaert tnavujda recnac tsaerb evitagenelpirt nitsava gr enildn recnac tsaerb citatsatem nitsava gr tnemtaert tnavujda recnac gnul llec llamsnon nitsava gr dionicrac ksirhgih nitsava gr enilts amotsalboilg nitsava gr senil elpitlum hguorht tnemtaert crc citatsatem nitsava gr enilts recnac nairavo nitsava gr mrof egasod cs recnac tsaerb evitisopreh nitpecreh gr sraey tnemtaert tnavujda cb evitisopreh nitpecreh gr recnac tsaerb ylrae evitisopreh bamuzutrep gr enilts snoitatum gnitavitcarfge clcsn avecrat gr tnemtaert tnavujda clcsn avecrat gr recnac tsaerb citatsatem decnavda evitisopreh etagujnoc gurdydobitna mdt gr enildr recnac tsaerb citatsatem evitisopreh etagujnoc gurdydobitna mdt gr enilts recnac tsaerb citatsatem evitisopreh etagujnoc gurdydobitna mdt gr recnac gnul llec llamsnon citatsatem bamtem bamuzutrano gr aimekuel citycohpmyl cinorhc ag bamuzutinibo gr despaler amohpmyl snikgdohnon tnelodni ag bamuzutinibo gr amohpmyl llec b egral esuffid ag bamuzutinibo gr eniltnorf amohpmyl snikgdohnon tnelodni ag bamuzutinibo gr noisufni tsaf amohpmyl snikgdohnon naxutirarehtbam gr recnac nairavo despaler nitsava gr enilts recnac tsaerb citatsatem evitisopreh bamuzutrep gr amonicrac llec lasab decnavda bigedomsiv gr amonalem citatsatem faroblez gr sesaesid enummiotua bam liitna gr amhtsa tsinogatna htrc gr amhtsa bam rplstitna gr sesaesid enummiotua bam liitna gr sitirhtra diotamuehr bam liitna uhc amhtsa ereves bamuzikirbel gr sitiloc evitareclu ateb bam uhr gr susotamehtyre supul cimetsys bamuzilatnor gr sitirhtra diotamuehr bam ahpla tlitna gr amhtsa bam emirp mitna gr sitilucsav detaicossaacna naxutirarehtbam gr mrof egasod cs sitirhtra diotamuehr armetcaorarmetca gr sitirhtra diotamuehr ylrae armetcaorarmetca gr bamumilada sv ridramd sitirhtra diotamuehr armetcaorarmetca gr airacitru cihtapoidi cinorhc rialox gr yhtaposehtne lynevus uhc c sititapeh tsinoga hrlt gr esaesid suoitcefni desolcsid ton gr c sititapeh enibaticirem gr c sititapeh riverponad gr c sititapeh rivubortes gr esaesid yendik cinorhc ni ksir ralucsavoidrac tsinogatna tac gr aimedipilsyd recudni acba gr sesaesid cilobatem desolcsid ton gr setebaid epyt tsinoga laud plgpig gr sesaesid cilobatem rotibihni dsh ateb gr esaesid ralucsavoidracemordnys yranoroc etuca bam nitceles pitna gr stneve ralucsavoidrac noitneverp yradnoces bam ldlxoitna gr setebaid epyt ni noitcuder ksir ralucsavoidrac razatilgela gr noitcuder ksir ralucsavoidrac sisorelcsorehta biparteclad gr setebaid epyt tlgs nizoflilgofot uhc ekorts cimehcsi etuca wodniw emit dednetxe esavitca gr sredrosid evitingoc tsinoga esrevni aabag gr msitua tsinogatna rotpecer v gr esaesid sremiehzla rotibihni ecab gr esaesid sremiehzla bamurenetnag gr esaesid sremiehzla rotibihni boam gr noisserped tsinogatna rulgm gr noisserped tnatsisertnemtaert tsinogatna rulgm gr esaesid sremiehzla bam atebaitna gr sisorelcs elpitlum gnittimergnispaler bamuzilerco gr sisorelcs elpitlum evissergorpyramirp bamuzilerco gr smotpmys evitagen ainerhpozihcs rotibihni ekatpuer enicylg nitrepotib gr dellortnoc yllamitpobus ainerhpozihcs rotibihni ekatpuer enicylg nitrepotib gr mrof egasod yrevileddeniatsus emdovrdma sitnecul gr yhporta cihpargoeg bam rotcafitna gr dedeen sa atan er orp gm dma sitnecul gr amede ralucam citebaid sitnecul gr aimena decudniyparehtomehc hcope uhc approved eu rgno roche andor genentechmanaged submitted eu chu chugaimanaged approved us chmp rg mabthera branded rituxan positive opinion eu us japan submitted us rg actemra branded roactemra personalised healthcare eu project amd agerelated macular degeneration mab monoclonal antibody bc breast cancer nsclc nonsmall cell lung cancer crc colorectal cancer rhu recombinant humanised dmardir diseasemodifying antirheumatic sc subcutaneous drug inadequate response dme diabetic macular edema rvo retinal vein occlusion ygolocno noitammalfni ygolonummi ygoloriv cilobatem ralucsavoidrac snc ygolomlahthpo srehto noitartsiger iii esahp ii esahp esahp roche business report pharmaceuticals pipeline pharmaceuticals pipeline roche business report seitenzahlpharmapipelineengindd ddnigneenilepipdrraehcortrastuzumab emtansine tdm extends pfs activating immune cells attack cancer cells herpositive breast cancer inducing direct cell death september promising phase ii proofofconcept data presented annual meeting european society medical oncology esmo results tdmg immunology ophthalmology study showed patients previously untreated positive metastatic breast cancer received tdm lived regulatory approvals filings along new data significantly longer disease control progres phase iii clinical trials confirmed benefits sionfree survival pfs experienced fewer side effects actemraroactemra rheumatoid arthritis ra typical chemotherapy patients received standard lucentis people common types eye disease addi treatment herceptin trastuzumab plus docetaxel che tion currently ten investigational new medicines motherapy recruitment completed phase iii development chronic progressive inflammatory trial emilia comparing tdm treatment versus combined autoimmune disorders rheumatoid arthritis ulcerative xeloda lapatinib patients whose herpositive meta colitis systemic lupus erythematosus asthma static breast cancer progressed previous therapy results expected second quarter plan lebrikizumab improves lung function adult asthma use data basis marketing applications europe positive results announced august milly phase ii us second half proofofconcept study investigational medicine leb rikizumab showed treatment lebrikizumab resulted trastuzumab emtansine tdm rg novel anti significant increase fev measure lung function bodydrug conjugate combines therapeutic effect adults asthma whose symptoms inadequately con trastuzumab active substance herceptin intracel trolled inhaled corticosteroids lular delivery dm highly potent chemotherapy agent specifically target herpositive tumours trastuzumab lebrikizumab humanised monoclonal antibody antibody component blocks signals make herposi developed treatment moderate severe persistent tive cancer cells aggressive sends message asthma designed bind specifically interleukin patients immune system destroy cancer cells also il thought play key role airway inflam delivers dm chemotherapy agent directly tumour cells mation hyperresponsiveness obstruction experienced induce cell death asthma patients addition contributing features asthma il increases levels periostin protein obinituzumab increases overall response rate measured blood test milly patients high relapsed nhl pretreatment periostin levels experienced greater improve final results phase ii study gauss comparing single ment lung function lebrikizumab patients low agent obinituzumab singleagent mabtherarituxan periostin levels results support investigation rituximab patients relapsed indolent nonhodgkins lebrikizumab potential personalised medicine patients lymphoma nhl announced first half suffer moderate severe uncontrolled asthma presented annual meeting american society roche developing periostin immunoassay companion hematology december study showed obinituzu diagnostic test used support phase iii studies mab increased overall response rate orr patients lebrikizumab planned start early cd indolent nhl common type blood cancer compared mabtherarituxan two phase iii registration actemraroactemra approved childhood arthritis trials firstline diffuse large bcell lymphoma dlbcl april fda approved actemra treatment active firstline indolent nhl initiated phase iii pro systemic juvenile idiopathic arthritis sjia also known juve gramme also includes ongoing studies assessing nile rheumatoid arthritis rare debilitating form arthritis obinituzumab chronic lymphocytic leukemia cll children aged two years older european commission relapsedrefractory indolent nhl approved roactemra indication august approv als based positive data phase iii tender study obinituzumab rg ga type ii glycoengineered showed treatment actemraroactemra anticd monoclonal antibody developed po significantly improve signs symptoms sjia actemra tential treatment nhl cll specifically roactemra given alone combination meth designed enhance destruction cancerous b cells otrexate patients sjia roche business report research developmenteffective ra used alone may twoyear phase macular edema following retinal vein occlusion rvo lllb study actray showed actemraroactemra lucentis designed bind inhibit vegf protein effective used people ra believed play critical role formation new blood respond methotrexate mtx results demonstrated vessels angiogenesis hyperpermeability leakiness actemraroactemra alone comparable clinical effi vessels wet amd blood vessels grow cacy actemraroactemra plus mtx diseasemodifying retina leak blood fluid causing rapid damage antirheumatic drug widely prescribed people ra macula central portion retina rvo angiogenesis people given mtx adequately respond hyperpermeability lead macular edema swelling treatment experience adverse events require thickening macula macular degeneration mac drugs help control inflammation ular edema may lead impairment loss vision lucentis discovered genentech retains commercial rights noninferiority new subcutaneous formulation july us novartis exclusive commercial rights rest chugai announced positive results phase iii trial world new subcutaneous formulation actemra ra patients showing noninferiority efficacy new formulation compared current intravenous formulation subcuta virology neous injection convenient patients healthcare providers require intravenous access takes expanded portfolio investigational less time administer intravenous infusion sub medicines hepatitis c cutaneous formulation developed chugai japan hepatitis market evolving meet different jointly chugai roche outside japan filings needs people infected hepatitis c virus hcv planned future treatment options likely include interferonfree well interferoncontaining triple quadruplecombina actemra tocilizumab known roactemra europe tion therapy regimens roche several oral directacting result research collaboration chugai osaka univer antiviral agents latestage development hepatitis c sity codeveloped globally roche chugai nucleoside polymerase inhibitor mericitabine rg part genentech actemraroactemra first interleukin il nered pharmasset protease inhibitor danoprevir receptorinhibiting monoclonal antibody approved treat ra rg following acquisition late anadys il immune system protein plays pivotal role pharmaceuticals nonnucleoside polymerase inhibitor inflammation process associated ra certain setrobuvir danoprevir phase ii development lip decision autoimmune conditions actemraroactemra available made mericitabine phase ii lip decision made us eu japan countries treat investigated combinations interferon ment ra alone combination methotrexate free interferoncontaining regimens results phase ii disease modifying antirheumatic drugs also approved trials inform svr dauphine matterhorn propel us eu treatment systemic juvenile idiopathic jumpc expected setrobuvir currently arthritis japan treatment castlemans disease evaluated phase ii study combination cur polyarticular systemic juvenile idiopathic arthritis rent standard care roches pegylated interferon pegasys ribavirin copegus strategic agreement roche lucentis filed dme us merck initiated first series clinical trials december fda accepted filed genentechs supple examine novel combinations marketed investigational mental biologics licence application sbla approval medicines chronic hepatitis c dynamo phase ii study lucentis treatment diabetic macular edema dme evaluating combination mericitabine mercks victrelis assigning action date august sbla based pegasys copegus patients responded results two phase iii studies rise ride prior therapy began late showed patients received lucentis experienced sig nificant rapid sustained improvement vision compared received placebo sham injections lucentis ranibizumab vascular endothelial growth factor vegf inhibitor approved fda treatment lifecycle investment point decision commence latestage neovascular wet agerelated macular degeneration amd development leading submission marketing applications research development roche business report pharmaceuticals division major regulatory approvals product clinical data supporting filing indication dosage form country avastin ribbon metastatic breast cancer combination xeloda eu avastin international phase iii data inoperable recurrent breast cancer firstline treatment japan japanese phase ii data avastin icon gog metastatic ovarian cancer following surgery eu actemra lithe year data rheumatoid arthritis reduction inhibition progression usa roactemra joint damage improvement physical function tender systemic onset juvenile idiopathic arthritis usa eu switzerland herceptin toga advanced herpositive stomach cancer patients japan candidates curative surgery herceptin noah japan noah data herpositive breast cancer neoadjuvant andor adjuvant japan eu public domain treatment mabthera prima advanced follicular lymphoma firstline maintenance usa rituxan following induction treatment rituxanmabthera plus chemotherapy rave wegeners granulomatosis microscopic polyangiitis usa severe forms ancaassociated vasculitis pegasys japanese phase iiiii data chronic hepatitis b japan clinical studies pegasys prefilled pen pegasys proclick autoinjector eu usa switzerland tarceva saturn nonsmall cell lung cancer firstline maintenance china chemotherapy eurtac published clinical metastatic nonsmall cell lung cancer epidermal growth eu experience factor receptoractivating mutations firstline treatment pa japanese phase ii data pancreatic cancer amenable curative resection japan combination gemcitabine xeloda data public domain advanced recurrent stomach cancer patients japan candidates curative surgery xeloxa adjuvant colon cancer combination oxaliplatin switzerland zelboraf brim brim brafmutated inoperable metastatic melanoma usa switzer land brazil metabolism cardiovascular diseases coronary heart disease studies presented major european medical conference support roche ten compounds development metabolic compounds safety profile potential slowing athero cardiovascular diseases two promising compounds sclerotic plaque progression novel modes action dalcetrapib treatment coronary heart disease atherosclerosis dyslipidemia dalcetrapib rg jtt licensed japan tobacco aleglitazar reduction risk heart attack stroke novel cholesteryl ester transfer protein cetp modulator patients type diabetes shown raise levels good functional high density lipoprotein cholesterol hdlc potentially promoting dalcetrapib development update removal cholesterol blood vessels ongoing august roche announced results two exploratory phase iii daloutcomes study involving patients phase iib studies investigating effects dalcetrapib investigating whether dalcetrapib reduces risk heart atherosclerotic disease progression dalplaque attack stroke patients experienced recent vascu lar function dalvessel patients risk acute coronary syndrome roche business report research developmentpharmaceuticals division major regulatory filings product clinical data supporting filing indication dosage form country avastin icon gog metastatic ovarian cancer switzerland oceans avf ovarian cancer relapsed eu herceptin noah japan noah data herpositive breast cancer neoadjuvant andor adjuvant eu switzer public domain treatment land japan lucentis rise ride diabetic macular edema us mabthera rave antineutrophil cytoplasm antibody ancaassociated switzerland rituxan vasculitis rate faster minute infusion schedule rituxan combination usa chemotherapy treatment nhl roactemra tender systemic onset juvenile idiopathic arthritis switzerland tarceva eurtac metastatic nonsmall cell lung cancer epidermal growth switzerland factor receptoractivating mutations firstline treatment pegasys japanese phase iiiii data chronic hepatitis b japan pertuzumab cleopatra herpositive metastatic breast cancer eu usa vismodegib erivance bcc shhg adult patients advanced basal cell carcinoma usa eu surgery considered inappropriate zelboraf brim brim brafmutated inoperable metastatic melanoma eu usa switzerland australia nz brazil aleglitazar development update neuroscience patients type diabetes td die heart disease stroke inability control blood roches pharmaceuticals pipeline includes ten novel com glucose aleglitazar rg oral medicine pounds development central nervous system disorders potential first therapy specifically reduce cardio representing high unmet medical need advanced vascular risk people td global phase iii programme investigational medicines phase iii clinical testing alecardio started investigating whether schizophrenia multiple sclerosis addition aleglitazar reduce cardiovascular morbidity mortality several compounds earlier stages development poten patients td suffered recent acute coro tial treatments alzheimers disease nary syndrome event addition enrolment com pleted phase ii study alenephro evaluating bitopertin development update benefits aleglitazar people td mild mod bitopertin rg formerly known glyt glycine erate renal kidney impairment reuptake inhibitor codeveloped globally chugai phase iii programme initiated late aleglitazar represents new approach reducing cardiovas three trials investigating bitopertin combination anti cular risk people td activates two key proteins psychotics treatment negative symptoms schizo regulate metabolic signalling pathways com phrenia another three trials patients suboptimally promised td peroxisome proliferatoractivated receptors controlled positive symptoms schizophrenia phase ii alfa gamma ppar ppar ppar activation proofofconcept study bitopertin monotherapy thought increase fat combustion lower triglycerides patients acute exacerbations schizophrenia began increase hdlc good cholesterol potentially slowing first quarter first new class medicines advance atherosclerosis activation ppar improves glu bitopertin potential become first compound cose metabolism combats insulin resistance type treatment negative symptoms schizophre nia addition bitopertin combination current treat ments potential treat suboptimally controlled posi research development roche business report tive symptoms little increase side effects novel tion study designed detect reduction cognitive decline mode action could also valuable therapeutic applica provide proof clinical activity blaze biomarker tions psychiatric disorders imaging study designed measure changes brain amyloid plaque load using pet ocrelizumab maintains reduction ms activity weeks ocrelizumab rg investigational humanised mono diagnostics better clonal antibody designed selectively target cdpositive treatment decisions b cells believed play critical role multiple sclerosis ms ocrelizumab phase iii clinical programme roche invested million swiss francs developing consists two studies opera ii patients relaps novel diagnostic tests platforms designed provide bet ingremitting multiple sclerosis rrms one oratorio ter information treatment decisions drive efficiency patients primaryprogressive multiple sclerosis ppms clinical laboratories research centres programme initiated enrolling patients three trials results phase ii study ocrelizumab patients rrms common clinical product launches form disease presented major medical confer ence october study showed significant reduc r efforts resulted tests new upgraded tion disease activity previously reported weeks instruments devices introduced key markets see maintained weeks treatment rrms charac table important approvals launches terised infrequent acute exacerbations full partial helping broaden differentiate offering summa recovery attacks approved therapy rised treat ppms much rarer form disease affects ms screening cervical cancer april us food drug administration approved differential targeting amyloid alzheimers disease cobas hpv test identifying women highest risk current research alzheimers disease ad suggests cervical cancer fdaapproved test iden accumulation amyloid beta abeta peptides brain tifies human papillomavirus hpv genotypes twelve hallmark disease main cause loss memory pooled result genotypes individually ad patients currently developing two monoclonal responsible cervical cancers thereby antibodies designed bind abeta helps detect disease missed current screening methods phase ii clinical testing represent two different approaches shown athena study one largestever diagnos reducing amyloid burden brain tics registration trials cobas hpv test currently piloted sweden primary cervical cancer screening gantenerumab rg fully human antibody originating research collaboration morphosys binds neu personalising cancer treatment tralises diseaserelevant aggregated forms abeta second half ce marks obtained three accumulate plaques brain inter automated molecular tests assist tailoring treatment fere braincell functioning phase study using positron melanoma colorectal lung cancer patients emission tomography pet imaging demonstrated treat cobas braf test companion diagnostic ment gantenerumab resulted reduction brain amy melanoma medicine zelboraf also approved loid possibly immunological clearance mechanism fda august see involving glial cells ongoing phase ii trial scarlet road cobas egfr test identifies patients nonsmall cell designed identify patients early prodromal ad lung cancer might eligible firstline treatment treat substantial damage brain epidermal growth factor receptor egfr inhibitors occurred tarceva rg humanised antibody licensed ac immune binds forms abeta including plaques brain two phase ii studies began evaluating treatment certification vitro diagnostic product complies rg patients mild moderate ad abby cogni requirements use european union roche business report research developmentdiagnostics division major product launches area product name description market timeline instrumentsdevices laboratories cobas c clinical chemistry module highvolume laboratories eu us q optiview detection system benchmark tissue staining instruments eu us q ultimate reagent upgrade benchmark ultra tissue stainer expedited ww q access slide processing iscan coreo scanner enables digital viewing tissue slides eu q diabetes accuchek mobile nextgeneration stripfree blood glucose meter eu ap q care accuchek fastclix oneclick lancing device supporting blood glucose monitoring eu q life sciences lightcycler nano desktop unit realtime pcr analysis ww q gs flx system upgraded sequencing instrument kit ww q seqcap ez choice microarrays sequence capture ww q seqcap ez exome v cgh microarrays highresolution analysis genomic variations ww q cghsnp cedex bio bioprocess analyser biotherapeutics manufacturing ww q testsassays oncology immunoassay early ovarian cancer detection eu q hpv pcr test cervical cancer screening us q braf pcr test identifies patients eligible treatment zelboraf eu us q kras pcr test supports therapy selection colorectal cancer eu q egfr pcr test supports therapy selection lung cancer eu q dual ish tissue test supports diagnosis herpositive breast cancer us q ihc primary ihc tissue testing including bcl lymphomas erg ww q antibodies prostate cancer h pylori precursor gastritis ulcers mlh colorectal cancer pr breast cancer b algorithm analytical imaging software supports diagnostics us q virology hbsag quant immunoassay hepatitis b therapy monitoring eu q infectious cmv avidity immunoassays help distinguish primary nonprimary eu q diseases toxo igg avidity cytomegalovirus infections pregnancy mpx pcr blood screening test detects hiv hcv hbv eu q dpx pcr test detects parvovirus b hav human plasma us q cmv pcr test monitor cytomegalovirus infections eu q hiv pcr dual test detects two hiv subtypes eu q hcv pcr test measure hepatitis c viral load us q hcv qual quant pcr tests detect active hcv infections measure viral load eu q hlab pcr test screen hiv patients hypersensitivity abacavir eu q metabolism vitamin total immunoassay measures vitamins eu q hgh immunoassay supports diagnosis human growth hormone eu us q disorders pth immunoassay monitor patients chronic kidney disease eu q maltoseindependent accuchek aviva blood glucose meter us q test strip chemistries japan gs gtype hla primer gene sequencing primer sets research immune ww q sets system black type new productfirst market launch grey type new productlaunch additional markets ap asiapacific eu european union us united states ww worldwide bcl bcell lymphoma gene braf bisoform rapidly growing fibrosarcoma oncogene cgh comparative genomic hybridisation egfr epidermal growth factor receptor erg ets etwentysixrelated gene gs genome sequencer hav hepatitis virus hbv hepatitis b virus hbsag hepatitis b surface antigen hcv hepatitis c virus human epididymis secretory protein e human epidermal growth receptor hiv human immunodeficiency virus hla human leucocyte antigen hpv human papillomavirus ihc immunohistochemistry ish situ hybridi sation kras member ras family oncogenes mlh mutl homolog gene pcr polymerase chain reaction pr progesterone receptor pth parathyroid hormone snp single nucleotide polymorphism toxo igg toxoplasmaspecific immunoglobulin g antibodies research development roche business report cobas kras test identifies mutations kras gene cobas analysers stands making broadest occur colorectal cancers immunoassay menu available single platform predictive nonresponse antiegfr antibody therapies cetuximab panitumumab bringing pcr analysis researchers june roche launched lightcycler nano compact three assays run cobas platform offer affordable desktop unit realtime polymerase chain reac unmatched levels sensitivity tion pcr analysis genotyping gene expression studies applications nano complements larger june fda approved inform dual ish test instruments lightcycler series putting realtime pcr helps verify whether patient breast cancer capabilities within reach many researchers around likely respond therapy herceptin first fully world automated tissuebased assay able detect gene central part chromosome single tissue slide test allows pathologists easily identify variations ongoing r priorities gene expression throughout tumour increasing accu racy diagnosis test combined roche diagnostics maintained significant r investments b ihc test companion algorithm b analyt developing technologies products launch ical imaging software making roche company offer coming years efforts focused five areas high ing complete diagnostic workflow solution labora lighted tories novel biomarkers improved monitoring hepatitis b therapy continued engage biomarker research february quantitative hbsag immunoassay hepatitis pharmaceutical partners drawing breadth technolo b monitoring received ce mark certification test uses gies protein genetic tissuebased testing primary elecsys technology measure levels hepatitis b virus sur focus oncology virology inflammatory cardiovascular face antigen serum plasma enables doctors metabolic diseases roche diagnostics collaborated assess sustained treatment success pegasys roche pharmaceuticals projects including interferonbased medicines helping tailor therapy addressing met expression periostin levels see individual needs pages pharmaceutical partners companion diagnostics making blood glucose monitoring safer easier september maltoseindependent test strips laboratory coagulation testing accuchek aviva blood glucose meter received clearance made significant investments novel solutions testing us fda new strips crossreact maltose patients blood coagulation hemostatic factors hence offer increased safety maltose interference plan introduce new instrument mid high rare occasions result falsely elevated blood sugar readings throughput testing laboratories together comprehen clearance paves way launch new sive assay menu complementing leading portable coagu accuchek portfolio us november started roll lation testing systems use home doctors offices nextgeneration accuchek mobile launches acquisition verum diagnostica leader platelet australia netherlands smaller predecessor function testing strengthen roches coagulation blood glucose meter provides tests continuous portfolio tape eliminating handling single test strips allinone diabetes care systems broadening laboratory offering development pipeline emphasises integrated solutions expanded cobas series fully automated modular ana facilitate personalised diabetes management reduce lysers central laboratories launch cobas number devices steps needed monitor blood glu c clinical chemistry module us eu capable cose deliver insulin solo micropump instance performing tests per hour modules inno features semidisposable insulin pump patch remote vative reagent manager provides uninterrupted workflow control allow micropump continuously deliver insu highvolume testing following launch seven immuno lin based patients needs scheduled launch assays including vitamin total test elecsys test menu eu addition development distribution roche business report research developmentdiagnostics division key product launches planned area product name description market instrumentsdevices laboratories cobas coagulation analyser mid highthroughput testing eu benchmark special stains fully automated tissue stainer ww ventana iscan ht highthroughput scanner enables digital viewing tissue slides ww pointof cobas b multiblood lipid glucose pointofcare analyser eu care cobas b blood gas analyser critical care us diabetes accuchek nano small blood glucose meter requiring coding test strips us care smartview accuchek mobile nextgeneration stripfree blood glucose meter eu accuchek combo insulin pump remote control blood glucose meter us solo micropump insulin micropump remote control blood glucose meter eu testsassays oncology immunoassay early ovarian cancer detection us p histology ihc tissue test cervical cancer early detection eu us er ihc tissue test diagnosis breast cancer us gs gtype tetcbl gene sequencing primer sets leukemia research ww kras runx primer sets virology cmv pcr test monitor cytomegalovirus infections us infectious ctng pcr test detect chlamydia gonorrhoea infections us diseases metabolism vitamin total immunoassay measures vitamins us black type new productfirst market launch grey type new productlaunch additional markets eu european union us united states ww worldwide products initially scheduled launch filed fda launched soon approved cbl casitas bcell lymphoma gene ctng chlamydia trachomatisneisseria gonorrhoeae er estrogen receptor gs genome sequencer human epididymis secretory protein e ihc immunohistochemistry kras member ras family oncogenes p protein pinka pcr polymerase chain reaction runx runtrelated transcription factor tet member tet family oncogenes agreement reached dexcom november en exclusive partnership dna electronics devel able roche integrate dexcoms leading continuous glucose opment electrochemical dna sequencer collabo sensing technologies future insulin delivery systems ration ibm develop nanoporebased single molecule sequencer october roche licensed several technologies highvolume dna testing arizona state university columbia university developing platforms expect first directly read sequence nucleic acids single dna combine molecular tests womens health virology molecule passes nanopore technologies blood screening platforms bring greater automation help advance development project ibm throughput cost efficiency molecular diagnostics bloodscreening laboratories simplifying workflows reducing equipment complexity development sched accessing external innovation uled continue access external innovation targeted acquisitions nextgeneration sequencing licensing agreements exchange intellectual property remained focused developing faster effi academic alliances significant means strengthening cient sequencing systems enable even broader study expanding global innovation network col human genome genetic causes disease maintained laboration agreements roche explores ideas research development roche business report worlds leading scientists translating science clinically global market leader providing customised automation differentiated medications novel diagnostics recent workflow solutions vitro diagnostic ivd testing survey boston consulting group measured large commercial hospital laboratories mtm tissue partnering functions major pharmaceutical companies diagnostics company leading portfolio ivds early biotech companies ranked roche one best compa detection diagnosis cervical cancer verum diagnostica nies partner highest average score specialised laboratory coagulation testing division across attributes particular strengths deal structure also entered number new research technology flexibility executive leadership alliance management man collaborations including development pcr biomarker ufacturing expertise also nominations top tests merck clovis tissuebased companion diagnostics partner survey respondents bayer pfizer automated target enrichment bio medical research caliper acquisitions licensing agreements academic alliances roche partnering signed new agreements includ ing three product transactions covering four products total roches innovation network expanded year research technology collaborations addition thanks new collaborations academic institutions around product outlicensing agreements signed special world pred developed academic network team created source open innovation collaborating partners academic institutions nations earliest stages academic institutions americas asia europe added several leading external partners establish product development partner academic institutions expanding innovation network ships among teams main transactions programme umbrella agreements including collaboration ptc therapeutics sma foun hebrew university jerusalem harvard uni dation giving roche access firstinclass treatment versity four new agreements pending europe us spinal muscular atrophy devastating disease effecting chil china collaborations already produced tangible dren adolescents leading genetic cause mortal results two projects brought inhouse joint intellec ity infants toddlers acquisition anadys pharma tual property created roche formed strategic part ceuticals brought setrobuvir roche virology pipeline nership cancer prevention research institute usbased company also developing ana oral texas cooperation swedish life science initiative smallmolecule inducer innate immunity currenly phase uppsala bio threeway research agreement har clinical trials may prove useful treating hcv vard university chinese biotechnology organisation chronic infections cancer addition roche entered biobay agreement evotec ag germany codevelop commercialise evt compound may slow pro since inception pred established translational gression alzheimers disease r hubs academic institutions academic alliances group operating france us canada switzer genentech partnering completed three product transactions land netherlands singapore hubs signed six new research technology collaborations programmes projects way yearend agreements support work gred include pred opened r institute france serves inlicensing agreement option purchase single entry point academic collaborations across multiple usbased forma therapeutics covering new cancer target disease areas scientific disciplines similarly transla agreement nominated alliance year tional research hub opened zurich foster collaborations vivo leading healthcare industry information provider roche pharmaceuticals roche diagnostics inlicensing agreement usbased array biopharma adds academic researchers swiss federal institute second compound important cancer target chk technology eth university zurich university inhibitor greds development portfolio hospital zurich roche diagnostics signed licensing agree ments well acquiring pvt probenverteiltechnik germanypvt lab systems us mtm laboratories ger many early verum diagnostica germany pvt roche business report research developmentconducting responsible r ethical practices clear policies procedures place maintain safe transparent clinical trials high ethical standards r activities including provid ing regular ethics training employees clinical trials determine safety efficacy new medi cines clinical value diagnostic tests also pro employees encounter ethical dilemma work vide critical information costeffectiveness treat resolve colleagues contact ment diagnostic test treatment improves quality global ethics liaison office consults internal life information shared regulatory authorities external experts seek solution office payers order gain marketing approval ultimately received resolved enquiries reimbursement patients received stateoftheart care free treatment participants company established roche scientific ethics rochesponsored clinical trials addition advisory group seag offer advice counsel broad participating medical centres received educational financial range ethical matters panel meets annually made medical support independent external experts appointed roche fields genetics bioethics law sociology well clinical trials lay members representatives patient advocacy groups seag provided valuable input roches new preapproval access policy policy provides global number clinical trials approach enabling access medicines prior commercial number healthcare approval patients lifethreatening diseases centres involved unable participate clinical trials seag also advised number patients development principles conducting stem cell phase iiv clinical trials research roche numbers include patients genentech studies initiated prior merger bioethics roche follows strict policies processes ensure safety wellbeing legal rights people participating roche integrates ethical practices scientific research clinical trials including international conference har responsible accountable transparent approaches monisation good clinical practice ichgcp guidelines development diagnostics therapeutics com ensure compliance standards train monitor pany published several position papers r activi audit involved clinical trials including contract ties areas genetics stem cells animal research research organisations cros conduct manage trials routinely review update positions poli behalf perform trials countries cies research involving either humans animals taking plan market medicine tested account scientific developments public concerns maintain searchable database clinical trials www roche charter genetics ensures excellence social clinicaltrialsgov wwwrochetrialscom details roche responsibility genetic research believe right clinical trials also available international fed every individual selfdetermination privacy confidenti eration pharmaceutical manufacturers associations ality regarding collection use genetic information clinical trials portal us national institutes health roche pursue creation genetically identical global registry human beings roche ensures sharing clinical data encouraging stem cells application drug research offer tremen scientists publish results work medical journals dous potential establish disease models help identify present scientific medical congresses potential novel targets screen compounds roche con roche scientist contributed scientific publications ducts stem cell research inhouse external col including articles appeared highimpact journals laborations means improving drug development nature cell science new england journal medicine reducing animal testing potential serious adverse events research development roche business report roche personalised healthcare personalised healthcare works average five ten patients receive given therapy actually benefit may experience side effects thanks advances new research disciplines scientists better understanding disease molecular level result able distinguish patient subgroups different causes drive traditionally regarded single disease oncology led efforts identify genetic characteristics affecting patients responses particular therapies identifying clinically significant patient subgroups key element personalised healthcare strategy marries new diagnostic techniques advances biotechnology effort develop targeted efficient therapies strategy systematically implemented every stage new product development roche aimed helping us better understand disease diversity identify differences patients identify best drug targets improve quality efficiency r efforts develop biomarkers diagnostic tests rroocchhee bbuussiinneessss rreeppoorrtt rreoscehaer pche rasnodn adliesveedl ohpemaletnhctare rochearboxed featuresengindd clinical trials goal establish treatment strategies animals used research roche contract research incurable inadequately treated severe diseases organisations central nervous system cardiovascular metabolic disor ders viral diseases roche also exploring potential mice rats therapeutic use stem cells incurable inadequately treated severe diseases rodents rabbits dogs animal welfare primates roche longstanding commitment maintaining high standards animal welfare take public concern animal research seriously wherever possible seek alterna tives use animals computer simulation vitro testing using differentiated cells stem cells rather animals enables researchers produce human antibodies first immunise laboratory animals even animal research remains indispensable biomedical research scientific legal reasons regulatory authori roche signatory swiss charter animal welfare ties require healthcare companies test safety adopted interpharma association efficacy new drugs animals used researchbased pharmaceutical companies switzerland humans roche committed acting ethically applying charter commits us consistently high standards ani highest standards care animals used scientific pro mal welfare programme auditing employee train cedures including conforming laws regulations ing stakeholder dialogue promotion rs approach industry standards management external contractors used animals research decrease number animals used cros web performing research behalf increased com pared approximately animals roches pharmaceuticals diagnostics pipelines wwwrochecompipeline used mice rats personalised healthcare wwwrochecompersonalisedhealthcare group policies positions guidelines wwwrochecom policiesguidelinesandpositions animals used research clinical trials patient safety wwwrochecomclinicaltrials aspire use animals possible without putting wwwrochecommanagingmedicationsafety new products technologies wwwrochecom risk reliability validity research test results innovationandtechnologies following rs approach ethical standards wwwrochecomethicalstandards genetics bioethics wwwrochecomgeneticsandbioethics reduce number animals needed animal welfare wwwrochecomanimalwelfare refine tailoring procedures minimise pain discom fort replace methods involve animals use cells tissues animals roche ethics committee animal welfare spon sored third roche rs award recognises employ ees contractors commitment rs approach improving animal welfare three categories labora tory animal care management scientific progress surgery methodology training techniques awardwin ning projects included development computeraided prediction tool used avoid toxicological effects reduce number animal experiments project research development roche business report manufacturing sites roche business report manufacturing procurement manufacturing sites reliable maintained steady supply medicines tests instruments patients health professionals around world agile supported development projects new medicines supplied around global clinical trials study medication ecofriendly reduced co emissions logistics pilot projects switching alternative modes transportation road sea ferry instead air roche business report manufacturing procurement key figures manufacturing sites pharmaceuticals diagnostics joint sites employees manufacturing logistics portfolio medicines tests instruments pharmaceuticals diagnostics divisions operate global tinuously build adapt networks optimise perfor manufacturing supply networks play vital role mance best serve product pipelines respond new every stage product lifecycle starting early product market opportunities changes quality regulatory development manufacturing process design divi requirements sions work towards common aim deliver highquality prod ucts meet quality compliance requirements procurement teams create sustainable value ensuring optimal financial performance regardless world efficient acquisition delivery goods services roche product made apply set rigorous accordance quality compliance standards safety quality ethical labour health environmental stan teams support business units achieving goals dards roches business based innovation con capturing savings reinvested business manufacturing pharmaceuticals network pharmaceutical manufacturing network contract manufacturing organisations cmos complement comprises sites europe americas asia including manufacturing capabilities help us transition drug three chugai sites japan employees facilities candidates pipeline quickly efficiently make different medicines commercial supply outsource various phases drug production cmos clinical trials synchronise supply demand global create capacity access specialised capabilities optimise production planning final delivery medicines cus operating costs roche dedicated team manages tomers synthesise drug substances small mole aspects relationships cmos assuring product cules chemically others biologics produced quality sustainability operational financial perfor sophisticated biotechnological processes employ living mance part roches emerging markets strategy organisms transform drug substances sterile work governments partners strengthen drug products vials prefilled syringes solid expand local manufacturing capabilities order improve dosage products like tablets capsules dualregister access healthcare see access emerging countries sites enables us produce key pharmaceutical pages products one site thereby reducing risk supply interruptions better balancing production roche global leader biopharmaceutical production capacity approximately global biologic production capacity roche business report manufacturing procurementmanufacturing sites roche group mannheim kaiserb aua gse stl penzberg graz rotkreuz burgdorf segrate reykjavik clarecastle hillsboro vacaville south san francisco indianapolis brab nr ca hn bf uo rr gd legans utsunomiya oceanside tucson florence shanghai fujiedaukima toluca puerto rico singapore rio de janeiro biologics drug small molecules sterile drug solid dosage pharma substances drug substances products drug products assays diagnostics instruments diabetes care per december reagents drawing decades experience biologics manufacturing objectives performance manufacturing organi challenging process involves use living cells sations primary objectives support roches highly sensitive even slightest changes envi growing r pipeline improve manufacturing net ronment various factors nutrient solution timing work processes maintaining strong focus equipment determine yield amounts unwanted supply chain reliability product quality continued products even structure active ingredient foster culture continuous improvement share best produced process steps illustrated next practices across sites improvements introduced include continue follow production copies biological additional common standards producing small molecules products biosimilars support regulatory activities help make site performance transparent ensure brought market safely effectively see establishing best practices materials flows productive biosimilars maintenance biologics production improved scrap handling practices resulting lower manufacturing costs manufacturing procurement roche business report higher yields improved manufacturing processes fda approval zelboraf illustrates effectiveness products pulmozyme nutropin integrated global manufacturing network basel switzer land provides drug substance segrate italy finalises pro supporting pipeline delivery pharmaceutical manu duction legans spain packages drug facturing supported development projects new medi cines included supplying investigational products investments invested new facilities upgraded approximately global clinical trials involved tens others executing major engineering projects thousands patients notable among efforts ensure meet growing global demand medicines accelerated development manufacturing processes prepared future product launches continued melanoma medicine zelboraf see r rapid scale transform manufacturing facility solid dosage forms chemistry innovative tablet formulation based shanghai local global supply operation early microprecipitated bulk powder helped roche develop facility received fda ema approvals produce launch zelboraf five years start clinical xeloda us eu markets approvals among trials including making available patients within five days first issued international company china biotech production process process steps performed sterile temperaturecontrolled conditions extensive testing throughout process assures product quality cell line culture fermentation purification formulation filling packaging specific human genes production cells cell culture trans protein separated drug substance inserted bacterial removed master ferred progressively biomass cells mulated stable dos mammalian cells create cell bank cultured larger bioreactors special culture medium waste age form sterile liquid unique master cell line liquid growth medium nutrient medium added products leading powder filled vials yields target ther transferred larger ves unique composition pure solution centri syringes packed apeutic protein mas sels cells multiply optimised cell fugation purification shipping ter cell bank frozen line enables produc concentration steps storage tion desired protein specific desired drug substance protein roche business report manufacturing procurementin june roche completed tp expand penzberg germany majority instruments tests manufactured million swiss francs project upgraded expanded inhouse allows us maintain cost quality advan sites therapeutic protein development production tages leverage proprietary technologies special exper capacity project entailed renovating five buildings tise general use external manufacturers access intel adding production lab facilities biotech manufacturing lectual property unique technologies enabling us focus development november completed construction core competencies optimise efficiencies costs new technical r facility basel cost million example outsource production handheld blood swiss francs facility houses labs offices smallscale glucose meters large work stations consumables production lines used develop innovative processes technologies turning active ingredients tablets objectives performance reorganised operations capsules injectable medicines across diagnostics division establish single integrated function driving excellence manufacturing supply chain challenges agility resilience supply chain management procurement since global supply chain tested march disastrous pursued agenda delivering cost savings build earthquake japan interrupted chugais utsunomiya opera ing capabilities sustainable high performance quality tions september fire damaged site cost supply reliability realised aggres segrate response roche chugai immediately set sive costsaving target contributed divisions supply chain taskforces worked close cooperation overall improvement profitability also advanced three health authorities ensure continued product supply performance initiatives regulatory compliance sites fully recovered asset management invested facilities expand incidents resumed production capacity alleviate bottlenecks mitigate supply risks transferred product manufacturing consolidate capac operational excellence part operational excel ity increase utilisation reduce costs also consoli lence programme announced late ongoing dated supplier base ensure optimal alignment evaluation manufacturing network divested techni external suppliers internal capacities cal development small molecule manufacturing operations rightfirsttime manufacturing introduced systemwide located boulder usa corden pharma corden con programme improve performance systematically elimi tinue supply us commercialscale peptides chemi nating errors driving improvements rightfirsttime rates cal active ingredients important medicines also sold quality cost sites programme also served clinical plant oceanside usa gilead sciences forum sharing best practices across network ongoing programme consolidate clinical process devel design quality manufacturability developed tools opment operations divestments along mea methodologies ensure establishment robust sures lowered number people employed pharma production processes applied product develop ceutical operations us ment projects across division expect changes pay dividends form improved quality manu facturability new products brought market diagnostics supporting pipeline delivery investments diagnostics network diagnostics operations network comprises operations maintained reliable supply growing manufacturing sites global supply hubs europe increasingly diverse portfolio instruments assays includ us network handles aspects procurement ing product launches see table meet manu facturing logistics broad portfolio diagnostics growing global demand support launches diabetes care products portfolio includes invested facilities equipment undertook tests use associated instruments translates major capital projects include building pro duction different instruments ranging large compounding filling facility mannheim germany work stations handheld meters reagent kits expanding cell fermentation facility penzberg reagent control components consuma used production immunoassays bles pipettes cuvettes dedicated function pro vides quality regulatory support global operations operational excellence part operational excel network lence programme consolidated diagnostics r oper ational functions several sites second half manufacturing procurement roche business report reducing logistics environmental footprint alternative modes transportation canada frankfurt amsterdam kaiseraugst us kaiseraugst athens rio de janeiro carbon dioxide co emissions switching transportation products air freight either road sea transport reduced co emissions roughly pilot projects began transfer chemical raw materials ana pharmaceuticals diagnostics divisions contin lytical services mannheim penzberg also started ued invest quality systems address changing regu set infrastructure instrument production blood gas latory requirements also took proactive steps drive sus electrolyte monitoring systems rotkreuz switzerland tainable quality compliance manage risks including support move production graz austria globally harmonising quality systems activities transfer production insulin delivery systems endtoend quality management programme roche burgdorf switzerland mannheim also track pharmaceuticals continuously optimise production pro cesses strengthening product quality oversight suppliers quality compliance cmos every patient right safe medicines reliable diag pharmaceutical operations successfully managed nostic test results robust comprehensive quality man site inspections health authorities worldwide agement systems designed comply relevant laws diagnostics operations passed inspections regulations based recent quality norms standards including cgmp ich iso also collaborated health authorities industry groups provide thought leadership technical quality requirements roche example served expert con cgmp current good manufacturing practices ich international sultant fda setting approval standards medicines conference harmonisation technical requirements regis labelled use companion diagnostic test roche also tration pharmaceuticals human use iso international organi zation standardization helped advance understanding use good manufac roche business report manufacturing procurementturing practices among activities chairing joint fdaemapda ich q implementation conference hosting training sessions health authority inspectors biologic drug substance aseptic processing facilities addition provided input guidance docu ments proposed regulations laws green logistics roche committed incorporating sustainable business practices areas supply chain improve processes also means ensuring patient safety product quality pharmaceuticals division established green logistics project reduce environmental footprint transpor tation raw materials finished products project includes several pilots study alternative modes transpor tation notable among changing air freight refrigerated road sea ferry transport coldchain prod ucts shipped switzerland greece change reduced carbon dioxide co emissions roughly packaging significant amount insulating material longer required similarly diagnostics division realised significant reduc tions co emissions using alternative modes transpor tation innovations packaging example emissions reduced shipments us france switching air freight truck sea transport italy changing road transport rail cut divisions co emissions co emissions freight ship ments germany great britain cut using temperaturecontrolled trailers first year tracking reductions co emissions waste production energy usage logistics revealed several challenges data availability quality including differences methodologies among roche sites measuring energy usage work develop reliable methods collecting consistent data throughout organisation information see environmental stewardship pages manufacturing procurement roche business report rroocchhee ppeerrssoonnaalliisseedd hheeaalltthhccaarree roche making personalised healthcare reality researchers across globe making enormous progress understanding diseases root causes knowledge leading dramatic increase identification biological targets fight many diseases roche combine strong inhouse research capacities knowhow latest external advances science identify potential drug candidates biomarkers pharmaceuticals diagnostics one roof roche crucial edge comes diagnostics research assay technically validated clinically validated ivd assay ivd assay integrating knowledge pharma ceuticals diagnostics divisions efficient way drawing throughout r process develop targeted early research approval new therapies diagnostic tests medicines use patients close crossdivisional pharma research development commercialisation cooperation r scientists distinguishes roche companies rroocchhee bbuussiinneessss rreeppoorrtt mroacnhuef apcetrusroinnga laisnedd p hroecaultrhecmareent rochearboxed featuresengindd procurement procurement key operating function roche pro audit critical suppliers compliance sustain curement teams work closely roche business units ability requirements conducted audits help achieve goals capture savings direct spend area audits service providers reinvested business teams carefully manage expen audits conducted china india russia eastern ditures third parties including direct expenses items europe majority suppliers audited met exceeded raw materials active pharmaceutical ingredients minimum sustainability requirements audit findings instruments components spare parts contract manufac requiring corrective action related mainly labour conditions turing indirect expenses services temporary health safety excessive work hours continue work labour travel credit cards laboratory supplies closely suppliers concerned ensure corrective actions taken offer training sustainability awareness pharmaceuticals division finished centralising pro mitigate risk information see environmental curement functions forming various departmental groups stewardship pages single procurement team simplify processes align strate gies leverage buying power together diagnostics together psci members adopted unified procurement team established structured process sustainability audit protocol protocol sets minimum stan major direct indirect expenditures shifting glob dards enabling sharing audit findings reduces ally aligned approach local execution expect gen duplication audits suppliers started share erate cost savings larger purchasing volumes selfassessment reports psci members stronger strategic relationships suppliers pilot joint supplier audits using new psci protocol roche realised significant savings direct indi rect expenses particularly temporary labour conferences web events travel also negotiated global corporate credit card agreement implemented gen roche product portfolio wwwrochecomproducts biotech production wwwrochecombiotechnologyproduction erate substantial savings pharmaceutical supply chain initiative wwwpharmaceuticalsupplychainorg supplier engagement wwwrochecomstakeholderengagement supplier code conduct wwwrochecom partnering suppliers rochesuppliercodeofconductpdf seek build mutually beneficial relationships sup pliers encourage suppliers continuously improve working together cost reduction financial stability ensuring integrated risk management reducing combined environmental footprint demanding ethical behaviour promoting innovation require suppliers commit sustainability prin ciples roche supplier code conduct code incor porates principles pharmaceutical supply chain ini tiative psci roche founding member sets standards ethics labour health safety environment related management systems addition educate employees ways encourage sustainability among suppliers manufacturing procurement roche business report patients received treatment innovative roche medicines roche business report marketing distribution demonstrating value collaborated payers stakeholders developing systematic methods evaluating cost efficacy new medicines diagnostics improving access continued pilot differential drug pricing programmes several leading roche therapies egypt brazil china emerging countries strengthening healthcare worked governments organisa tions strengthening healthcare systems education healthcare professionals supporting hospital infrastructure improving outcomes funded programmes increase awareness understanding disease improve screening early diagnosis foster treatment compliance rehabilitation roche business report marketing distribution key figures core marketing distribution md expenditures roche group millions chf cer sales pharmaceuticals millions chf cer sales diagnostics millions chf cer sales decrease due tight cost management savings operational excellence programme increase reflecting higher launch costs several business areas along increased distribution costs following earthquake japan constant exchange rates average fullyear employees md roche group pharmaceuticals diagnostics answering demand medical innovation improved demonstrating value patient access healthcare challenge requires cooperation many different segments society break focus medical value products starting throughs science enabling roche improve lives earliest stages development objective com patients transform delivery medicine truly mercialise medicines diagnostic tests effective however must identify meet differing improve length quality patients lives bring needs various patients customers collaboration clear medical economic benefit healthcare systems partnership society approach increase emphasis regional local work closely payers demonstrate value activities deliver value improve access maintain high products services turn gain appropriate reim standards patient care safety objective deliver bursement market access collaborate various innovative pharmaceuticals diagnostics offer signifi authorities policymakers develop health technology cant medical economic social value existing options assessments htas models systematically eval uating costs benefits efficient use new medicines patients everywhere seeking better healthcare diagnostics aim sustain medical innovation meet options better access healthcare market access medical need help address mounting pressure strategy addresses need focusing growing healthcare budgets demand emerging developing markets effective ness strategy reflected strong sales growth example order attain appropriate reimbursement key roche medicines diagnostics despite challeng new oncology test identifies patients carrying ing conditions many markets mutated braf gene german affiliate roche diagnos tics prepared comprehensive hta demonstrating im information performance products proved performance roche test compared found business review pages finance methods hta showed switching test fewer report part annual report pages false results improves treatment outcomes patients reduces costs payers laboratories roche business report marketing distributionsimilarly diagnostics divisions uk affiliate collaborated reduce limit growth healthcare budgets face national institute health clinical excellence mounting pressure public finances nice providing input institutes establishment diagnostics assessment programme goal pro access developed countries mote rapid consistent adoption diagnostic tests even developed countries advanced healthcare sys clinically costeffective improve treatment tems many people afford treatment patients choice evaluating diagnostics potential insurance still might able pay treatment improve key clinical decisions fully reimbursed roche joined stakeholders early cofound recognising disparity roche maintains number green park collaborative gpc international initiative patient assistance programmes improve access exploring feasibility developing guidelines medicines united states example genentech access design clinical studies meet needs hta organi solutions helps insured patients navigate complexities sations payers expect programme improve health insurance cover outofpocket costs associated relevance clinical research accelerate patient access medicine genentech access care new drugs technologies foundation gatcf provides free medicines patients uninsured rendered uninsured meet certain finan furthermore actively participated joint initiative cial medical criteria genentech access solutions tween pharmaceutical industry santsuisse asso helped fully insured underinsured un ciation swiss health insurers develop basic principles insured patients access issues alone gatcf pro future htas switzerland reached consensus pro vided medicine uninsured patients posals valuation health technologies objec needed products tive improving quality transparency healthcare system well increasing efficiency thus reducing access emerging countries costs demand healthcare services growing worldwide emerging countries however infrastructure funding needed meet demand varies considerably improving access healthcare sustainability healthcare systems roche actively supports governments emerging countries efforts access remains systemic cause healthcare inequality strengthen public healthcare systems strategy focus requires cooperation governments healthcare provid running local clinical trials working accelerate regulatory ers media patient groups companies nongovern approvals supporting market development fund pro mental organisations roche committed making contri grammes raising disease awareness collaborate devel bution effort working stakeholders enable oping appropriate treatment policies provide education improve access healthcare associated services globally training healthcare professionals along activities seek sustainable effective ways expand access med help develop healthcare infrastructure icines diagnostics also tackle wider problems lack disease awareness low use diagnostics limited cost medicines low rates diagnostic testing healthcare infrastructure budgets order improve also barriers treatment emerging countries improve health conditions generally affordability reach people need conduct ing pilot programmes differential pricing treatments continued work payers establish cancer hepatitis c chronic illnesses commercial arrangements improve access prod arrangements sell products public healthcare ucts include flexible options volumebased dis system prices lower established markets return counts price capping cost sharing pay performance assurances product reimbursement exploring also maintained patient assistance programmes help effectiveness access models include people obtain insurance copay support instances discount schemes drugs prescribed public partial supply medicines start continue treatment healthcare systems patientfocused solutions particularly important second brands government contracts maintaining access products financial contracting local companies fill package distribute crises many governments sought brands marketing distribution roche business report topselling pharmaceuticals millions chf product mabthera avastin herceptin lucentis pegasys rituxan sales growth cer active substance rituximab bevacizumab trastuzumab ranibizumab peginterferon alfaa indications nonhodgkins lymphoma colorectal cancer breast herpositive breast wet agerelated macular hepatitis b c chronic lymphocytic cancer nonsmall cell cancer advanced degeneration macular leukemia rheumatoid lung cancer kidney positive stomach cancer edema following retinal arthritis ancaassoci cancer ovarian cancer vein occlusion ated vasculitis glioblastoma constant exchange rates average fullyear us sales lucentis marketed outside united states novartis roche business report marketing distributiontopselling diagnostics millions chf accuchek aviva nano cobas e cobas c cobas taqman ventana ihc reagents product accuchek cobas e modules cobas c modules cobas ampliprep immunohistochemistry monitoring systems modular analytics modular analytics cobas taqman situ hybridisation elecsys cobas integra sales growth cer market segment blood glucose monitoring immunoassays clinical chemistry virology hepatitis b advanced tissue staining hepatitis c hiv business area diabetes care professional diagnostics professional diagnostics molecular diagnostics tissue diagnostics marketing distribution roche business report seek partnerships governments emerging coun china less women herpositive breast tries develop tailored programmes cancer receive herceptin address many challenges meet local pricing service distribution participation needs limiting access treatment roche china started several objective sustainable business model balances programmes association chinese governmental institu needs stakeholders commitment improve tions nonprofit organisations included improving access emerging markets testing quality running patient education pro grammes august worked cancer foundation piloted differential pricing programmes several china establish patient assistance programme eli leading therapies egypt brazil ukraine china gible patients pay first half treatment cancer countries egypt programme includes local pack foundation support roche provides sec aging branding alternative formulation pegasys ond half ensuring women receive full benefit treat hepatitis c treatment egypt one topselling ment although early already seen significant markets patients received treatment crease number women gaining access herceptin since working brazil government roche nego tiated discount mabthera drug used treat patients access least developed countries nonhodgkins lymphoma condition drug worlds least developed countries ldcs suffer high reimbursed previously mabthera available est levels disease weakest healthcare systems many patients covered private insurance paying outof face large budget constraints critical shortage health pocket result significant expansion access care professionals facilities well low levels reaching patients standing causes prevention treatment disease access healthcare programme highlights details available website people reached rural south patients received free medicines children supported nine african africa transnetphelophepa genentech access countries india monitoring healthcare train since inception care foundation diabetes partnership novo nordisks changing diabetes children programme infants tested hiv countries roche file hivaids technology agreements amplicare initiative enforce patents medicines reached companies ldcs ssa countries onsite technical help manufacture generic versions roches hiv medicine saquinavir month secondments granted treatment courses antiinflu healthcare professionals partici employees contributing skills enza medicine tamiflu donated pated pilot online university courses expertise help make difference countries need oncology educare initiative health services ldcs ssa countries partnership iaea roche business report marketing distributionto address inequalities use expertise support providing valueadded services modernisation healthcare systems rather donating money form programmes partnerships provide research development innovative medicines diag sustainable patent pricing policies nostics cornerstone contribution tackling research diseases high unmet medical need healthcare challenges believe however education training knowledge transfer capacity building responsibility leading healthcare company help patients holistic approach healthcare put establishing operating programmes beyond action providing numerous valueadded services scope single entity reason roche collaborates develop healthcare infrastructure raise disease awareness local governments nonprofit organisations host screening programmes educate healthcare profession companies deliver healthcare patients facilitates als provide patient support networks experience exchange education healthcare profes sionals emphasis local engagement also work governments payers increase healthcare productivity make efficient use financial partnership novo nordisk changing resources services support negotiations diabetes children programme expanded nine countries payers price drugs tests overriding con addition india ethiopia kenya approxi cern help people get better faster remain healthy live mately children enrolled programme longer productive lives provides insulin diabetes care supplies well basic education training families healthcare work increasing healthcare awareness ers date clinics established health healthcare awareness education important care professionals trained patients wellbeing proper medical diagnosis treat ment mind publish newsletters magazines amplicare programme started diagnostics division periodicals aimed helping people make healthy choices continues supply hiv viral load tests lowest prevent disease activities include organising dis possible price ssa countries several countries south ease awareness campaigns association patient groups america asia worked health ministries local hospitals conducting screening programmes funding agencies secure financing amplicares early campaigns seek increase gen infant diagnosis hiv initiative yearend partici eral awareness also advance early detection dis pating countries selffinancing programme eases breast lung colon cancer rheumatoid accessing global funds resources third arthritis hepatitis osteoporosis diabetes party funders remained dependent unitaid funds addition renegotiated funding agreement organised multidisciplinary workshop ovarian clinton health access initiative global healthcare cancer rome national observatory womens organisation aims strengthen integrated health systems health patients group acto attendees included developing world expand access care treat national regional authorities representatives regional ment hivaids malaria tuberculosis institutions scientific societies clinicians media event highlighted need increased cooperation amongst patents fundamental requirement business model stakeholders establishment centres excellence investing complex expensive risky process greater awareness understanding ovarian innovation however aware patents present cancer including importance regular medical check one many barriers providing basic medical care ups worlds poorest countries reason roche file new patents enforce existing patents roche med roche cooperation four patient associations argen icines disease ldcs defined united tina published reflejos del alma reflections soul nations lowincome countries defined world increase awareness breast cancer book tells stories bank file enforce patents antiretroviral hiv women breast cancer demonstrates medicines hardhit subsaharan african ssa coun possible face disease positive attitude tries consequently generic versions roche medicine life goes even breast surgery chemotherapy andor produced distributed countries without radio therapy possible relapses book message applying license hope reached thousands women argentina marketing distribution roche business report valueadded services develop health run rehabilitation education material sessions run disease offer therapy awareness campaigns adherence program promot e li fh ee sa tylt lh ey p w e l l k e p thr eo rv aid pe inis foe ra mse io n e w ke e l people l patients host screening organise patient programs support programs provide codevelop education training economic models healthcare professionals payers collaborate enable clinical therapy guidelines trial participation establish healthcare support managed networks care programs strengthen hospital establish patient registries lab infrastructure breast cancer leading cause female cancer mortality events demonstrate food exercise impact blood new cases every year glucose levels us roche funded diabetes hands foundations big blue test awareness campaign every year world diabetes day roche diabetes care con inforces importance exercise managing diabetes ducts numerous campaigns raise awareness encourage people take action prevent diabetes activities offering patient support resources include blood glucose screening campuses also produce information patients family members public venues germany switzerland france spain italy caregivers help understand diseases treatment accompanied workshops healthy food sporting options proper use products maintain web roche business report marketing distributionsites provide latest information diagnostic tests contributions patient organisations treatment options including monitoring managing poten tial side effects websites serve portals resource disease awareness centres patient support programmes provide access general education trained nurses along strategies living disease workshops seminars addition operate counselling centres telephone help meetings lines coordinate services improve treatment compliance educational rehabilitation grants treatment adherence online resources include wwwaccuchekconnectcom projects offers personal discovery tools resources living diabetes well clinical evidence case studies healthcare professionals osteoporosis preven around world provided forum discussing tion care wwwbonivacom supports roche prescrip trends challenges healthcare advocacy tion therapy boniva safety information myboniva program personal resource centre helps compli july held rheumatoid arthritis ra advocacy training ance similarly wwwherceptincom offers guidance workshop patient groups also provided support treated herceptin herpositive breast ra patient groups attend eu parliamentary event gastric cancer information financial support among help raise awareness social economic impact resources disease working patient groups roche continued longstanding collaboration euro patient groups important partners roche give us pean patient network medical research health egan insight challenges facing patients families holding seventh joint strategy workshop patient share interest helping patients understand organisations health authorities academia industry ask manage condition changing role patient groups ing improve patient involvement stages patients passive active informed users research clinical development roche egan trans increased level engagement lated workshop discussions ten strategic recommenda tions make reality transparency essential endeavours publicly declare patient group relationships provide short furthering professional development description activities website also acknowl help healthcare professionals improve patient care pub edge financial nonfinancial support guided lishing broad range education training materials european federation pharmaceutical industries asso diseases treatment options safety concerns product use ciations efpia general healthcare topics addition medical teams organise symposiums educate support physicians using variety channels collaborate education example established virtual medical conferences training materials services often developed glob connected annual meeting american society ally adapted administered locally cultural sensitiv clinical oncology asco worlds largest clinical ity language preferences provide financial support oncology event asco attracts thousands healthcare pro projects mutual interest benefit areas fessionals learn latest clinical trials research breast colorectal cancer well cancer general area cancer also support hepatitis world hepatitis alliance european liver patient association provide advocacy interaction healthcare professionals aimed support meeting individuals responding patient exchanging scientific information improves use requests new therapies zelboraf effectiveness products services reason routinely seek input healthcare professionals identify among many patient advocacy activities roche unmet medical needs specific disease areas develop hosted third annual international experience exchange clinical trials publications educational materials patient organisations frankfurt germany twoday also conduct accredited continuing education courses event attended representatives patient groups areas epidemiology treatment options patient marketing distribution roche business report contributions healthcare institutions comprehensive programmes oncology patient care management addition work payers education determine economics healthcare plans providing healthcare professionals capacity planning costing models assist planning education patients budgeting general public research managing customer relationships counselling moreover help develop healthcare networks customers ranging patients healthcare profes proven invaluable helping healthcare profes sionals hospitals laboratories healthcare payers sionals share knowledge diseases new technologies must meet diverse range needs expectations regard encouraging discussion standards care less customer seek build longterm relationships professional transparent area diagnostics establish testing laboratories train technicians correct use instrumentation run meeting customer needs pathology educational courses set quality control pro track customer satisfaction regular intervals usually grammes ensure reliability diagnostic test results annually biannually benchmarking performance also educate diagnostic products improve medical peers industry averages surveys conducted value assist development testing treatment roche third parties gauge customer satisfaction guidelines improve patient outcomes representatives knowledge helpfulness visits effectiveness medical support clinical data dis asean association southeast asia nations tribution quality information educatio cancer stakeholders forum roche announced landmark nal materials addition diagnostics division looks deli prospective study burden cancer economic times service technical support levels social impact asean communities involving cancer patients ten asean countries analyse feedback identify appropriate com study wholly supported roche conducted munication channels establish sales marketing george institute global health sydney australia plans setting targets areas identified serve tool inform evidencebased policy decisions important customers see opportunities cancer control planning research prioritysetting improve performance region number countries transitioning teams us provided educational grant omnia educa transactional selling consultative selling means tion fullservice continuing medical education provider forming closer working relationships partnerships key exclusive focus womens health issues grant helped customers spain example developed practices deliver educational course cervical cancer hpv several years increase understanding customer needs including report results hpv trial expectations also gauging satisfaction services result roche spain received madrid exce managed care programmes financial modelling lente award customer confidence creating sustainable apply industryleading expertise innovative think value first pharmaceutical company selected ing develop healthcare networks managed care pro award grammes payers hospitals establish patient regis tries new medicines collect realworld data swiss programme effect roche way selling puts effectiveness safety patient compliance payers customers needs centre sales dialogue healthcare professionals use data make order create value customer roche informed decisions treatment budgeting purposes programme custom tailors sales representatives competency training coaching framework aims achieve excel managed care programmes cancer cham lence valuebased selling continuous improvement pion provide resources healthcare organisations start infield teams roche business report marketing distributiondriving commercial effectiveness earliest stages development carrying organisation focused developing innovative medi commercialisation perform joint sales calls explain cines diagnostic tests majority expenditures value effectiveness products making better directed proving clinical safety efficacy data clinical decisions team host sciencebased generate clinical trials used produce articles symposiums publish clinician training materials develop professional publications educational materials reli combined reimbursement strategies ability data confirming commercial effectiveness equally critical roche increasingly clinicians france example two divisions codeveloped qual seek apply evidence gained clinical trials ity assurance programme testing decreases clinical decisionmaking false negative results increased reliability diag nosis resulted nearly women france becoming eli addition nontraditional customers payers regula gible herceptin therapy otherwise would tors managed care organisations increasingly emerging received targeted treatment activities like key players decisionmaking process regu provide value customers allowing make better latory delivery patients reason ability address use available resources also difficult mimic new audiences translate complex data provide duplicate peers clearly differentiate roche us new opportunities marketplace due shifts sales marketing practices evolved focus primarily educating customers pa ensuring patient safety tients today sales representatives must deep medi cal knowledge often required discuss clinical roche products must effective must safe data safety profiles depth healthcare professionals throughout life market medicine may drive commercial effectiveness intensive train cause side effects priority minimise make ing courses professional selling skills customercentred sure benefits outweigh risks patients approaches build longterm business partnerships indicated customers global systems place collect data adverse spain introduced qualitative performance measure events monitor safety profile time medicine ment system representatives based sales excellence evaluated clinical studies withdrawn system mirrors commercial excellence departments market products proactive safety management plan established number affiliates offering professional supported qualified physician continuously selling skills courses professional coaching sales man monitors overall safety risk management plans agers place reviewed approved regulatory authorities increasing use social media created opportunities drug safety committee responsible drug safety gov reach patients stakeholders improve effec ernance proactively ensuring patient safety com tiveness business following introduction roches mittee chaired either roches global head safety risk social media guidelines social media advisory management chief medical officer board developed employee training materials high light best practices support business goals regularly analyse medicines reference safety data policies governing use social media include train bases help us identify potential safety risks ing programmes employees internal educational skilled people processes systems place collect campaign raise awareness various social media channels safety information healthcare providers patients use socialmedia ambassadors trained monitor medical literature extract new relevant fullday classes ten countries safety information medicines employees required immediately report issue relating safety collaborating across divisions quality medicines advances personalised healthcare representa tives pharmaceuticals diagnostics divisions adverse events stored global safety database increasingly work together many disease areas starting reviewed qualified physician selected reports marketing distribution roche business report network global professionals overseeing patient safety approval phase clinical trials market health authorities study management roche representatives teams healthcare providers patients safety information captured drug safety database drug safety operations department submission relevant regulatory authorities usually days integrated safety risk management process notification new adverse signal detection signal evaluation drug reaction label change n recall action governance drug safety committee promptly submitted appropriate regulatory authorities completed activities related merger required link one products evaluate genentech roche including implementing single set whether benefits medicine still outweigh risks safety processes global safety database procedures place promptly inform physicians healthcare providers regulators new safety information counterfeits update product labelling new safety information counterfeit medicines diagnostic products often look required inform healthcare providers updated advice identical authentic versions difficult detect par use medicines strict product recall ticularly patients counterfeits cause serious illness process ensure withdraw products rapidly even death contain harmful ingredients well quality safety problems arise quality depriving patients proper treatment ineffective processes systems regularly audited internally counterfeiting also creates financial burden govern inspected major regulatory authorities ments money wasted counterfeits related roche business report marketing distributionenforcement measures also costs resulting counter manufacturing processes difficult reproduce cop feits causing severe damage patients health ies biological products therefore similar identical original biosimilar products consid estimates scale problem vary widely traf ered generic medicines approved based limited data ficking counterfeit medicinal products including medical regulatory bodies accept generics devices diagnostics widespread affects devel oping developed countries world health organiza support development clear regulatory framework tion identified counterfeiting growing often approval biosimilar products european medi underestimated danger citing particular problems cines agency established system united product toxicity instability ineffectiveness states congress introduced legislative process approv ing biosimilars part us healthcare reform responsibility preventing controlling counterfeiting countries framework believe regula rests primarily national governments international tory authorities follow guidelines evalua organisations roche cooperates contributes tion similar biotherapeutic products believe efforts develop stronger laws improve enforcement minimum standard ensuring similar versions well educate public train local officials goal biotherapeutic products brought market safely prevent negative impacts public health caused coun effectively information found manufac terfeit medicinal products also implemented internal turing procurement chapter pages position anticounterfeiting measures design packaging biosimilars available roche website labelling products additionally continue work authorities system track trace products roche actively engaged discussions provided feed back distribution dispensary national regulatory agencies throughout develop ing appropriate pathways approving biosimilar products membership efpia contributed including biosimilar antibodies activities largely con european commissions falsified medicines directive ducted associations including emerging bio adopted directive aims protect europes pharmaceutical enterprises ebe biotechnology industry patients prevent counterfeit medicines entering sociation america international federation supply chain strong safety measures including unique pharmaceutical manufacturers associations ifpma product identification numbers tamperevident packaging restrictions repackaging actions include steps en regulatory authorities developing markets sure reliability wholesale distribution increased scrutiny including argentina brazil mexico peru implemented suppliers active ingredients stronger collaboration directives guidance approval biosimilar prod customs authorities especially world customs orga ucts chile columbia india several countries nisation intensified investigative work together process developing similar regulations together companies prevent counterfeits hired investigative actions signal strong commitment developing countries staff shanghai china plan implement new measures follow guidance principles biosimilars highrisk regions latin america middle east continue meanwhile push harmonised eu system contributing public policy product verification resolution issues related sale products internet additionally roche contributes democratic process sharing advocate increased public awareness counterfeiting views expertise governments regulators help provided information website explains develop effective laws regulations policies public risks counterfeits provides contact information health also collaborate general areas reporting possible counterfeits assessing value healthcare working public health organisations think tanks academics biosimilars unlike traditional medicines contain small molecules pro contribute policy development membership duced chemical synthesis biological medical products industry bodies including european diagnostics manu complex molecular structures produced living facturers association edma advanced medical technology organisms unique genetic property using sophisticated association advamed ebe ifpma efpia marketing distribution roche business report participation efpia assisted new ration assurance acknowledging compliance eu legislation aimed strengthening systems monitoring practices safety medicines particular protecting counterfeit medicines ensuring patients receive reliable strengthened practices promoting information prescription medicines additionally en good business practices ensuring compliance new gaged discussions eu directives protecting personal regulatory requirements around transparency especially data marketing vitro diagnostic ivd products sunshine act united states guidelines associa provided input several eu legislative processes aiming tion british pharmaceutical industry please refer modernise rules conducting clinical trials responsible business chapter pages conjunction advamed advocated regulatory reimbursement reform us fda cen web ters medicare medicaid services cms focus speedier fda approvals timelier cms coverage products wwwrochecomproducts assessing value products pricing wwwrochecom payment determinations also engaged united medicalvaluepatentsandpricing states congress along patient organisations access healthcare overview wwwrochecom accesstohealthcare national health council use ivds enabling early genentech access solutions detection disease targeting right treatments wwwgenentechaccesssolutionscom list patient groups supported wwwrochecompatientgroups right patients plus value diagnostics reducing overall roche clinical trials patient safety wwwrochecom healthcare costs clinicaltrials wwwrochecommanagingmedicationsafety counterfeiting wwwrochecomcounterfeiting patents biosimilars wwwrochecompatents roche diabetes care advocated eu responsible marketing wwwrochecom businessintegrityandresponsiblemarketing innovative approach personalised diabetes management roches policies guidelines positions wwwrochecom case study chronic disease management policiesguidelinesandpositions stakeholder engagement wwwrochecom stakeholderengagement marketing responsibly ethically pharmaceutical industry governed strict regulations industry guidelines sale marketing products one worlds largest healthcare companies roche takes seriously obligation meet high standards rigorous internal processes ensure employees adhere laws regulations industry codes conduct support good marketing practices include uphold ing social responsibility ensuring decisions healthcare products services made using transparent open fair consistent processes code conduct sets standards interacting engaging healthcare professionals goal enable healthcare professionals make decisions independently based relevant data available delivering greatest medical benefit patients continuously train staff interact healthcare professionals increase awareness understanding code conduct well industry countryspecific marketing codes guidelines best practices addition roche uses global marketing sales compliance questionnaire help local managers assess compliance awareness responsible marketing practices general managers moreover must sign decla roche business report marketing distributionpersonalised healthcare benefits seen patients experts investigator physician patient prof henry likyuen chan dr caroline robert doretha dee burrell insurance executive researcher medical laboratory scientist prof thomas szucs dr shirin khambata ford dr jos gilberto vieira personalised healthcare roche business report immediate combination diagnosis therapy monitoring treatment success hepatitis b infection major step forward increases benefits patients enormously million people infected hepatitis b virus percent people living asia predicting better earlier going respond therapy allows us provide effective care assurance patients also increases compliance therapy resulting increase desired treatment outcome patients respond well may able modify treatment increase chances respond benefit modern therapies investigator prof henry likyuen chan roche business report personalised healthcaredirector cheng suen man shook centre hepatitis studies director centre liver health chinese university hong kong hong kong china personalised healthcare roche business report exciting time us aware entering new era skin cancer treatment skin cancer area high unmet medical need new compounds becoming available going improve survival patients stratification targeted treatment fatal disease represents major step forward next steps establish screening relevant genetic mutations also need learn best combine various compounds still development order maximise impact benefit patients physician dr caroline robert roche business report personalised healthcarechef de service cancer institute gustave roussy villejuif near paris france personalised healthcare roche business report option targeted treatment gave hope better quality life hearing words breast cancer devastating words ever heard frightened sure life would going forward gives peace know oncologist believed targeted therapy grateful administered treatment improved quality life past four years patient doretha dee burrell roche business report personalised healthcareauthor motivational speaker mother grandmother lover life philadelphia usa personalised healthcare roche business report view personalised healthcare way husbanding resources way makes good business sense insurance companies personalised healthcare extremely important future simply able afford stick onesizefitsall method providing patients medicines technologies roughandready manner professional analyses tell us economic medical viewpoint diagnosticsbased optimised therapy say hepatitis c superior standard treatment strategies insurance executive prof thomas szucs roche business report personalised healthcarechairman helsana insurance group zurich switzerland personalised healthcare roche business report researcher strongly committed driving personalised healthcare forward appreciate distinct advantages pharmaceuticals diagnostics one roof field oncology particularly helpful involve diagnostics early possible clinical development increases efficiency speed discovering developing patient selection markers could actual impact clinic make important difference patients lives order high frequency drug candidates across multiple indications dedicated inhouse diagnostics effort required roche clearly one largest strongest industry scientificbiomarker expert dr shirin khambata ford roche business report personalised healthcaresenior biomarker experimental medicine leader oncology translational medicine roche nutley usa personalised healthcare roche business report see tremendous changes tasks personalised healthcare diagnostic services gain relevance rapidly since test results become integral factors development modern treatment strategies increasingly treatment decisions based sophisticated laboratory analysis covering complex diseases cancer example modern diagnostic methods enable us provide precise data thus offer reliable basis treatment decisions rapid initiation right therapy opti mised use limited resources healthcare system result strategy real winwin sit uation patients society whole medical laboratory scientist dr jos gilberto vieira roche business report personalised healthcaremedical advisor fleury laboratory paulo brazil personalised healthcare roche business report employees worldwide roche business report people global roche employs people countries worldwide employees working rd diverse workforce represents nationalities percentage women key positions increased line fiveyear goal engaged conducted first global employee survey roche group participation rate overall aligned performancefocused aligned compensation strategy performance management principles worldwide create stronger link company individual performance reward roche business report people key figures women key positions since track reach goal roche employees worldwide fulltime equivalentsfte employees fte function europe servicing north america manufacturing logistics asia marketing distribution latin america research development australia general administration africa total total full time equivalent fte used reflect actual working time full part time employees example two parttime employees working would result equivalent one full time equivalent employees contract type fte versus two employees headcount employees fte operating unit regular fte fixed term fte full time headcount roche pharmaceuticals part time headcount chugai diagnostics division total roche dedicated translating innovation science engagement turn fosters productivity creativity clear benefits patients need highly skilled people worldwide set us apart make passionate motivated people inspired make roche employer choice ability attract engage difference improving health around world retain diverse talent ensures continue deliver innovative healthcare solutions patients well future work achieve developing people levels realise full potential offering inclusive culture draws diverse skill building great workplace background knowledge every employee every day identifying internal external talent right skillsets current future business require people drive business consistently employing ments developing best people roche achieved business goals excelled science innovation year year together activities improve ability solve problems attract retain best brightest minds roche discover innovative solutions enhance effectiveness committed maintaining excellent workplace one performance teams leaders inclusion supports goes beyond offering attractive compensation benefits roche business report peopleproviding employees chance develop personally table highlights awards received professionally build career gain recognition achievements make mark area expertise engaging employees roche consistently recognised excellent employer one measure great work environment whether employ range wellrespected organisations reflects ees actively engaged emotionally intellectually steadfast commitment create maintain working cul experience numerous studies show employee ture embodies roche core values integrity courage engagement key driver employee wellbeing well passion organisational structure aims strike bal better individual business performance rea ance diversity scale reach speed cohesion sons constantly seek new opportunities engage enable leverage innovation throughout value chain employees drive innovation additionally one roches strategic fiveyear strategic goals achieve employee october roche honoured one best multi engagement level would bring us line national employers great place work institute best employers multinational companies chosen participate inaugural competition three medical compa help realise objective carried firstever nies selected best employers roche group global employee opinion survey geos selected external awards recognition rank award roche site exame roche brazil best pharmaceutical company brazil crf institute roche china top employer china universum ideal employers roche switzerland top employer natural sciences universum ideal employers paneuropean top employer natural sciences universum ideal employers roche germany top employer natural sciences deloitte best company work south africa standard excellence award fortunes best companies size genentech ssf science top employers roche basel great place work roche portugal great place work roche group top multinational employers great place work latin america region top fortunes best companies work genentech ssf among large companies top working mother magazine best companies genentech ssf south san francisco people roche business report conducted sites worldwide offered languages positions achieve roche established survey gave employees opportunity provide man host programmes practices better support women agement candid anonymous feedback variety top diverse talent throughout career ics geos questionnaire measured needs expecta range basic measures granting parental leave tions desires employees helps us continue permitting flexible work schedules enhancing mentor build engagement identify areas may need inter ing sponsorship programmes maintaining ties vention additional support employee response rate leadership networks provides solid data infer key findings highlight best practices identify areas improvement gender diversity design effective programmes topline standpoint survey indicated overall engagement level places us slightly pharmaceutical industry bench women total workforce mark women line management women top executive groupwide results indicate employees proud work positions company believe future success also women key positions high satisfaction immediate work environment includes factors colleagues line managers implemented initiatives attract diverse talent physical working conditions facets working life roche branding recruitment activities emphasise diver lower scores include decisionmaking work processes sity inclusion additionally roche careers portal high employee connection senior leaders areas lights commitment respect empowerment opportu focus initiatives sponsored corporate nity another example comes roche italy executive committee coming months business unit participated diversity work event milan aims connect diverse candidates ethnicity roche continue measure employee engagement gender physical ability potential employers followup surveys months intervals efforts open positions leave us well positioned create deliver engagement initiatives required attract retain top talent roche affiliates asked report effective ness local benefit programmes supporting roches diver leveraging diversity sity strategy use data identify areas realise roches innovation goals work sustain improvement family friendly benefits flexible culture mutual respect integrity trust differing workplace workschedule arrangements improved views perspectives freely exchanged debated childcare support added local plans appropriate addi refined ultimately leveraged valuable scientific break tionally pharmaceuticals division diversity action plans throughs business results place top affiliates plans address local needs assessment strengths opportunities affil today employees women employ iates six diversity best practices ranging recruit ees worldwide represent different nationalities ment flexible work arrangements people nationalities work global headquarters basel revised benefit mobility policies implementing new programmes example expand opportunities know diverse workforce provides inspiration women gain international experience also sought ways innovation future business depends people better assist working parents delivering improved child diverse backgrounds bring different methodologies ideas care services enhanced support dualcareer families knowledge workplace spurring greater creativity im launched support programme help partners proved problemsolving unique collaborations assignees find employment host country key area focus increasing proportion women roches top management committed highest defined roles critical business delivery drive significant value greatest breadth depth responsi executive level increase percentage women key bility roche business report peoplewe programmes support positive worklife balance fostering innovation work one example family career network formed basel help employees combine family responsibilities innovation critical roches success talent man career network executed several initiatives agement approach actively fosters generation expres including championing recommendations internal sion new ideas review included outlining commuting needs working parents studying summarising best practices strategy fourfold countries launching bilingual website make attract retain cross section exceptional people life easier working parents basel create inclusive environment fosters ongoing dia logue performance feedback roche also working ensure gender balance global support employees personal professional development leadership development programmes recognise reward outstanding performance participants key leadership programmes women slightly programmes per roche sponsors numerous annual competitions symposiums centage female high potentials promising employees awards encourage creativity spur collaboration prepared leadership positions remained stable recognise companys innovative thinkers also actively support promising young people programmes provide increased access leading scientists leadership pipeline resources pursue scientific discoveries thinking socie tys future workforce needs scientists interacted youth children spark understanding interest number high potentials career science commemorate unescos inter percentage women national year chemistry part bring high potentials kids roche day scientists basel presented theatri percentage women global leadership cal play exhibition explained new molecules programmes become medicine others involved regular basis swiss youth researchers special projects development efforts beginning show results number female succession candidates top positions cases goal igniting fostering viable rising additionally key innovative ideas create maximum value patients leadership positions within roche held women customers employees investors end towards end sophie kornowskibonnet former attracting top talent general manager roche pharmaceuticals france appointed head roche partnering assumes new hire outstanding people central element role february joins roches enlarged corporate global hr vision since employing best talent key executive committee ensuring steady stream promising new ideas drive innovation roche became member catalyst international nonprofit organisation works build inclusive work ability attract engage retain diverse workforce places expand opportunities women business worldwide continue affected certain vari result every roche employee free access ables including resource research information advice also worked competition key talent promote understanding awareness diversity across changes emerging market dynamics organisation internal communication activities rise technology enables flexible working including launching roche group diversity inclusion new working styles intranet updating diversity section website changes worldwide demographics people roche business report response challenges roche continuously develops attracting employees staffing rates innovative recruitment strategies reflect best practices market conditions deploy team talent scouts example strengthen talent pipelines critical target new hires groups also target top business schools attend key internal staffing rate business events build awareness roche employer external staffing rate choice progressive engaging company ensure reach target candidates imple retaining employees turnover mented global social media strategy initiative talent relationship management strategy recognised corporate leadership council international organisa total tion identifies builds best practices europe worlds top companies north america asia reach maximum number potential candidates roche latin america hosts career websites countries roche australia career sites drew approximately million visits genen africa tech site attracted additional million visits total roche received applications posted vacancies registered new candidates roche group talent reasons leaving pool database employees job seekers interested becoming roche employees approximately annual vacancies filled internally encourage employees employeeinitiated constantly identify pursue new career opportunities employerinitiated neutral maintain success developing innovative products aim attract best scientific minds promoting leading edge research strengthening innovation network building scientific collaboration academia ini developing employees tiatives postdoctoral programmes research early development gred pred programmes roche recognise developing training employ seek foster advances science emphasising basic fun ees critical personal growth people damental discovery research work performed alongside also success company employees leading scientists clear commitment publish top successful positions prepared take future scientific medical journals gred postdoctoral roles including leadership positions deliver best programme positions pred programme possible performance commitment developing projects offer active postdocs employees remains steadfast times organisational change top employer pay close attention changing val ues expectations workforce recognise employees example many employees today different attitudes roche provides development opportunities employees expectations working flexibly merging range formal technical leadership training work social life continually review policies programmes job assignments offer valuable onthe address emerging trends ensure roche job experience also offer mentoring coaching pro remains attractive employer choice current future grammes continued refresh local offerings generations wellestablished markets south san francisco basel introduced suites programmes emerging markets roche china academy shanghai opens early roche business report peoplewe supplementing classroom training technology leader roche furnish leaders skills enabled programmes webbased simulations vir need excel foster approach leaders leading lead tual classrooms shown next table approaches ers features significant mentoring coaching allow us manage training investment ensuring access executives addition executive committee meets indi development opportunities employees vidually prospective leaders reviews develop ment plans quarterly continued encourage learning development development leaders rotating talent across organi sation conducting crossfunctional crossdivisional talent reviews commitment developing leadership skills total training investment vital roche continuing lead science innovation million chf globally culturally diverse workforce training spend per employee chf global mobility total number training hours million average training hours international experience important contributor per employee development future leaders encourages shar number postdoc students ing diverse perspectives improving global business interns manner respects local cultures number roche international assignments risen sharply recent years excluding chugai part diversity strat egy also increased number women international support development activity encourage every employ ee assignment participate career development discussions manager discussions help guide personal develop ease transition new cultures environments ment identify skills training employees need support return home roche assists employees achieve career goals introduced suite families assignment abroad online tools support career development planning activities also continuously assess mobility programmes including building core competencies establishing develop ensure support needs diverse assignee popu ment focus areas providing guidance career paths lation going forward maintain efforts strengthen stimulate employee development introducing system health safety international assignees wide process online development planning tool families one primary concerns rolled available every roche employee manager global health insurance programme leading expa triate health insurer programme offers firstclass current future leaders treatment ensures access highquality medical facilities leadership succession planning strategic priority regardless location addition implemented security continue roche number briefing programme assignees family members initiatives place accelerate development next gen advance assignments highrisk countries eration leaders example perspectives global leadership rotation programme twenty alumni pro focus harmonisation global desti gramme building impressive careers across roche nation services immigration support welcome ser world hong kong vietnam shanghai spain basel vices house hunting goal ensure consistent san francisco quality experience assignees families regardless destination addition offer comprehensive suite leadership development programmes help new prospective lead ers progress careers include specially designed development assessment centres action learning special global project teams objective edu cate leaders across organisation means people roche business report rewarding recognising ees may access supplementary communications materials employees performance management annual bonus guides webbased training reward strong performance transparent consistent process encourages fairness continuous feed build educational efforts con back dialogue development approach together ducting workshops ensure people knowl roches competitive compensation benefits programme edge expertise required fully support performance contributes significantly attracting retaining best oriented culture people following integration genentech focused aligning remuneration policies processes compensation culminated rollout new compensation remuneration one aspect roches comprehensive strat strategy global performance management principles egy attract talented people motivate retain current bring common philosophy approach roche employ employees encourage strong performance ees worldwide companys total investment remuneration billion swiss francs performance management employees work increasing number projects association new global performance management tasks across borders functions sites become principles roche implementing globally aligned compen ever important adopt cohesive standards man sation strategy new common approach creates stronger age reward employee performance made link performance reward positioning employ good progress objective laying groundwork ees share roches success linking goals corpo roll roches global performance management principles rate goals promoting culture performance growth new unified approach better enable roche innovation maximise scientific business results creating stronger link performance reward moreover enables roches new compensation strategy also establishes com managers better differentiate reward strong employee mon bonus system eligible employees annual bonus performance comprise three components individual performance per formance individuals global function region affiliate new programme also emphasises encourages con organisation roche groups achievement strategic tinuous twoway dialogue employees man goals agers instead formal onceperyear performance evalua tion enables parties reach shared understanding roche employees transition new approach jan objectives achievements compensation provid uary first bonus payout new approach ing frequent opportunities share ideas define busi scheduled early key objective ness objectives adjust strategies advance employee support managers employees adoption prin development employees took part per ciples approaches ongoing training work formance management discussions shops also analyse share information gained roche business units north america pharmaceuticals workplace evaluations roche employees follow implemented approach common policies processes performance ratings calibrated ensure fairness consistency additionally align employee interests share evaluations focus results achieved holders maintain employee stock purchase programme whether individual team objectives met well roche connect employees countries results achieved whether roche values purchase nonvoting equity shares discount integrity courage passion well leadership com employees countries petencies demonstrated eligible participated programme purchasing securities worth million swiss francs additionally managers promote adoption roches global performance man employees received nonvoting equity securities agement principles human resources team together roche longterm incentive plan senior leaders conducted workshops briefing sessions throughout primary markets additionally employ roche business report peoplebenefits implementing chris major undertaking roches hr competitive benefit programme integral reward organisation prime challenges included package roche offers employees typical packages ensure aligning legacy systems across multiple plat employees protected financially case illness disability forms countries well translating system retirement death also offering series supplemen languages project encompassed virtually roche affili tary programmes designed improve health wellness ates team members located around world affiliates offer extensive benefits plans november chris reached major milestone roche regularly reviews benefit programmes make cer roches north america pharmaceuticals division switched tain reflect evolving needs workforce new system minimal disruption january implemented benefit plans emerging markets chris live countries affiliates agencies sought align affiliates benefit programmes within coun tries ensure fairness benefit economies scale january rolled international sos global assis maintaining fair employment tance programme provides employees immediate practices family members access emergency medical secu rity support services business personal travel roche employment policy governs human rights labour relations every roche site setting inclusive roche diligent efforts mitigate financial risks associ workplace philosophy exacting employment practices ated benefit plans given uncertainty worlds roche tolerate form workplace discrimination financial markets monitored funding status based gender race age skin colour religion marital status major pension funds closely cash injections made sexual preference heritage physical mental disability countries often combination pension plan policy specific roche sites tolerate forms discrimina changes elimination early retirement incentives tion prohibited law regulation countries localities also continued introduce flexible retirement mod operate els better accommodate diverse needs ageing workforce chief compliance officer monitors implementation compliance policy association network hr work increase employees awareness managers compliance officers site also benefits roche offers series communication ensure appropriate policies programmes place initiatives promote fair respectful consistent treatment employees example basel site reviewed remuneration fairness external expert achieving good results equal aligning human resource processes pay equal work men women reality roches new approaches toward performance management directive protection personal data ensures compensation supported operationally safeguard employee information comply rele common human resource information solution chris vant local legislation comprehensive system integrates major human resource processes including organisational management compensa respect employees right freedom association tion benefits performance succession talent man collective bargaining desire roche employees agement international assignment management learning represented unions works councils similar organisa training programmes payroll time management tions currently roche employees trade union mem certain countries bers belong labour groups additionally roche europe forum represents interests chris incorporates best practices genentech employees countries goal roche sets foundation efficient effec maintain open dialogue employee representatives tive hr organisation streamlining standardising simpli times example approached employee repre fying data management across national affiliate bounda sentative councils locations european level ries implementation advances roches ability operate involve implementation new compensa effectively internationally tion strategy performance management principles people roche business report roche personalised healthcare intervening molecular level thanks ultramodern methods sequencing genome including series innovative technologies roche todays scientists identified genes involved genesis cancer example braf gene found mutated form cases metastatic melanoma aggressive form skin cancer approximately solid tumours receptors grb raf mek ksr erk oncogenic braf erk transcription factor mutation braf gene results abnormal braf protein locked active state may lead uncontrolled cell growth survival potentially driving development progression tumour new cancer medicine zelboraf selectively blocks action altered braf protein may cause cancer cells stop growing even die turn lead tumour shrinkage reduce risk disease progression extend patients life personalised healthcare strategy future cancer also fighting infectious diseases like hepatitis b c inflammatory diseases asthma diseases central nervous system rroocchhee bbuussiinneessss rreeppoorrtt oroucr hpee oppelresonalised healthcare rochearboxed featuresengindd treat employees fairly throughout employment cycle including supporting affected organisational changes operational excellence programme date around positions reduced roche phar maceuticals result programme reductions took place including transfers third parties changes partially offset headcount increases diagnostics division emerging markets china continue build capacities capabilities given increas ing importance markets roche end march concluded consultations employee representative bodies operational excel lence ensured social plans support measures place meet needs affected employees measures included severance pay outplacement ser vices counselling access career centres retraining redeployment options web employees wwwrochecomemployees global careers portal httpcareersrochecom employment policy wwwrochecomemploymentpolicypdf group policies positions guidelines wwwrochecom policiesguidelinesandpositions commitments employees wwwrochecomcommitments people roche business report community involvement focused giving direct efforts across four strategic areas emphasis innovation collaboration sustainability exemplified educare programme trains healthcare professionals oncology subsaharan africa measuring impacts assess engagement outcomes projects support advance strengthened processes collecting outcome information affiliates community redevelopment particular area focus redevelopment projects communities devastated natural disasters rebuilding schools haiti pakistan supporting education partnership unicef switzerland laid foundation new teachers training college malawi house train teachers roche business report approach breakdown giving area core business activities roches philanthropic humanitarian work aims leverage innovation collaboration create social projects lasting benefit reason evaluate philanthropic science projects impact cost education arts direct giving four areas priority humanitarian culture social projects science education arts culture community community environment also seek respond environment needs would addressed without roche involve ment emphasis placed projects reflect four criteria innovation applies creative effective solutions soci humanitarian social projects etys challenges largest part philanthropic giving directed toward sustainability delivers enduring effects dynamic humanitarian social projects believe improving resourceconstrained world human services support systems effective way collaboration draws strengths capacities help build stronger healthier communities also aim respective partners provide support maintained longterm basis outcomes provides tangible longterm benefits local resources countries adequate people involved healthcare infrastructure delivery systems find invest ments education prevention often sustainable actions guided roches corporate donations solution medicine diagnostic donations noncommercial sponsorship policy activities included continued support philanthropic donations company fully educare programme launched programme supported philanthropic entities may made regis supports training healthcare professionals subsaharan tered accredited nongovernmental organisations africa conducted international atomic energy forprofit charities additionally donations made local agency launch virtual university cancer affiliates directed local purposes enables roche control regional african cancer training network tailor activities local culture need also support educare conducted proofofconcept training model ing employee engagement allowing quick response hour inservice cervical cancer training course required plus enrollees identified ten training priorities among pilot member states ghana tanzania uganda preference engage true collaborator zambia earliest possible stage aim active longterm part ner sharing risks commitments investments association albert einstein college medicine achieve project success focus resources select initiated model programme ethiopia enhance cancer projects lasting impact rather across many care cancer awareness reducing delays treatment initiatives increasing capacity deliver basic care improving quality care focus womens reproductive cancers affiliates must report annual donation amounts programme launched oncology national roche financial group reporting system conference working forum attended close ethio also solicit data project outcomes number pian cancer care leaders practitioners patients benefiting disaster relief number health care workers trained number classrooms con roche employee action charity trust structed act launched disaster relief campaign aid commu community involvement roche business report examples indicators measures success category community beneficiaries roche employee engagement infrastructure system changes humanitarian individuals screened field relief medicines logistics social service centres renovated social consultations student teachers trained volunteers disabled children prototype schools constructed children enrolled secondary employee walkers raising funds mobile health clinic operations school vulnerable children construction health train disabled children assisted teachers training college constructed electricity installed day centres mothers maternal health community bore holes drilled sessions repaired science teachers professional scientists workshop trainers industrial placement students education development workshops children aided tutoring sciencetechnology educational teaching methods adopted presentors secondary students conducting volunteer tutors mentors academic research arts culture museum visitors roche expert workshop leaders creativity workshops established arts science students joint performances commissioned projects music children creativity workshop ongoing museum operations concert audiences challenging music community individuals families assisted workforce volunteers local cultural groups sustained environment community services programmes family counseling sessions recreation programmes established public sites cleaned list exemplary outcomes representative activities roche affiliates around globe corporate headquarters nity redevelopment following devastating earthquake instruments diabetes care supplies help treat almost haiti extensive flooding pakistan employees patients affiliates raised donations along core funding roche helping build equip oper encourage employee engagement year june ate two schools haiti one school pakistan three roche employees worldwide join roche childrens walk schools expected open spring projects generate support children need nearly deliver benefit beyond initial schools since establish employees participated sites raised one models replicated million swiss francs including matching funds roche majority contributions managed locally majority funds used continue supporting allows business unit determine best address programmes malawi provide hivaids orphans needs community disastrous earth food education skills training walk proceeds also quake occurred japan march colleagues enabled roche partner unicef switzerland assist chugai initiated emergency support making significant building critical new teachers training college malawi donation japanese red cross help relief april helped break ground college efforts gift augmented courses tamiflu house train teachers balance walk funds donated health authorities help fight influenza used individual roche sites support vulnerable refugee centres also contributed range diagnostic children locally roche business report community involvementsharing knowhow yield lasting benefit strict provide support creative expression material financial contribution since roche sup monthly roche n jazz events together roche ported international committee red cross icrc founded museum tinguely birds eye jazz club work provide displaced people access clean bring modern inventive jazz community basel water time roche assisted million sixth year roche n jazz entertained civilian beneficiaries seven countries cash people performances ensembles kind donations extended annual commitment support icrc community environment one keys roches success involvement science education communities operate maximise effect business founded excellence innovation projects selected managed locally two exem science technology essentially aim attract plary affiliate programmes made positive difference brazil best scientific minds promoting leadingedge research turkey strengthening innovation network building scientific collaboration academia also support programmes roche planted seeds would grow become improve science education draw talent science careers programa vizinho legal good neighbour programme engage outstanding young scientists paulo brazil aims transform jaguar local commu nity confronted numerous social vulnerabilities encourage young people choose science career healthier place commitment better future support initiatives promote interest natural sciences switzerland funded launch science public facilities four hours school provided move nationwide competition conducted identify daily programme works mitigate social idleness secondary school class greatest dedication keep children streets toward end good commitment field natural sciences culminating neighbour programme developed numerous cultural competition held roche headquarters finalists earned sports activities also built proactive attitudes toward science day basel rotkreuz winning class healthcare critical health issues awarded science week california since initiating programme roche seen progress september lead sponsor swiss talent many measures including social skills selfesteem cultural forum gathered selected secondary college repertoire better societal interactions good students switzerland around europe discuss neighbour programme reached children adolescents future health following extensive debate young per families since helped children sons think tank developed several concrete proposals adolescents address emerging healthcare challenges roche turkey also deeply engaged local communities arts culture often partnership unicef turkey roche turkey support arts culture reflection passion participated stars istanbul largescale arts event innovative thinking characterised creativity excellence emphasising brighter future children giant starshaped distinctiveness presented roche conti sculptures inspired culture history city nents salzburg festival programme encourages art displayed throughout istanbul auctioned raise science students across europe explore con money unicef additionally roche turkey used portion nection two realms series creativity funds raised roche childrens walk help workshops related contemporary music performances unicef turkey establish new kindergarten opened march pupils aged three six february toshio hosokawas orchestral piece woven dreams received new york city premiere carnegie hall hosokawas composition fifth work roche commis web sioned outstanding contemporary composer auspices roche commissions donations sponsorship wwwrochecom donationsandsponsorship community programmes wwwrochecomsociety roche employee action charity trust httpreactrochecom community involvement roche business report professionals employed globally field health safety security environmental protection roche business report environmental stewardship prevention continued foster employee engagement responsibility safety security environmental protection education awareness training minimised footprint introduced new sustainable technologies processes minimise impact environment improved ecobalance reduced ecological impact per employee target improvement levels reduced energy use reduced energy consumption co emissions track reach fiveyear goal reduction roche business report environmental stewardship key figures roche accident rate rar track reach goal energy efficiency tjemployee track reach goal co efficiency temployee track reach goal total environmental impact million impact pointsemployee track reach goal protecting people environment essential busi ideas database includes solutions simple proce ness roche refer safety security health environ dures like safe method opening cardboard boxes best mental protection approach sense practices operating complex energy management systems responsibility methodically issues con guidelines ergonomic office seating cerning quality productivity cost efficiency roche responsible care award recognises best con strive continuous improvement wherever pos tributors applications practices received sible economically viable seek sustainable longterm entries award saw implementation improvement changing behaviour adapting equipment numerous solutions found database sites recent standards developing innovative pro awarded cesses throughout organisation audits assessments assess performance comparing results improving monitoring laws regulations internal standards set performance organisations international chamber com merces business charter sustainable development employee engagement training international organization standardization chemi prevention key effective management cal industrys responsible care programme employees support programmes worldwide teams roche site identify risks develop mitigation conduct internal audits every three years critical chemi plans communicate policy guidelines employ cal pharmaceutical diagnostics manufacturing sites ees stakeholders audit frequency facilities determined risk potential strategic importance past performance believe education awareness training best sitespecific circumstances internal audits stipulate nec way foster employee engagement responsibility essary improvements plant management local therefore conduct regular training sessions regional officers meanwhile conduct frequent spot checks conferences workshops provide online tools local inspections assess compliance standards languages employees employees partici pated hours training also expect external manufacturers suppliers service pro encourage employees identify areas improvement viders meet standards ensure periodically review effectiveness management compliance standards thirdparty auditors system retained us periodically audit operations suppli ers issue recommendations improvement event using wikistyle database good practices unsatisfactory performance may terminate con employees regularly share knowledge exchange new tract refuse award contract supplier roche business report environmental stewardshipshe audits site rir corresponds number working days lost due occupational illnesses per employee per year internal audits maintain integrated programme employee consulta followup tion workplace inspections training across areas first time business approach promote strong safety culture external audits empowers employees report address followup na safety issues expect similarly rigorous policies first time contractors also encourage safety wellbeing employees selling protective equipment recreational direct materials suppliers activities discount conducting bicycle safety checks among activities internal followup audits almost sites improved performance recommended improve health safety activities included expanding ments following audits included increasing involvement successful us driversafety programme roche sites line management improving business continuity man includes defensive driving techniques specific agement details found chapter manu health checks vision hearing number sites facturing procurement pleasanton california usa offer special training ergonomic showroom prevent injuries poor use furniture machines equipment safeguarding employees property ongoing efforts improve workplace safety resulted decline approximately security number workrelated accidents per million working hours goal protect employees visitors physical employees reported occupational acci assets intellectual property products harm loss dents decrease frequency compared addition separate security organisation man resulting number lost days increased ages issues virus protection overall roche accident rate worsened roche implemented travel security help services number reported cases occupational illnesses decreased employees family members services cases increase include hour hotline professional advice support roche illness rate lost days due occupational illnesses case medical security emergency travel also due single case causing absence nearly year provide preventive medical security information countries cities regions year overall positive trend occupational accidents illness end issued guidelines emergency evacuation recognised roche spain received social expats business travellers safety bonus low accident rate mannheim site received chemical industry associations responsible security activities included attending east care award ergonomics training programme ern europe security workshop istanbul turkey site security officers together chief security officer dis occupational accident illness profile remains consis cussed priority issues transportation security product tent slips falls repetitive strains representing counterfeiting information security majority workrelated incidents major acci dents three consecutive years outside workplace health safety however two employees died tragically summer party employee health safety first priority primary organised company switzerland employees objective keep roche accident rate rar hit falling tree thunderstorm reduce reduce roche illness rate rir less rar corresponds number working days lost due occupational accidents per employee year roche environmental stewardship roche business report employee safety health ecoefficiency ecoefficiency based concept creating goods services using fewer resources creating less roche accident rate waste pollution quantify ecoefficiency eco roche illness rate efficiency rate eer ratio sales expenditures envi number occupational ronmental protection environmental impact points accidents calculated accordance swiss federal office cases occupational environment foen efficiently increase illnesses sales reduce environmental harm keeping growth workrelated fatalities expenditures environmental protection lower higher workrelated accidents eer value thus ecoefficiency per million working hours seek improve ecoefficiency focusing primarily reducing material energy consumption reducing waste using renewable resources efforts protecting property resulted eer improving counterfeit products major risk patients reputation implemented number anticounter feiting measures continue work authorities ecoefficiency rate eer system track trace products distribution dis pensary details found chapter marketing distribution pages sales million chf environmental minimising environmental expenditure footprint million chf environmental part commitment sustainable development impact proactively seek employ new sustainable technolo environmental gies processes minimise impact environ impact points ment eer x ecobalance ecobalance measures demand place earths invested million swiss francs measures ecosystems allocating environmental impact points two compared million costs ecologically relevant factors consumption resources million swiss francs raw materials water energy impact waste emissions air water soil points increasing energy efficiency added related number employees goal reduce total energy consumption fossil fuels enables us monitor environmental impact per employee electricity gigajoules per employee million impact points baseline based levels longterm goal reduce energy consumption established groupwide goal ecobalance per employee approximately levels allows management roche site establish local strategies objectives reducing environmental impacts longterm strategy improve energy efficiency aggres best fitted individual situation sively substituting fossil fuels sustainable energy goal increase proportion sustainable energy total environmental impact per employee use since energy use main source million impact points improvement greenhouse gas emissions reducing energy consumption targeted improve ecobalance levels also lowers operating costs energy conservation priority roche business report environmental stewardshipecobalance r aw materials primary energy emissions air water emissions water landfilled waste environmental impact per employee mio impact points products throughout group systematic approach energy reducing automobile fuel consumption fleet emissions management includes meet lower co emissions targets gkm constructing energyefficient buildings standard set western european pharmaceutical oper retrofitting heating cooling air conditioning installations ations reducing fossil fuel electricity consumption adjusting range acceptable temperatures offices recovering waste heat building cooling systems basel workplaces developing green programmes use low purchasing energyefficient equipment including hybrid energy led screens consolidating data centres using dieselefficient cars heat generated heating buildings changing work processes using recycled sustainably harvested building materials reviewing employees travel needs renovate office building nutley new jersey us achieved leadership energy environmental continued focus responsible use design leed gold certification sources continuous reductions energy consumption installing window film buildings genentech campus activities included usa provides additional insulation blocking environmental stewardship roche business report energy use type greenhouse gas emissions consequence energy savings measures fuel used company vehicles greenhouse gas emissions co equivalents oil grid electricity total emissions million tonnes fuel due business air travel total emissions per million chf district heating sales tonnes waste energy use terajoules natural gas total energy use total energy use per ultraviolet radiation infrared heat million chf sales visible light total energy use per employee activities resulted improved energy usage several areas including reduction business travel related fuel consumption reducing use halogenated hydrocarbons decrease car fuel consumption halogenated hydrocarbons use refrigerants cooling increase use sustainably generated electricity equipment chlorinated compounds deplete ozone layer whereas fluorinated partially fluorinated ones together reduced energy consumption buildings considerable global warming potential persis stationary equipment relatively stable staffing level tent thus stay atmosphere long period time overall energy consumption declined energy con plan reduce halogenated refrigerants roche sites sumption per employee gigajoules per employee newly acquired sites genentech surpassed target gigajoules ventana work towards separate timelines lowering greenhouse gas emissions even though less ghg emissions haloge greenhouse gas ghg emissions roche originate nated hydrocarbons preference eliminate generation use energy goal therefore improv emissions however recent acquisitions lack alter ing energy efficiency reducing energy consumption also natives countries make complete elimination applies ghg emissions reduction measured chemicals unrealistic nevertheless continue tonnes per employee levels examine alternatives work refrigeration suppliers reduction levels expect achieve fur make reductions ther reductions substituting fossil fuels energy sustainable sources made significant progress reducing emissions halo genated hydrocarbons since eliminated seek decrease ghg emissions establishing energy halons reduced fully halogenated compounds standards ensure new plants buildings designed excluding genentech sites maximum energy efficiency optimising retrofit ting existing assets also encourage exchange best halogenated hydrocarbons tonnes practices variety communication channels reducing amount fuel use heat cool inventory operate sites businessrelated travel however emissions latter declining slower rate nevertheless reduced roche business report environmental stewardshipdecreasing air emissions plants may dispose nonhazardous general waste minimise emissions air variety technologies authorised landfills practices priorities avoid pollutants reduce quantities pollutants control remaining pollutant emis increase total production waste gen sions line ecobalance goals overall objective eration went slightly incorporated waste keep emissions low levels achieved mitigation measures increased solvent recycling recent years singapore general waste meanwhile declined mainly lower amounts construction waste new strategy prescribes continuous improvement pro recycling methods south san francisco ponc puerto gramme reducing emissions air manufacturing rico operations include flue gas scrubbers reduce nitro gen oxides sulphur dioxide various incin roche environmental awareness chemical tech x eration freezing processes reduce release volatile nology react programme awarded proposals improving organic compounds vocs may also reduce energy sustainability chemical processes syntheses use received submissions replacing hazardous chemicals avoiding waste reducing energy consumption completed pilot studies using cryogenic equip also cut costs one winning team reduced onehalf ment reduce air emissions plan install equipment amount reagents solvents needed manufacture florence us site freeze volatile organic com equal amount product replacing hazardous reagents pounds waste air emissions air fluctuate year previously used less problematic ones year remain low levels roche participated technical investigation emissions air tonnes kesslergrube landfill grenzach germany former user site evaluation remediation options ongoing switzerland roche companies continued clean vocs hazardous waste landfills klliken bonfol particulates nitrogen oxides belleville new jersey usa site roche dismantled sulphur dioxide buildings studying various remediation options nutley usa site roche conducting fullscale technical volatile organic compounds investigation soil groundwater conditions local ised remediation activities completed managing waste way including groundwater treatment soil excavation waste parameter ecobalance waste reduction installation soilvapour extraction systems targets therefore reflected goal improve groups ecobalance maintain waste waste tonnes reduction goals individual sites however set group goal large yeartoyear fluctuations mainly due waste construction demolition activities general waste produced roche pharmaceutical diagnostics compa general waste nies produces relatively low volumes chemicals thus per million chf generates small quantities chemical waste reducing sales already low volumes waste produce biotech chemical waste products fewer chemicalbased products neverthe produced less accept responsibility waste generated chemical waste operations including deposited past sites per million chf landfills permit landfilling last resort even sales inert materials slag incineration ash depending availability suitable local wastetreatment environmental stewardship roche business report conserving protecting water resources eliminating chemical containing octyl phenol moiety roche supports global efforts promote water protection processes potentially negative impacts conserve water reserves improve access clean drinking aquatic life water longterm goal reduce total wastewater toxicity analysing waterrelated risks using world business baseline however continue council sustainable development water tool iden investigate reliable performance indicators measurement tified five sites studied determine availabil methods establishing baseline meantime ity clean water meet future business needs striving stabilise water consumption throughout group commissioning wastewater treatment plant anaerobic degradation penzberg germany captures methane half total quantity water utilised used cooling generate heat electricity surplus energy fed circuits thus chemically contaminated analysis site grids buildings discharged rest purified treatment plants released watercourses result activities water consumption decreased million cubic metres major even though operate sites demand large vol reductions achieved cooling irrigation cooler umes water areas water scarcity adopt conserva weather particularly california tion reduction programmes according local conditions needs example californian sites use drought transferred million cubic meters water resistant landscaping sites reduce water con treatment plants resulting discharge tonnes sumption organic matter addition kilogrammes heavy metals collecting recycling water cooling towers creating leaching metal pipes discharged closedloop system operations watercourses reusing cleaning water next first rinse recycling used water water usage discharge reducing cooling requirements improving cooling pro cesses improving heat recovery water withdrawn million cubic metres record organic emissions water total organic car water used bon toc treatment wastewater treatment plant million cubic metres discharge wastewaters pollutants comply fully wastewater discharged relevant regulations including pretreatment require treatment plant ments elimination rates wastewater million cubic metres treatment plants already high seek minimise organic matter contamination water discharged reducing discharges toxic poorly biodegradable sub watercourses stances heavy metals treatment tonnes reducing wastewater production heavy metals treating pretreating wastewater ozone discharged cases non poorly degradable contaminants watercourses treatment kilogrammes method calculating environmental impact ecobal ance includes water usage reflecting importance reducing total withdrawal overall environmental target activities area water management included collaborating german scientific institute wasserver sorgung langenau establishing new indicator meas uring total toxicity wastewater rather total organic carbon toc roche business report environmental stewardshipsupporting biodiversity evidence suggests exposure trace concentra tions surface ground drinking water pose roche supports principles resource stewardship defined harm human health risks aquatic life thought convention biological diversity cbd three greater scientific studies identified shortterm main goals covering effects exposure lowlevel concentrations pharma conservation biological diversity ceuticals research conducted evaluate sustainable use components potential longterm impacts therefore recognise fair equitable sharing benefits use need research possible effects support genetic resources scientific work field avoid use noncommodity naturalresource materi als source products discovery development legislation compliance pharmaceuticals however discover develop com mercial product derived natural plant microbial animal meet local laws regulations however group pol genetic materials use resources guided icies often rigorous external standards principles goals cbd fully track registration chemical otherwise operate facilities protected areas materials according european legislation registra areas high biodiversity values sites require access tion evaluation authorisation restriction chemicals city infrastructure urban environments reach requirements globally harmonised system classification labelling chemicals pharmaceuticals environment eight consecutive years prior incurred sig nificant fines sherelated violations however consider entire lifecycle drugs take steps assessed small fines four minor infractions minimise release pharmaceuticals environment respect environmental issues one failing comply stages equipment safety regulations incidents pre sented significant risk employees local com design manufacturing sites reduce risk active munity take incidents seriously taken steps ingredients entering wastewater also support pharmaceu correct problem prevent similar incidents tical takeback programmes employ proactive measures occurring future additionally fire caused electrical prevent release products environment failure finishedgoods warehouse budars hungary several ways destroyed products stored hungarian market offering financial incentives ensure unused fire segrate italy plant resulted overheating dated products returned retailers others powder mill fortunately nobody hurt either incident supply chain establishing policies require returned waste pharma ceutical product incinerated rather disposed landfills supporting research effects pharmaceuticals environment providing authorities environmental risk assessments new medicines traces pharmaceutical products enter environment variety ways manufacturing process improper dis posal unused medicines natural process fol lowing normal patient use patient use however generally recognised primary contributor environmental stewardship roche business report roche personalised healthcare personalised treatment strategies infection hepatitis c virus hcv cause acute chronic liver damage ultimately lead liver failure cirrhosis cancer liver worldwide million people infected hcv today know number subtypes hcv differ molecular structure also responsiveness treatment roche developed molecular tests identify hcv subtype patient information helps physicians predict long patient continue treatment eg weeks order achieve lasting virological response start ek e treatment w st weeks te therapy weeks therapy treatment stopped test week test week hcv concentration viral load reduced significantly treatment stopped viral load weeks reduced slightly therapy viral load reduced personalised healthcare improving physicians ability predict response adjust treatment roches personalised healthcare strategy draws advances molecular biology monitor patients responses therapy adjust duration therapy patients needs administer medicines precisely right time within longterm treatment strategy develop new diagnostic tests medicines focused efficient way rroocchhee bbuussiinneessss rreeppoorrtt ernovcihroen pmeersnotanla slisteewd ahrdesahltihpcare rochearboxed featuresengindd goals environmental protection education goal basis target date improve energy efficiency goal basis target date gjemployee improve education increasing training per employee increase share sustainable average hryear energies total energy consumption reduce co emission per employee safety line improving energy efficiency goal basis target date reduce total environmental impacts improve roche accident rate calculated ecobalance according number lost working days due swiss federal office occupational accidents environment bafu per employee rar rar reduce total waste water toxicity reduce number occupational accidents causing lost working days cases per working hours web environmental protection wwwrochecomenvironment keep roche illness rate number policy wwwrochecom lost working days due safetyhealthandenvironmentalprotectionpdf eer ecobalance wwwrochecom occupational illnesses factsheetecoefficiencypdf bring number cases occupational goals wwwrochecomshegoals performance wwwrochecomsheperformance illnesses causing lost working days services wwwrochecomsheservices cases per working hours group fact sheets positions policies guidelines wwwrochecompoliciesguidelinesandpositions wwwrochecompolicyguidelinesandaudits environmental stewardship roche business report foundation years ago roche years specialised leader researchfocused healthcare combined strengths pharmaceuticals diagnostics roche business report corporate governance roche committed stakeholders operating businesses focus value creation innovation management culture conforms modern standards corporate governance groups policy communicating transparently build basis successful implementation commitments stakeholders remuneration report roches success depends abilities dedication people recognition forms basis guidelines system roches performanceoriented remuneration policy roche business report corporate governance corporate governance roche complies relevant corporate governance agm march board directors nomi requirements particular applicable laws swiss nate john bell andr hoffmann und franz b humer stock exchange six swiss exchange directives including election board commentaries thereto swiss code best prac tice corporate governance promulgated swiss busi ness federation economiesuisse companys internal gov corporate executive committee ernance framework particularly articles incorporation bylaws embodies principles needed ensure erich hunziker chief financial officer chief information offi companys businesses managed supervised cer deputy head corporate executive committee manner consistent good corporate governance including decided retire roche end march necessary checks balances board directors appointed alan hippe succeed printed annual report contains selected links erich hunziker chief financial officer mem roche website wwwrochecom readers thus provided ber corporate executive committee april snapshot company reporting date also directed sources consult sophie kornowskibonnet former general manager roche time uptodate information corporate governance pharma france appointed head roche partner roche whereas annual report covers single financial ing groups headquarters basel joined year ending december website contains information enlarged corporate executive committee new member permanent nature well latest roche news february reporting severin schwan ceo companys articles incorporation bylaws curricula roche group vitae members board directors corpo rate executive committee published website succeeded dan zabrowski took position head roche applied science diagnostics division located penzberg germany february dan board directors zabrowski member diagnostics leadership team reporting daniel oday coo roche diagnostics rd annual general meeting agm roche holding ltd march shareholders approved shortening information member board directors includ term office new directors reelection three ing years elected years two years reelected pius baschera bruno gehrig terms end member corporate execu lodewijk jr de vink andreas oeri members tive committee listed pages board directors new term two years provided articles incorporation walter frey wolfgang ruttenstorfer decided retire members board information relating directors paul bulcke peter r voser christoph franz corporate governance elected new members board term two years provided articles incorporation group structure shareholders roches operating businesses organised two divi organising meeting immediately following agm sions pharmaceuticals diagnostics pharmaceuti board directors approved committees structure cals division comprises two business segments roche committees memberships shown pharmaceuticals chugai whereas genentech former third segment integrated roche phar maceuticals diagnostics division consists follow ing five business areas applied science diabetes care httpwwwrochecomaboutrochecorporategovernancehtm molecular diagnostics professional diagnostics tissue roche business report corporate governancediagnostics business activities carried rights one share participate available earn group subsidiaries associated companies detailed ings liquidation proceeds following repayment information roche holding ltd significant subsidi share capital roches nes rights pertaining aries associated companies including company name thereto including provisions protecting interests listing information domicile share capital equity inter nes holders described articles incor est listed finance report note roche porat ion roche holding ltd group consolidated financial statements subsidiaries information debt instruments issued associates outstanding bonds provided finance report major shareholders listed finance report notes note roche group consolidated financial state roche group consolidated financial state ments debt ments equity attributable roche shareholders additional information employee stock options pro related parties pages note vided finance report note roche group financial statements roche holding ltd significant consolidated financial statements employee stock options shareholders equity compensation plans andr hoffmann vicechairman board directors roche issued options apart employee stock andreas oeri member board directors options stocksettled stock appreciation rights ssars chairman boards corporate governance sustain options issued connection debt instruments ability committee serve respective capacities neither options awarded employees debt board committees representatives share instruments issued effect holders group pooled voting rights receive roches share capital remuneration set forth remuneration report finance report note roche group board directors corporate executive committee consolidated financial statements related parties information member board directors note financial statements roche hold including years elected years ing ltd board executive remuneration terms end member corpo lukas duschmal member shareholders rate executive committee listed pages cur group pooled voting rights makes sixmonth intern ricula vitae information including information ship roche singapore shanghai relation board memberships available continuously updated ships exist shareholders pooled voting rights internet crossshareholdings annual general meeting elects members board directors staggered elections capital structure nominee voted separately see articles information roches capital structure provided incorporation roche holding ltd minutes finance report notes financial statements roche rd annual general meeting roche holding ltd held holding ltd additional details contained march articles incorporation roche holding ltd exception franz b humer william burns changes equity detailed finance report notes arthur levinson none members board financial statements roche holding ltd directors member roches corporate execu company share capital swiss tive committee served executive capacity francs divided fully paid bearer shares group subsidiary three financial years proceeding nominal value swiss franc restric current reporting period tions exercise voting rights shares internal organisation board directors upon deposit shares voted without restrictions division authority responsibilities board authorised conditional capital management remits board committees addition nonvoting equity securities nes issued bearer form form part share capital confer voting rights nes confers httpwwwrochecomaboutrochemanagement boardofdirectorshtm httpwwwrochecomaboutroche managementexecutivecommitteehtm httpwwwrochecomaboutrochecorporategovernance articleofincorporationhtm httpwwwrochecomaboutrochecorporategovernance httpwwwrochecomaboutrochecorporategovernance articleofincorporationhtm annualgeneralmeetingshtm corporate governance roche business report information control mechanisms available details risk management including risk factors board dealings corporate management gov risk management charter see risk management erned bylaws compliance website financial risk management board directors roche holding ltd organised specifically described finance report ensure groups businesses conducted system internal controls financial reporting see responsibly focus longterm value creation pages finance report end roche board delegated certain responsi internal audit bilities several committees composition chair group audit reports general counsel direct persons january described access regular briefings audit committee committees authorities responsibilities defined ongoing activities audit reports chief audit detail bylaws board directors risk advisory executive attends audit committee committees except presidium chaired inde meetings external auditors pendent directors group audit independent appraisal function according bylaws board directors evaluates reviews groups activities service request members board meeting without management annual audit plan yearly defined chairman present may convened roche board focus areas eg emerging markets thirdparty manage meets year assess chairmans performance ment validated senior management presented meeting attended chairman audit committee roche group committed chaired one vicechairmen maintain high standard internal control throughout part management information system board worldwide operations management responsible directors informed important issues sales assess business risks aspects operation development etc monthly basis board access implement effective efficient processes con electronic information platform provides timely trols whilst ensuring compliance internal external information board directors boards com rules regulations mittees along systems controls set forth conducting operational audits group audit determines board directors established system controls managements response risks surrounding business continuously monitored audit committee processes systems evaluates appropriate corporate governance sustainability committee ness completeness efficiency processes consists following elements controls action plans implement necessary changes report operating financial risks risk management enhancements developed together busi system nessauditee tracked completion roche system place identify manage type external auditors see risks potentially affecting business roches risk chief compliance officer compliance officers sub management charter sets approach accom sidiaries see panying responsibilities pharmaceuticals diagnostics safety health environmental protection department divisions global functions conduct formal risk corporate sustainability committee assessment process least year must develop science ethics advisory group seag issues risk plans material risks monitored relating genetics genetic engineering established deviations reviewed regular performance dialogues consolidated group risk report including target risk members corporate executive committee profile discussed corporate executive committee invited attend report person agenda approved together group business plan items concerning situation warrants mem also presented audit committee process bers enlarged corporate executive committee may subject regular reviews findings presented audit committee full board httpwwwrochecomcorporateresponsibilitybusinessethics riskmanagementandcompliancehtm additional information provided finance report note httpwwwrochecomaboutrochecorporategovernance roche group consolidated financial statements risk management articleofincorporationhtm httpwwwrochecomaboutrochecorporategovernance httpwwwrochecomcorporateresponsibilityenvironmenthtm committeeshtm httpwwwrochecomcorporateresponsibilityhtm httpwwwrochecomaboutrochecorporategovernance httpwwwrochecomcorporateresponsibility articleofincorporationhtm csrresearchanddevelopmentgeneticsandbioethicshtm roche business report corporate governanceboard board committees attendance corporate governance presidium nomination remuneration audit sustainability board committee committee committee committee number meetings f b humer b gehrig hoffmann p baschera j bell p bulcke w burns l j r de vink ch franz julius levinson oeri p r voser b weder di mauro member committee new board committee member since march franz b humer invited guest board committee meetings board board committees attendance february retired board members w frey w ruttenstorfer also invited attend board committees invite threeday visit major subsidiary board chairman board corporate executive com committees met follows mittee members deliver reports committee meetings presidium board directorsnomination commit may elect commission independent expert reports tee four meetings approx hours call services consultants remuneration committee two meetings approx year several blackout periods imposed hours senior employees prohibited trading com audit committee four meetings approx hours pany stock following blackout periods effect corporate governance sustainability committee december february three meetings approx hours april april june july march boards committees partly october october changed membership individual participation blackout periods changed chairman board members committee meetings outlined chart board directors circumstances warrant reflect attendance old january board directors met four meetings february new march com hours length fullday meeting mittee compositions figures indicate actual length meetings include remuneration committee members permitted contribute directors extensive premeeting preparations postmeeting attend remuneration committee meetings matters concerning followup activities deliberated decided corporate governance roche business report board directors regularly conducts assessment relationship statutory auditors performance annual general meeting roche holding ltd members corporate executive committee march shareholders voted appoint kpmg ag maximum ordinary notice period twelve months kpmg statutory auditors based existing legal management contracts fall within requirements swiss code obligations article scope subsection annex six directive maximum term office seven years audi information relating corporate governance tor charge ian starkey replaced predecessor john morris auditor charge starting business year remuneration shareholdings loans information long auditors auditor details regarding remuneration shareholdings loans charge serving capacities provided set forth separate remuneration report pages statutory auditors participate audit commit finance report notes tee meetings prepare written oral reports roche group consolidated financial statements equity results audits audit committee oversees attributable roche shareholders related parties assesses auditors makes recommendations pages listed notes board information responsibilities audit financial statements roche holding ltd board committee see article bylaws statutory executive remuneration board executive share auditors participated four meetings audit commit holdings pages tee participatory rights shareholders reports statutory auditors consolidated finan participatory rights shareholders defined cial statements financial statements roches articles incorporation roche shares found pages respectively years issued bearer restrictions admission finance report annual general meetings exception shares must deposited within specified period date kpmg received following remuneration services meeting admittance card must issued statutory auditors roche holding ltd audi shareholders name provided articles tors roche companies new including chugai incorporation shareholder elect represented third party annual general meeting articles incorporation contain restrictions exercise vot millions chf ing rights quorum requirements stip auditing services ulated conformity swiss code obliga auditrelated services tions tax consultancy services articles incorporation shareholders total representing shares nominal value least million swiss francs request placement items statutory auditors elected year annual agenda annual general meeting must done general meeting later days date meeting information policy change control defensive measures provided articles incorporation corpo articles incorporation contain provisions rate notices published swiss official gazette mandatory bid rule swiss law applies commerce daily newspapers designated changeofcontrol clauses components board directors basler zeitung finanz und wirtschaft remuneration based roche nes would terminated lagefi le temps neue zrcher zeitung event acquisition vesting period restrictions roche reports halfyear fullyear results business preexisting awards would removed reports published print online formats media options could exercised immediately httpwwwrochecomaboutrochecorporategovernance articleofincorporationhtm httpwwwrochecomaboutrochecorporategovernance httpwwwrochecomaboutrochecorporategovernance articleofincorporationhtm articleofincorporationhtm roche business report corporate governanceevents addition detailed first thirdquarter sales fig concrete information material alleged violation ures published year april october roche group code conduct one certain predefined current list publication dates available english categories corporate governance sustainability german internet committee audit committee board direc relevant information documents including media tors informed substantial violations releases investor updates presentations analyst investor conferences available internet fur chief compliance officer reports general counsel ther publications ordered email fax telephone regularly corporate governance sustainabil baselwebmasterrochecom ity committee audit committee board tel directors fax contact address investor relations f hoffmann nonapplicabilitynegative disclosure la roche ltd investor relations group finance basel expressly noted information contained switzerland mentioned herein nonapplicable omission tel construed negative declaration provided six fax swiss exchange corporate governance directive commentary thereto additional information including details specific contact persons available internet chief compliance officer compliance officers network chief compliance officer compliance officers network committed ensuring roche group code conduct consistently complied throughout roche group also serves contact person shareholders employees customers suppliers gen eral public issues relating implementation compliance code employees parties become aware violations roche group code conduct bring attention managers supervisors report chief compliance officer urs jaisli direct phone number email ursjaislirochecom disclosures treated confidentially addition end employees may anonymously report irregularities com plaints corresponding mother language via speak hotline addition roche established business ethics incident reporting beir system enables chief compli ance officer capture track monitor alleged violations initial reports local compliance officers resolution business ethics incidents recorded sys tem local compliance officer receives specific httpwwwrochecommediahtm httpwwwrochecominvestorshtm httpwwwrochecominvestorscontactshtm httpwwwrochecomaboutrochecorporategovernance httpwwwrochecomcorporateresponsibilitybusinessethics codeofconducthtm riskmanagementandcompliancehtm corporate governance roche business report remuneration report remuneration report summary helping roche employees perform consistently roches success depends abilities dedication high levels remuneration policy designed foster value people recognition forms basis remuneration creation reinforce culture performance innova policy system tion applies nonmanagerial employees well managers one primary aims remuneration policy encourage longterm focus align managements inter key principles underpinning policy ests interests roches shareholders holders focus value creation roches nonvoting equity securities nes pay performance enabling employees share companys success remuneration report submitted separately fairness transparency remuneration decisions consultative vote annual general meeting balanced mix long shortterm remuneration remuneration corporate executive committee mem components bers senior roche executives comprised market competitiveness base salary fixed base salaries remained un changed exception daniel odays base salary base pay bonuses blocked nonvoting equity securities bonus variable corporate executive com nes awards stocksettled stock appreciation rights mittee bonus provided cash payments ssars performance share plan psp support nonvoting equity securities blocked principles remuneration components linked years blocking period according corpo companys financial performance commercial success rate executive committee members individual decision thus align interests roche employees stocksettled stock appreciation rights ssars vari shareholders able performance share plan psp awards variable amount separate components remuneration psp nes awarded individual member corporate executive committee ssars granted strike shown individual description remuneration prices nes price december corporate executive committee report time value recipients change roches future nes price improves base pay change base remuneration base pay cash payment levels determined according board directors since market data worlds biggest pharmaceuticals compa nies specific positions individual employees abilities please see rest report full details experience performance time pay increases linked individual performance also take account remuneration policy prevailing market conditions companys overall eco roche fundamentally renewed remuneration policy nomic situation base pay pay increases conclusively reviewed reconfirming key principles monitored determined remuneration committee part framework employee policies aimed motivating retaining current employees attracting talented new ones bonuses bonuses awarded recognition individual contributions value creation go beyond normal job expectations see stocksettled stock appreciation rights ssars pages see also finance report note roche group consoli dated financial statements related parties notes peer set abbott laboratories amgen astellas astrazeneca financial statements roche holding ltd board bayer becton dickinson bristolmyers squibb eli lilly executive remuneration board executive shareholdings glaxosmithkline johnson johnson merck co novartis pfizer pages sanofiaventis takeda roche business report remuneration reportvariable remuneration elements bonuses ssars psp relation fixed base pay members corporate executive committee bonus ssars psp individual target value assessed max consideration performance based annual base pay competitors measured january macroeconomic development first year cycle relation value base pay minimum maximum relation value base pay cash payment value development value development blocked nes determined determined performance nes performance nes grant grant performance criteria group objectives group individual contributions group performance divisional business upon remuneration tsr relation performance committees decision tsr performance individual objectives discretion peer set considering profit see pages sales growth opac operating profit capital charge split group objectives na b individual objectives na meant incentive create strengthen performance share plan psp new business opportunities strive outstanding results members corporate executive committee bonus amounts linked group divisional business per members senior management currently individu formance considering profit sales growth opac operating als worldwide participate performance share plan profit capital charge performance achieve psp psp established periods three ment individual functional measurable qualitative years based threeyear comparison performance objectives reasons competitiveness roche total shareholder return tsr competing companies disclose details individual objectives mem three overlapping performance cycles bers corporate executive committee remuner psp psp psp ation committee board directors defined psp closed december terms corporate executive committee members bonuses decem performance share plan determined annually board ber based mentioned objectives cor directors acting upon recommendations remu responding results achieved neration committee stocksettled stock appreciation rights ssars details psp calculation additional infor stocksettled stock appreciation rights introduced mation set forth remuneration members cor january thus establishing uniform system remu porate executive committee performance share plan neration throughout roche ssars entitle holders benefit psp financially increase value roches nonvoting equity securities grant date exercise date remuneration board directors awards allocated individually upon remuneration corporate executive committee committees decision discretion detailed informa year remuneration committee board direc tion available pages tors sets remuneration members board direc remuneration report roche business report tors corporate executive committee cash payments bonuses remuneration chairman board bonuses stocksettled stock appreciation rights policy directors members corporate executive committee decisions pension benefits terms perfor taking consideration personnel changes mance share plan determined annually board directors acting upon recommendations remunera following pages provide detailed information remu tion committee remuneration committee continuously neration earned member board directors tracks salary trends market worlds biggest phar member corporate executive committee maceuticals companies reports board directors information committees remit powers proce dures making remuneration decisions found remuneration bylaws roche board directors remuneration members board directors members board directors received following revision remuneration policy including remuneration cash shown table remuneration market comparisons worlds major pharmaceutical members board directors board activ companies remuneration committee determined httpwwwrochecomaboutrochecorporategovernance list members positions committee memberships articleofincorporationhtm chairmanship see remuneration members board directors additional compensation remuneration committee memberschairs additional special compensation chf chf f b humer see remuneration chairman board directors see b gehrig hoffmann p baschera j bell p bulcke w burns l j r de vink ch franz julius levinson oeri p r voser b weder di mauro remuneration former members board directors additional compensation remuneration committee memberschairs additional special compensation chf chf w frey w ruttenstorfer exception members presidium vicechairmen board members receive chf year committee serve chf year committee chair see g highest total remuneration member board directors pages remuneration serving vicechairman board prorated remuneration period march december prorated remuneration period january march roche business report remuneration reportities remuneration members board directors members board directors received remain unchanged remuneration totalling swiss francs swiss francs swiss francs beside cash payments nonexecutive members board directors awarded shares nonvoting additional remuneration paid members board equity securities stocksettled stock appreciation rights directors ssars restricted stock units rsus remuneration members corporate executive william burns received honoraria amounting total committee general provisions assigning authority us dollars swiss francs serving mem decisions corporate executive committee remuneration ber board directors chugai pharmaceutical co remuneration committee board directors ltd arthur levinson received payments consulting outlined pages remuneration report work board membership genentech amounting us dollars swiss francs john bell due contractual obligations former roche assign received payments consulting work scientific ment us daniel oday received swiss advisory board roche totalling swiss francs francs addition remuneration horst teltschik former member board alan hippe received additional payments costs occurred directors received honoraria amounting euros relocation switzerland etc amounting swiss swiss francs serving boards several francs roche subsidiaries germany see stocksettled stock appreciation rights ssars see remuneration members board directors remuneration members corporate executive committee base pay chf annual salary annual salary annual salary schwan ayyoubi hippe g keller oday p soriot total member corporate executive committee prorated remuneration period april december members corporate executive committee b bonus received remuneration totalling swiss francs members corporate executive committee receive million swiss francs million swiss bonus cash payment form francs roche nonvoting equity securities blocked years blocking period according corporate execu tive committee members individual decision cash payment due end april roche nonvoting equity securities granted beginning based see remuneration members corporate executive committee af h including ahvivalv pages market value averaged last three months remuneration report roche business report bonus bonus bonus bonus total total total chf chf chf schwan cash payment blocked nonvoting equity securities total bonus ayyoubi cash payment blocked nonvoting equity securities total bonus hippe cash payment blocked nonvoting equity securities total bonus g keller cash payment blocked nonvoting equity securities total bonus oday cash payment blocked nonvoting equity securities total bonus p soriot cash payment blocked nonvoting equity securities total bonus total member corporate executive committee calculation value consideration reduction value due blocking period reduced market value years value grant date january chf per nonvoting equity security number blocked nonvoting equity securities granted based market value averaged last three months value chf per nonvoting equity security calculation value consideration reduction value due blocking period reduced market value years value grant date january chf per nonvoting equity security number blocked nonvoting equity securities granted based market value averaged last three months value chf per nonvoting equity security including additional compensation successful integration genentech amounting chf paid prorated remuneration period april december number blocked nonvoting equity securities granted schwan ayyoubi hippe g keller oday p soriot c stocksettled stock appreciation rights ssars ssars ssars ssars value chf value chf value chf schwan ayyoubi hippe g keller oday p soriot total member corporate executive committee see stocksettled stock appreciation rights ssars pages blackscholes value described stocksettled stock appreciation rights ssars pages values according annual report roche business report remuneration reportthe ssars granted strike provisions plan number nonvoting prices nes price december equity securities reserved participants time value recipients change cycle number securities actually awarded roches future nes price improves depend whether extent investment roche securities shares nes outperforms average return members corporate executive committee additionally investment securities issued peer set compara receive annual expense allowances swiss francs tor companies comparisons based securities totalling swiss francs market prices dividend yields ie total shareholder return tsr reduce effect shortterm market fluc performance share plan psp tuations security prices averaged three months members corporate executive committee october december prior start performance members senior management currently individu cycle three months october december als worldwide participate performance share plan end cycle roche securities perform well psp better peer set addition roches tsr increases least cycle board psp moved overlapping threeyear performance directors elect increase maximum nes award cycles new cycle beginning year much twofold event investment roche thus three cycles progress psp psp securities underperforms average return delivered psp previous years psp peer companies fewer nes awarded psp psp ended december without awards targeted nes nes reserved plan members corporate executive committee shown table board directors decide actual level nes cash equivalent awards cycles see strike prices table ssars see footnote performance share plan psp total estimated value psp awards awards nes nes nes targeted awarded awarded awarded target number target number number nes nes psp nes psp psp psp psp psp value chf value chf value chf value chf schwan ayyoubi hippe g keller oday p soriot total member corporate executive committee total estimated value psp none originally targeted nes awarded psp estimated value calculated using yearend price december chf per nonvoting equity security nes based number nes originally targeted subject changes number value nes awardable plan december december respectively spread relevant period time ie year board directors vote actual allocation nes originally targeted december december respectively according tsr achieved remuneration report roche business report close financial years ing industry therefore according terms respectively aim psp provide incentive plan participants received none originally tar participants achieve steady value growth geted nes see table details end psp cycle based three e indirect benefits month moving average distributed dividends totalling employer contributions made social security billion swiss francs billion swiss francs schemes pension plans groupwide employee stock billion swiss francs billion swiss purchase plan roche connect respect members francs tsr roche securities nes shares corporate executive committee shown table indi ranked compared peer set companies operat rect benefits indirect benefits payments pension fundsmgb ahvivalv roche connect tax consulting services chf chf chf chf schwan ayyoubi hippe g keller oday p soriot total mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitsharing foundation supplementing occupational pension benefits ahvivalv swiss social security programmes providing retirement disability unemployment benefits roche connect voluntary stock purchase plan offering members corporate executive committee maxi employees opportunity buy roche nonvoting equity mum notice period twelve months connection securities nes amount equal annual new company personnel structure members cor salary discount nes purchased plan porate executive committee receive compensation one subject holding period four years switzerland annual base pay case termination contract company termination fault based lack f remuneration emoluments loans performance age sixty erich hunziker chief financial officer retired roche end march erich hunziker received fol g highest total remuneration member lowing payments based existing contractual obligations board directors salary swiss francs last payment per december franz b humer chairman member board bonus swiss francs paid april highest total remuneration see remunera employer contribution pension funds etc swiss tion members board directors pages francs receive agreed payment per chairmans remuneration consists base salary contract consisting oneyear salary million swiss bonus awards chairman board handover francs bonus million swiss francs payment executive function ceo annual general meeting already included corporate executive committee mem march receive additional ssars bers total amount swiss francs nes new psp cycles longer enrolled roche ssars programme pensions totalling swiss francs paid two former corporate executive committee members roche business report remuneration reporthighest total remuneration member board directors chf chf chf salary bonus cash payment blocked nonvoting equity securities total pension fundsmgb roche connect total value calculation value consideration reduction value due year blocking period reduced market value years detailed calculation remuneration see annual report mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitsharing foundation supplementing occupational pension benefits includes additional compensation committee members chf payments tax consulting services chf chugai advisory mandate usd chf including employer contribution ahvivalv chf highest total remuneration member corporate executive committee chf chf chf salary bonus cash payment blocked nonvoting equity securities total ssars blackscholes value grant minus pension fundsmgb roche connect estimated value targeted awarded nes according performance share plan awardsvalue nes total total value calculation value consideration reduction value due year blocking period reduced market value years detailed calculation remuneration see annual report blackscholes value described stocksettled stock appreciation rights ssars pages mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitsharing foundation supplementing occupational pension benefits basic rules detailed calculation see remuneration members corporate executive committee performance share plan footnote respectively includes annual expense allowance chf payments tax consulting services chf excluding employer contribution ahvivalv payments h highest total remuneration member additional remuneration stated pay corporate executive committee ments paid current former members corporate severin schwan ceo member corporate executive committee executive committee highest total remuneration see remuneration members corporate execu tive committee af pages table remuneration report roche business report security holdings directors andr hoffmann andreas oeri members founders families closely associated belong shareholder group pooled voting rights end group held shares issued shares detailed informa tion group found finance report note roche group consolidated financial statements related parties note financial statements roche holding ltd significant shareholders addition december members board directors persons closely associated members executive committee per sons closely associated held shares nes shown table stocksettled stock appreciation rights ssars december franz b humer william burns members board directors holding ssars due former positions members corporate executive committee held stocksettled stock appreciation rights ssars shown table ssars ssars shown table introduced roche january place stock options ssars entitle holders benefit financially increase value roches nes grant date exercise date strike price ssars terms multi year plan closing price roche nes grant date ssars vest within three years grant date ie onethird vest end one year onethird end two years onethird end three years vested ssars must exercised converted nes within seven years grant date unexercised ssars lapse without compensa tion fair value ssars calculated date issue using blackscholes formula ssars tradable deduction average twoyear vesting period strike prices expiry dates grant values ssars shown table numbers ssars calculated time issue entered values table remuneration members corporate execu tive committee c stocksettled stock appreciation rights ssars roche business report remuneration reportsecurity holdings december close relatives shares nes security holdings others number number numbertype number board directors f b humer ssars see rogtpk trackerplus cert zrcher kantonalbank roche genussschein rog underlying valor isin ch b gehrig hoffmann ubs longshort certificates linked roche bearer shares roche nonvoting equity securities valor isin ch p baschera j bell p bulcke w burns ssars see l j r de vink american depository receipts adr rhhby us isin us ch franz julius nes levinson oeri ubs longshort certificate linked roche bearer shares roche nonvoting equity securities valor isin ch p r voser b weder di mauro total nes corporate executive committee schwan nes ssars see ayyoubi ssars see hippe ssars see g keller shares ssars see oday ssars see p soriot ssars see total nes shares shares held shareholders group pooled voting rights listed remuneration report roche business report ssars number ssars held current former members corporate executive committee december total corporate executive committee schwan ayyoubi hippe g keller oday p soriot total former corporate executive committee members f b humer none none none none w burns none none strike price chf market price per nes december chf expiry date grant value per ssar chf blackscholes value minus franz b humer receive additional ssars franz b humer received ssars member corporate executive committee william burns receive additional ssars william burns received ssars member corporate executive committee roche business report remuneration reportindependent assurance report corporate governance sustainability committee criteria roche holding ltd basel roche roche group internal corporate responsibility reporting guidelines based responsible care health safety performed assurance procedures provide assur environmental protection reporting guidelines published ance following aspects corporate responsi european chemical industry council cefic sus bility reporting roche tainability reporting guidelines g published global reporting initiative gri subject matter roche group internal corporate reporting manual ver data information disclosed corporate responsibility sion sustainability reporting economic performance reporting roche consolidated subsidiaries exclud data ing chugai pharmaceutical co ltd business year defined procedures people dona ended december following aspects tions sponsorships key figures gathered collated indicated level assurance aggregated internally management reporting processes respect good practice procedures internal reporting sys corporate responsibility reporting preparation tems processes designed managed operated people donations sponsorships key figures well control environment relation data aggre responsibility methodology gation key figures reasonable assurance accuracy completeness corporate responsibility key figures tables pages indicators subject inherent limitations given nature selected people key figures disclosed pages methods determining calculating estimating roche business report limited assur data assurance report therefore read con ance nection roches internal guidelines definitions pro consolidated data information roche group cedures reporting corporate responsibility per level relation donations sponsorships data disclosed formance excluding health care professionals hcps related activities limited assurance roche corporate governance sustainability commit tee responsible subject matter criteria responsibility provide conclusion subject matter based assurance procedures accordance international standard assurance engagements isae subject matters limited assurance evi dencegathering procedures limited rea sonable assurance example audit financial state ments therefore less assurance obtained overall reasonable assurance engagement roche business report independent assurance reportmain assurance procedures conclusions assurance procedures included following work opinion evaluation application group guidelines internal corporate responsibility reporting guidelines reviewing application roche internal corporate applied properly responsibility reporting donations sponsorships internal reporting systems collect aggregate guide lines people donations sponsorships key figures func site visits tioning designed provide appropriate basis visiting selected sites roches pharmaceuticals diag disclosure nostics divisions austria ukraine poland romania tur key uk ireland puerto rico selection based based work described report assess quantitative qualitative criteria ment criteria nothing come attention causes interviewing personnel responsible internal corporate us believe corporate responsibility information men responsibility reporting data collection sites tioned subject matter disclosed corporate visited group level determine understand responsibility reporting roche business report ing application roche internal corporate responsibility give fair picture roches performance guidelines assessment key figures performing tests sample basis evidence supporting zurich january selected people donations sponsorships key fig ures roche accident rate energy consumption co emis pricewaterhousecoopers ag sions related energy consumption release halogenated hydrocarbons use water general waste headcountfte data staff turnover labor practices information contri butions philanthropic organizations patient organizations health institutions public policy bodies concerning com clive bellingham stephan hirschi pleteness accuracy adequacy consistency review documentation analysis relevant policies basic principles reviewing relevant documentation sample basis including group corporate responsibility policies manage ment reporting structures documentation assessment processes data consolidation reviewing appropriateness management reporting processes corporate responsibility reporting assessing consolidation process data group level independent assurance report roche business report published cautionary statement regarding forwardlooking f hoffmannla roche ltd statements basel switzerland annual report contains certain forwardlooking statements tel forwardlooking statements may identified words believes expects anticipates projects intends seeks fax estimates future similar expressions discussion among things strategy goals plans intentions various factors may media office cause actual results differ materially future group communications reflected forwardlooking statements contained annual basel switzerland report among others pricing product initiatives competi tel tors legislative regulatory developments economic con fax ditions delay inability obtaining regulatory approvals bring ing products market fluctuations currency exchange rates general financial market conditions uncertainties dis investor relations covery development marketing new products new uses basel switzerland existing products including without limitation negative results clini tel cal trials research projects unexpected side effects pipeline fax marketed products increased government pricing pressures interruptions production loss inability obtain adequate world wide web protection intellectual property rights litigation loss key wwwrochecom executives employees adverse publicity news coverage corporate sustainability committee statement regarding earnings per share growth profit tel forecast interpreted mean roches earnings email corporatesustainabilityrochecom earnings per share subsequent period neces sarily match exceed historical published earnings earnings order publications per share roche tel fax trademarks mentioned enjoy legal protection email baselwebmasterrochecom links third party pages provided convenience express opinion content thirdparty pages next annual general meeting expressly disclaim liability thirdparty information march use roche annual report published german english printed nonchlorine bleached fsccertified paper roche annual report issued f hoffmannla roche ltd basel group communications x key figures highlights february march march roche group index study avastin shows women roche annual general meeting votes launch innovative fully auto sales mchf free cash flow mchf newly diagnosed advanced ovar increase shareholder dividend mated clinical chemistry module ian cancer live significantly longer cobas c eu without disease getting worse research development mchf total dividend mchf operating profit mchf number employees april april may roche announces positive clinical fda approves cobas hpv test investigational medicine metmab test results investigational medi cervical cancer screening combination tarceva doubles cine tdm aggressive form detects highrisk genotypes time people lung cancer live metastatic breast cancer without disease getting worse income taxes mchf total employee remuneration mchf net income mchf patients clinical trials august september september us marketing approval targeted roche named healthcare super tarceva receives european approval skin cancer medicine zelboraf sector leader dow jones firstline use genetically distinct core earnings per share chf ecoefficiency rate cobas braf test companion sustainability indexes third type lung cancer diagnostic year running index index october november december price development nonvoting equity security genussschein chf investigational medicine ocrelizumab fda grants priority review new marketing applications submitted shows significant reduction drug application vismodegib eu us pertuzumab multiple sclerosis disease main advanced form skin cancer positive metastatic breast cancer tained almost two years roche nonvoting equity security swiss market index rebased key figures indexed figures annual report core results full index global reporting initiative gri proposed board directors indicators used report see development phase iv numbers exclude patients wwwrochecomreportingandindices genentech studies initiated prior merger calculation ecoefficiency rate see wwwrochecomenvironment rochearkey figuresengindd rochearhighlightsengindd f hoffmannla roche ltd basel switzerland trademarks legally protected wwwrochecom e roche annual report x annual report landmark year roche personalised healthcare annual report highlights progress made advancing strategic priority shared entire roche group successfully launched new tests medicines tailored needs specific patient popu lations made good progress developing others also promise make treatment safer effective roche believe medically differentiated products benefit healthcare stakeholders patients physicians regulators payers rochearfront coverengindd rochearourbusinesstopicengindd